Abstract
Regulated cell death (RCD) encompasses genetically encoded and pharmacologically modifiable pathways that govern cellular demise. In the nervous system, RCD assumes unique biological and clinical relevance due to neurons’ post-mitotic status, the functional integration of neural circuits, and the central role of glial cells in homeostasis and inflammation. This review synthesizes current knowledge on apoptotic and non-apoptotic RCD modalities in neurons and glia, integrates molecular mechanisms with ultrastructural hallmarks, and discusses specific patterns of pathway engagement. We emphasize compartmentalized death, pathway crosstalk, and cell-type specificity.
1 Introduction
Multicellular animals maintain tissue homeostasis and remove damaged cells by regulated cell death (RCD). The classical dichotomy between necrosis, the only initially recognized form of (unregulated) cell death, and apoptosis, the first discovered and most widely known form of RCD, has now proven insufficient to explain the diversity of cell death phenotypes in tissues. Advances in molecular genetics, imaging, and biochemistry have revealed multiple RCD programs that are actively executed and tightly controlled. In the nervous tissue, where cellular replacement is limited and proper functional connectivity is fundamental, even low-level RCD activation can have disproportionate consequences. Today, we recognize numerous types of RCD in addition to apoptosis. Apoptosis may follow an intrinsic pathway, in which the pro-apoptotic members of B-cell lymphoma 2 (BCL-2) family of proteins permeabilizes the mitochondrial outer membrane (MOM) to trigger death, or an extrinsic pathway, mediated by cell-surface receptors. The intrinsic and extrinsic pathways of apoptosis activate caspases, a class of proteases that mediate cell death during the execution phase, to which various forms of RCD converge. Although these mechanisms have been widely investigated, grand challenges in the field include understanding the reciprocal interactions and biological significance of the various forms of RCD, as well as their compartmentalization within neurons. This review will analyze the different types of RCD based on their molecular, structural, and morphological characteristics. Notably, the diverse forms of RCD in the nervous tissue are highly context-dependent, often incomplete, and frequently overlap at the molecular and morphological levels. Understanding the biological mechanisms of RCD is essential to cellular and molecular biology and to translating fundamental knowledge into potential therapeutic applications.
1.1 Historical notes
Following Schleiden and Schwann’s 1838 cellular theory, embryologists began studying cellular generation, development, and death. However, it took more than a century to fully understand the evolutionary and functional significance of cell death, and more than 100 publications on the subject appeared in the 19th century, attesting to its importance at the time (). Pathologists were among the first to notice cell death in injured tissues (Virchow, 1858). However, to convince academics of the importance of cell death in normal development, growth, and aging, substantial experimental research was required. Eventually, studies of insect and amphibian metamorphosis led to the recognition of cell death as non-pathological ().
Namely, in 1842, Vogt studied the formation of the anuran notochord, which initially developed from the chordamesoderm and was later replaced by cartilage as its cells were eliminated (Vogt, 1842). The cellular death modes of complex organisms were at that time revealed through simultaneous investigations at the organ- and tissue-levels. Various species were studied for endochondral ossification, a process in which cartilage is replaced by bone. This process involves chondrocyte loss and osteoblast replacement, leading to the formation of mature bone (Stieda, 1872). Also examined were granulosa cell degeneration in mature ovarian follicles and mammary gland cell death during breastfeeding. In 1885, Flemming began studying dying mammary gland cells and made the first detailed observations on well-preserved tissues, coining the term ‘chromatolysis’ to describe the loss of staining in dying cells (Flemming, 1885). However, as observations of physiological cell death accumulated, the conceptual framework for understanding necrosis as a distinct pathological process was being developed in parallel. Virchow was the first to recognize that more than one form of cell death could occur, applying the term necrosis to an advanced state of tissue breakdown at the gross level, while coining the term ‘necrobiosis’ to describe a separate, cell-level process in which the cell vanishes and can no longer be seen in its original form (Virchow, 1858). He explicitly defined necrobiosis as the result of “spontaneous wearing out of living parts,” distinguishing it from necrosis as a natural rather than violent form of cell death (Virchow, 1858). This early distinction between regulated and unregulated cell death would prove conceptually important, though its significance would not be fully appreciated for over a century (). In 1914, Gräper proposed that some mechanism must counterbalance mitosis, and that this process likely involved the chromatolysis described by Flemming (Gräper, 1919). This paper was subsequently rediscovered by Glücksmann in 1951 (Glücksmann, 1951). In this landmark review, Glücksmann systematically compiled observations of cell death in normal vertebrate development from the literature of the preceding half century, emphasizing the frequent occurrence of cell death across a wide range of developmental contexts (Glücksmann, 1951). Glücksmann identified three phases of developmental cell death—phylogenetic, morphogenetic, and histogenetic—providing the first systematic classification of physiological cell death. This work helped to reestablish cell death as a normal developmental phenomenon rather than a purely pathological one, at a time when the field had largely turned its attention elsewhere (Fricker et al., 2018; Park et al., 2023). The direct precursor to the concept of apoptosis came from pathological studies of the liver. In 1965, Kerr ligated a branch of the hepatic portal vein in rats, inducing liver atrophy, and observed two distinct forms of cell death: classical necrosis and a separate process in which hepatocytes rounded off into small cytoplasmic bodies that were subsequently engulfed by neighboring cells or histiocytes (Kerr, 1965). Between 1967 and 1970, Kerr carried out an electron-microscopic study of this process, finding that its earliest recognizable stage involved condensation of the cytoplasm and nuclear chromatin, with compacted chromatin aggregating beneath the nuclear envelope; at the same time, the resulting membrane-bounded bodies contained well-preserved organelles (Kerr, 1969). Kerr termed this form of death “shrinkage necrosis” and, in his 1971 paper, formally described it as a distinct mode of cellular death, showing through ultrastructural analysis how it differed from classical necrosis (Kerr, 1971). In the following year, Kerr, Wyllie, and Currie (Kerr et al., 1972) were the first to coin the term apoptosis to denote this form of cell death, different from necrosis, the prototype of non-regulated cell death. The term apoptosis was derived from the Greek words “apo” and “ptosis,” which indicate “to detach” or “to fall off,” for example, of ripe fruit or decaying tree leaves. However, although at that time it was well known that many cells die during normal development and that these dying cell populations were often eliminated during the evolution of multicellular organisms, it took at least a couple of decades before apoptosis, also referred to as programmed cell death (PCD), became recognized as the prototype of several forms of RCD. Today we know that apoptosis, as an ultrastructurally well-defined form of RCD, occurs throughout normal development and tissue turnover (Migheli et al., 1994; Stewart, 1994; White, 1996; Marks and Berg, 1999). Studies of PCD in Caenorhabditis elegans, a worm in which 131 of its 1,090 somatic cells undergo apoptosis during adulthood, have substantially improved our understanding of mammalian apoptotic mechanisms by identifying the genes that regulate its progression (Horvitz, 1999). Since then, the field of RCD has expanded dramatically and revealed an unforeseen complexity. There is today accumulating evidence that other forms of RCD, distinct from apoptosis, are important under pathological conditions and have a role during normal development. For example, autophagic cell death has been shown to play a role in embryonic cavitation (Qu et al., 2007), Drosophila metamorphosis (), and zebrafish cardiac morphogenesis (Lee et al., 2014).
2 RCD pathways
RCD may take several forms, be mediated by distinct cellular signaling pathways, and, at least in principle, be modulated by genetic or pharmacological interventions. The pathways activated in various forms of RCD often lead to distinct morphological changes in dying cells. Classification schemes proposed by the Nomenclature Committee on Cell Death (NCCD) emphasize molecular executors rather than morphology alone (Galluzzi et al., 2018), as many ultrastructural similarities exist among the different types of RCD. Importantly, RCD pathways are not mutually exclusive, and hybrid and sequential activation states are common, particularly in neural cells.
2.1 Apoptosis
In the nervous system, apoptosis represents the archetypal RCD program. As we will discuss in the following sections, it occurs through a cellular pathway involving several molecules, the most important of which are BCL-2 and its family members, the apoptosome, and the initiator and effector caspases. Apoptosis is indispensable during development, sculpting neuronal populations and refining synaptic connectivity. Developmental apoptosis is tightly regulated by the availability of growth factors (neurotrophins and others) and by transcriptional programs primarily involving BCL-2 family proteins. In mature neurons, however, apoptotic execution is constrained by high levels of endogenous caspase inhibitors and by the spatial segregation of death signals, suggesting that neurons, at least under certain conditions, may develop apoptotic resistance (; Hollville et al., 2019). Resistance is achieved by inhibiting the intrinsic apoptotic pathway through multiple redundant and complementary mechanisms, such as downregulating pro-apoptotic proteins (e.g., caspases, apoptosis protease-activating factor 1 [Apaf1]), elevating miR-29 levels to target Bcl-2 Homology 3 (BH3)-only proteins, and augmenting inhibitors of apoptosis proteins (IAP)-mediated suppression. Yet, despite their resistance, neurons can still undergo apoptosis in response to several pathological conditions.
Research on C. elegans and D. melanogaster has taught us much about genes involved in apoptosis (Yuan, 1995; Meier and Evan, 1998; Liu and Hengartner, 1999; Hengartner, 2001). After cloning the orthologs of C. elegans death machinery genes in mammals and D. melanogaster, it became evident that these genes exhibit analogous functions in regulating apoptosis across all species examined to date. The ‘death mechanism’ in C. elegans consists of four genes - cell death abnormality gene 3 (ced-3), 4 (ced-4), 9 (ced-9), and egg-laying defective protein 1 (egl-1) - that execute PCD (Hengartner, 1997). Subsequent genetic studies in mutant mice demonstrated that orthologs of ced-3 and ced-4 were crucial for cellular apoptosis in mammals as well (Woo et al., 2000). These genes encode proteins that act sequentially to promote apoptosis. Ced-9 inhibits ced-3 and ced-4 activity and acts as a survival factor (Hengartner et al., 1992). Cells can die due to aberrant CED-4 protein synthesis, an adaptor molecule that regulates CED-3’s lethal function. Ced-4 functions upstream of ced-3 and is regulated by ced-9. Therefore, by interacting with CED-4, CED-9 protects cells from self-destruction (Shaham and Horvitz, 1996). EGL-1 is another C. elegans death effector (Liu and Hengartner, 1999). When the egl-1 function is compromised, all apoptotic cells survive. EGL-1 can cause PCD by binding to CED-9 and inhibiting its action. Inhibition of CED-9 produces an apoptosome tetramer composed of four CED-4 molecules, which initiates apoptosis (Conradt and Horvitz, 1998).
After the discovery of the ced-9 gene in C. elegans, a comparable protein, BCL-2, was found in mammals (Vaux et al., 1992; Hengartner and Horvitz, 1994). BCL-2 was the first of a family of proteins that includes at least twenty to twenty-five CED-9-related proteins that regulate apoptosis by either promoting or inhibiting it. Numerous reports have been published on the biology of these proteins (Edlich, 2018; Kale et al., 2018; Singh et al., 2019; Vogler et al., 2025). Based on their structure and function, they can be subdivided into anti-apoptotic, multidomain pro-apoptotic, and BH3-only pro-apoptotic proteins. Each family member possesses one of the four conserved BCL2-homology (BH) domains (BH1, BH2, BH3, or BH4). B-cell lymphoma-extra-large (BCL-XL) and BCL-2-like 2 (BCL-W) are anti-apoptotic, while Bcl-2-associated X-protein (BAX), Bcl-2 homologous antagonist/killer (BAK), Bcl-XL/Bcl-2-associated death promoter (BAD), and BH3-interacting domain death agonist (BID) promote cell death. Anti-apoptotic BCL-2 family members inhibit apoptosis by preventing BAX and BAK from forming pores in the mitochondrial outer membrane (MOM), thereby preventing the passage of ions and proteins into the cytosol (Liang and Fesik, 1997). Blocking of pore formation inhibits mitochondrial cytochrome c release, apoptosome formation, and cell death (Li et al., 1998; Luo et al., 1998). In nematodes, a second mechanism that suppresses cell death involves the interaction between CED-9 and CED-4, which regulate CED-3 to prevent apoptosis. This interaction inhibits the apoptosome assembly and CED3 activation (). However, it does not occur in Xenopus oocytes and mammalian cells because BCL-2 and BCL-XL bind to Apaf1 but do not block CASP9 activation (Newmeyer et al., 2000).
The mammalian apoptosome consists of Apaf1, the homolog of CED-4; cytochrome c (also referred to as apoptotic protease activating factor 2, Apaf2); and the initiator caspase 9 (CASP9, also referred to as apoptotic protease activating factor 3, Apaf3). Caspases can degrade cellular components, but many apoptosome scaffolding proteins are required to activate them. CASP9, Apaf1, and cytochrome c are essential for the effector caspase 3 (CASP3) activation by cleaving the inactive zymogen (Liu et al., 1996; Li et al., 1997). Apaf1, which is inactive in monomeric form, binds cytochrome c released from mitochondria during apoptosis, and then associates with proCASP9 to form multimers, resulting in the formation of a heptameric wheel-like structure that forms the core of the approximately 1 MDa apoptosome (). By this arrangement, the CARD (caspase recruitment domain) of Apaf1 is optimally positioned to engage with proCASP9 (Saleh et al., 1999), so that the N-terminal CARD domain of proCASP9 binds to the apoptosome and interacts directly with the Apaf1 CARD (). There are a few steps in the CASP9 activation process. First, the apoptosome acts as a scaffold that recruits proCASP9, which then induces a conformational change in the molecule. Then Apaf1 causes proCASP9 to oligomerize, forming active dimers. At this step, although not strictly required for initiation, the high local concentration of dimers enables rapid autocatalytic cleavage of proCASP9. Subsequently, the Apaf1 CARD can form a large, functional hetero-oligomer with active CASP9, suggesting that the CARD domain is sufficient for allosterically up-regulating protease activity. Apaf1 and CASP9 CARD interact to sequester the CASP9 CARD, which, when it is not bound, dramatically lowers the protease activity (Li et al., 2017). Activated CASP9 on the apoptosome functions as a holoenzyme to cleave and activate downstream effector caspases, namely, CASP3 and CASP7 (). This process is a very important step in the intrinsic apoptotic pathway. It switches CASP9 from “off” to “on” via the scaffolded heptamer. Research on human embryonic kidney 293T cells has shown that BCL-XL (Singh et al., 2019) interacts with CASP9 and Apaf1 to inhibit CASP9 maturation, a mechanism believed to be conserved from nematodes to humans (Hu et al., 1998). However, other studies have shown that members of the BCL-2 family do not interact with Apaf1 (Moriishi et al., 1999; Conus et al., 2000; Newmeyer et al., 2000).
The mammalian homologs of CED-3 are the caspases (Thornberry and Lazebnik, 1998). The first mammalian caspase identified was CASP1, also known as interleukin-1 beta-converting enzyme (ICE) (Yuan et al., 1993; Schwartz and Milligan, 1996). ICE is expressed in undifferentiated progenitors and granule cell precursors in the postnatal human cerebellar cortex, where it is associated with developmental apoptosis (Lossi et al., 1998). Further research indicated that CASP3 and CED-3 shared the greatest sequence homology (Fernandez-Alnemri et al., 1994; Nicholson et al., 1995). A total of 18 mammalian caspases have been identified across species, 12 in humans and 10 in mice. In contrast, other species have unique caspases, such as CASP13 in cattle (Koenig et al., 2001) and CASP16-18 in birds, fish, and non-placental mammals (Eckhart et al., 2008; Eckhart et al., 2025). The better characterized fourteen caspases are divided into three subfamilies based on their peptide preferences: (i) the ICE-protease subfamily of inflammatory caspases (CASP1, 4, 5, 13, and 14, along with murine CASP11 and 12); (ii) the CED-3 subfamily of apoptotic effector caspases (CASP3, 6, and 7); and (iii) the CASP2 subfamily of initiator caspases (CASP2, 8, 9, and 10) (Julien and Wells, 2017). Effector caspases with a short pro-domain degrade cell-essential proteins. However, initiator/inflammatory caspases have longer prodomains that facilitate protein interactions and may induce apoptosis only under specific conditions (perhaps not CASP1 and CASP11) (Thornberry and Lazebnik, 1998). Each caspase is synthesized as a zymogen that must be cleaved to become an active enzyme. Initiator caspases activate downstream caspases, triggering a proteolytic cascade that leads to apoptosis. Distinct pro-apoptotic signals activate different groups of caspases. CASP8, CASP10, CASP3, and CASP7 intervene in extrinsic apoptosis (see below), whereas CASP9, CASP7, and CASP3 mediate intrinsic apoptosis (Zimmermann et al., 2001). Through BID, a protein that controls mitochondrial cytochrome c release when cell-surface death receptors are activated, these two pathways are linked (Li et al., 1998; Luo et al., 1998).
CASP3 substrate selectivity is similar to that of CED-3 (Xue et al., 1996). Thus, the C. elegans CED-4/CED-3 apoptotic cascade and the D. melanogaster Dark/dApaf1/Dronc apoptosome are orthologs of the mammalian apoptosome. Remarkably, unlike mammals and D. melanogaster, C. elegans apoptotic cells display chromatin shrinkage and cytoplasmic condensation but no apoptotic bodies, highlighting distinct downstream mechanisms across phyla (; Kutscher and Shaham, 2017). Another notable difference with mammals is that cytochrome c is not required for apoptosome formation in flies (Yuan and Akey, 2013).
Many cell-killing events activate apoptotic pathways. The observation of comparable morphological and biochemical alterations across diverse apoptotic triggering events suggests that most apoptotic pathways converge on a few effectors (Sastry and Rao, 2000; Elmore, 2007). The order of caspase activation and mitochondrial cytochrome c release defines two main apoptotic pathways: the intrinsic and extrinsic pathways (Lossi, 2022). In intrinsic apoptosis, cytochrome c is released from the mitochondrial intermembrane space before caspase activation as a consequence of the MOM permeabilization (MOMP). Extrinsic apoptosis, on the other hand, begins with the activation of an initiator caspase (CASP8 or CASP10) independently of mitochondrial alterations. Intrinsic apoptosis is initiated by intracellular sensors that detect DNA damage, viral infection, or the absence of survival signals from surrounding cells. Pro-apoptotic signals from natural killer cells or CD8-positive cytotoxic T lymphocytes initiate the extrinsic apoptotic pathway (Yanumula and Cusick, 2021). One should not view the two pathways as separate or unrelated, as they cross-talk via BID in mitochondria. The final step of apoptosis, the execution, occurs at the end of both paths.
2.1.1 Intrinsic pathway
In neurons, the intrinsic (mitochondrial) pathway predominates. Ultrastructurally, neuronal apoptosis is characterized by chromatin margination, nuclear fragmentation, cytoplasmic condensation, and preservation of plasma membrane integrity, features that distinguish it from lytic RCD modalities (Galluzzi et al., 2007). Intrinsic apoptosis can be caused by several factors, including depletion of growth factors, DNA damage, endoplasmic reticulum (ER) stress, reactive oxygen species (ROS) buildup, replication stress, microtubule alterations, and mitotic abnormalities (Nuñez et al., 1990; Nuñez and Clarke, 1994; ; Czabotar et al., 2014; Roos et al., 2016; Pihán et al., 2017; Vitale et al., 2017). MOMP is a crucial step in the intrinsic apoptotic pathway (Galluzzi et al., 2018). As a consequence of MOMP, initiator caspases, particularly CASP9, are activated. Remarkably, CASP9 also promotes a feedback amplification of mitochondrial damage (Guerrero et al., 2012). The release of cytochrome c into the cytosol is also decisive. Cell-free experiments have shown that it results from a breakdown of the MOM and/or the mitochondrial permeability transition (MPT), which is governed by the voltage- and Ca2+−sensitive permeability transition pore (). Pore opening causes irreversible and extensive MOMP (Tait and Green, 2010).
The intrinsic apoptotic pathway begins with pro- and anti-apoptotic interactions among BCL-2 family members, which carefully regulate MOMP. Regulation of MOMP and its execution exhibit distinctive features in non-neuronal cells and in developing and mature neurons (Table 1). There are also differences in the regulation and implementation of MOMP between neurons and glia, particularly regarding the baseline apoptotic threshold, the expression of APAF1 and XIAP, the apoptosome competence, the primary consequences of MOMP, and the relevance of minority MOMP (Table 2).
TABLE 1
| Feature | Non-neuronal cells with proliferative capacity | Developing neurons | Mature neurons |
|---|---|---|---|
| Physiological/pathological role | Homeostasis, stress response (Fadeel and Oorrenius, 2005) | Cell number matching, connection pruning (Hidalgo and ffrench-Constant, 2003) | Injury and neurodegeneration (Martin et al., 2001; Okouchi et al., 2007) |
| Caspase dependence of death | Predominantly caspase-dependent (Galluzzi et al., 2018) | Caspase-dependent (Putcha et al., 2000) | Frequently caspase-independent or mixed (Galluzzi et al., 2015) |
| Effect of caspase inhibition | Partial protection against death with possible switch to necrosis (Lemaire et al., 1998) | Delayed death (Stefanis et al., 1999) | Delays but does not prevent death (Deshmukh et al., 2000) |
| Apoptosome competence | Fully competent (Li et al., 1997) | Fully competent (Potts et al., 2003) | Restricted by low APAF1 and high XIAP (Wright et al., 2007) |
| APAF1 expression | High (Li et al., 1997) | High (Potts et al., 2003) | Strongly downregulated with maturation (Wright et al., 2007) |
| Cytochrome c microinjection response | Fast caspase activation (Li et al., 1997) | Efficace CASP9/CASP3 activation (Potts et al., 2003) | Unsuccessful unless XIAP is neutralized (Potts et al., 2003; Wright et al., 2007) |
| XIAP tone | Fair (Eckelman and Salvesen, 2006) | Low–fair (Potts et al., 2003) | High, main caspase brake (Potts et al., 2003) |
| Role of SMAC/DIABLO | Caspase amplification (Verhagen et al., 2000) | Eases developmental apoptosis (Haanen and Vermes, 1996; Stoka et al., 2007) | Required to relieve XIAP inhibition (Potts et al., 2003) |
| MOMP threshold (BCL-2 rheostat) | Moderate (Sochalska et al., 2015) | Developmentally tuned () | High anti-apoptotic buffering () |
| Executioner caspase activation after MOMP | Fast and strong (Tait and Green, 2013) | Robust (Putcha et al., 2000) | Delayed or minimal (Wright et al., 2007) |
| Δψm loss after MOMP | Rapid and terminal (Ricci et al., 2003) | Rapid (Wadia et al., 1998) | Progressive, linked to respiratory failure (Nunnari and Suomalainen, 2012) |
| Minority MOMP result | Genomic instability and transformation risk (Ichim et al., 2015) | Usually progresses to apoptosis (Pacher and Hajnóczky, 2001; Nguyen et al., 2021) | DNA damage, synaptic dysfunction, slow degeneration (Hollville et al., 2019) |
| Dominant cell disassembly mechanisms | Caspase proteolysis (Salvesen and Dixit, 1997) | Caspase proteolysis (Nguyen et al., 2021) | Bioenergetic failure, AIF translocation, calpains (Galluzzi et al., 2015) |
| Morphology | Classical apoptosis (Elmore, 2007) | Classical developmental apoptosis (Thomaidou et al., 1997) | Hybrid apoptosis-like degeneration (Kole et al., 2013) |
Apoptotic post-MOMP execution in mitotic cells, developing neurons, and mature neurons.
TABLE 2
| Feature | Neurons | Astrocytes | Oligodendrocytes |
|---|---|---|---|
| Baseline apoptotic threshold | Very high (Hollville et al., 2019) | Intermediate (Gürer et al., 2009) | Relatively low () |
| BCL-2 family balance | High levels of BCL-XL, MCL-1 (Hardwick and Soane, 2013) | Expression of BCL-XL and BCL-2 (Phelka et al., 2006) | Developmental BAX dependence (Sun et al., 2018) |
| APAF1 expression | Strong (Wright et al., 2007) | Maintained (Liu et al., 2006) | Maintained (Springer et al., 1999) |
| XIAP expression | High (Potts et al., 2003) | Moderate (Kernt et al., 2010) | Moderate (Rena Hesse et al., 2012) |
| Apoptosome competence | Restricted (Hollville et al., 2019) | Competent (Takuma et al., 2004) | Competent () |
| Metabolic profile | Oxidative phosphorylation-dependent (Nunnari and Suomalainen, 2012) | Glycolytic flexibility () | Glucose/lactate dependency for development and myelination (Rinholm et al., 2011) |
| Primary consequence of MOMP | Bioenergetic collapse and axonal degeneration (Pemberton et al., 2021) | Caspase-dependent apoptosis (Paranjape et al., 2024) | Rapid apoptosis and demyelination () |
| Effect of caspase inhibition | Delays degeneration (Galluzzi et al., 2015) | Significant protection () | Significant protection (Gu et al., 1999) |
| AIF-dependent death | Prominent in excitotoxicity and ischemia (Culmsee et al., 2005) | Context-dependent (García-Cáceres et al., 2008) | Reported in development () |
| Sensitivity to oxidative stress | High (Harrison et al., 2005) | High but death-resistant (Giffard and Swanson, 2005) | Very high (Pajarillo et al., 2023) |
| Minority MOMP relevance | High (Ichim et al., 2015) | Lower turnover (Voloboueva et al., 2007) | Moderate () |
| Physiological apoptosis | Developmental pruning (Putcha et al., 2000) | Limited (Takuma et al., 2004) | Extensive during development () |
Intrinsic apoptosis and post-MOMP execution in main CNS cell types.
Another mitochondrial membrane protein involved in intrinsic apoptosis is apoptosis-inducing factor (AIF). It is an ancient, bifunctional flavoprotein, similar to cytochrome c and bacterial oxidoreductases (Susin et al., 1999; Susin et al., 2000). In response to cell-killing signals, like oxidative stress or poly (ADP-Ribose) polymerase 1 (PARP1) hyperactivation, mitochondrial AIF bypasses the caspase/CAD cascade entirely. Even if caspases are chemically inhibited or genetically knocked out, AIF still translocates to the nucleus and causes chromatin condensation and DNA fragmentation. Specifically, AIF binds directly to DNA via its positively charged surface and then recruits caspase-independent partner proteins, primarily Cyclophilin A (CypA) and histone H2AX. Together, this AIF/CypA/H2AX complex acts as a functional endonuclease, causing large-scale DNA fragmentation into ∼50-kilobase fragments (). BCL-2 overexpression reduces mitochondrial AIF release but does not block its apoptogenic activity (Susin et al., 1999; Susin et al., 2000). The mitochondrial release of AIF is independent of cytochrome c but requires PARP1 (Yu et al., 2002) and induces a distinct form of RCD called parthanatos (see below).
As mentioned, BCL-2 family members are among the most important regulators of MOMP. According to their structure and function, BCL-2 family proteins can be divided into three groups: BH3-only proteins, multidomain pro-apoptotic effectors, and anti-apoptotic members (Kale et al., 2018). BH3-only proteins (BAD, BID, BCL-2 interacting killer - BIK, BCL-2 like 11 - BIM, BCL-2-modifying factor - BMF, activator of apoptosis harakiri - HRK, phorbol-12-myristate-13-acetate-induced protein 1 - NOXA, and p53 upregulated modulator of apoptosis - PUMA) are stress sensors that respond to cell injury by activating the effectors BAX, BAK, and BCL-2 related ovarian killer (BOK). BH3-only proteins permeabilize the MOM. As a result, cytochrome c and other intermembrane-space proteins can reach the cytosol. Anti-apoptotic proteins, such as BCL-2 and BCL-XL, block both BH3-only activators and multidomain effectors, thereby preventing MOMP and apoptosis (Kluck et al., 1997; Yang et al., 1997). BCL-2 family members were initially believed to be localized solely in mitochondria; however, they are now known to be dynamically distributed across various organelles, including the ER, Golgi apparatus, nucleus, and peroxisomes, where they regulate calcium homeostasis, cell-cycle progression, cell migration, and apoptosis (Lossi et al., 2009; Lossi et al., 2010; Popgeorgiev et al., 2018). As a result, their subcellular location is quite flexible and depends on the cellular environment.
In non-apoptotic cells, BAX constantly moves between the cytosol and the MOM. BAK, on the other hand, is primarily localized to mitochondria but can also return to the cytosol, a process known as retrotranslocation (; Edlich et al., 2011; Todt et al., 2015). Retrotranslocation, mostly mediated by BCL-XL, is an essential anti-apoptotic mechanism that maintains reduced mitochondrial levels of active BAX and BAK (Edlich et al., 2011; Garner et al., 2016). For this to be effective, the C-terminal helix of BCL-XL and the BAX BH3 domain must interact. This interaction removes BAX from the MOM. BH3-only activators such as BIM and BID prevent BCL-XL from acting during apoptosis. As a consequence, it prevents retrotranslocation, allowing BAX and BAK to accumulate, join together, and form pores in the mitochondria. BH3-mimetic drugs (such as Bcl-2 Inhibitor VI - ABT-737) facilitate apoptosis by inhibiting BCL-XL activity and enhancing mitochondrial BAX retention (Renault et al., 2015; Murad and Garcia-Saez, 2021).
BH3-only proteins are activated either transcriptionally (e.g., PUMA, BIM, NOXA) or post-translationally (e.g., BID) in response to compartment-specific stress signals (; Villunger et al., 2003; Elmore, 2007). When they come into contact with BAX or BAK, they alter their shape, expose the BH3 domain, favoring dimerization, and leading to the formation of higher-order oligomers (; ). Super-resolution imaging has shown that BAX/BAK oligomers make toroidal lipidic pores in MOM. In these pores, membrane lipids help shape the pore rather than just forming proteinaceous channels (Große et al., 2016; Cowan et al., 2020).
Not all BH3-only proteins directly activate BAX/BAK. Sensitizer BH3-only proteins (e.g., BAD, BMF, HRK) improve MOMP by selectively binding anti-apoptotic BCL-2 members, therefore freeing activator BH3-only proteins and effectors (Giam et al., 2008). BCL-2, BCL-XL, BCL-W, MCL-1, and BCL-2-related protein A1 (BCL-2A1) are pro-survival proteins that prevent MOMP by either directly sequestering BAX/BAK or enabling them to return to the cytosol (; Llambi et al., 2011; Czabotar et al., 2014; Lee et al., 2016). The differences in binding affinity between these interactions constitute a selective network that determines whether apoptosis occurs.
Pro-survival BCL-2 family members inhibit MOMP through two distinct ways that align with the apoptotic primed state of the cell (). In healthy, unprimed cells, BAX and BAK are largely inactive, and mitochondrial integrity does not require continuous anti-apoptotic restraint. In contrast, primed cells accumulate BH3-only activator proteins at anti-apoptotic BCL-2 homologs and become dependent on them for survival. Dependency on BCL-2 homologs may occur in two modes.
In mode 1, anti-apoptotic proteins, including BCL-2, BCL-XL, and MCL-1, prevent BH3-only proteins such as BID, BIM, and PUMA from exerting their pro-apoptotic functions. This association is quite unstable and can be disrupted by BH3-only sensitizer proteins (such as BAD and NOXA), which displace the activators, allowing BAX/BAK activation. In mode 2, which occurs when stress is high or persists for a long time, pro-survival proteins bind directly to active BAX and BAK, reducing the likelihood of MOMP. If unsuccessful, BAX/BAK can oligomerize, producing pores in the MOM. Inactive BAX and BAK help maintain mitochondrial homeostasis by promoting mitochondrial fusion in healthy cells. When activated, they alter mitochondrial function, leading to mitochondrial fragmentation (Kalkavan and Green, 2018). MCL-1 is a pro-survival member with a short half-life and is regulated at the transcriptional, translational, and post-translational levels, allowing apoptotic thresholds to be quickly adjusted. Caspases cleave MCL-1, generating a pro-apoptotic fragment and thereby rendering the execution phase irreversible (Michels et al., 2005). Genetic studies demonstrate that the intrinsic apoptotic machinery is broadly conserved across cell types, yet individual BCL-2 homologs fulfill non-redundant, tissue-specific survival functions. For example, BCL-2 is essential for lymphocyte survival, BCL-XL is required for erythropoiesis and neurogenesis, and BCL-W supports spermatogenesis (Madden Felicella and Jen, 2013). Remarkably, combined deletion of Bax, Bak1, and Bok makes cells strongly resistant to multiple apoptotic stimuli but causes perinatal lethality (; ; Ke et al., 2015).
In the nervous system, perturbation of the BCL-2 control has marked developmental and postnatal consequences, as reduced developmental neuronal apoptosis occurs in BCL-XL/BAX-deficient mice (Shindler et al., 1997), while reduced neuronal vulnerability to apoptosis is described in BCL-XL-overexpressing models (Parsadanian et al., 1998); compromised neuronal survival occurs in BCL-2-null mice (Michaelidis et al., 1996; Tanabe et al., 1997; Llambi et al., 2016), and sufficient MCL-1 levels are essential for cortical neurogenesis (Arbour et al., 2008). These results underscore that apoptotic regulation in vivo is highly complex and sustained by combinatorial interactions that are difficult to reproduce in conventional in vitro systems.
The conventional model asserts that BH3-only proteins are essential for effector activation; however, transformed cells deficient in BID, BIM, PUMA, and NOXA can still undergo apoptosis when anti-apoptotic BCL-2 proteins are counterbalanced, suggesting that BAX/BAK can self-activate under specific conditions (Chen et al., 2015). Moreover, BOK can trigger MOMP without the involvement of BAX/BAK or other BCL-2 family members (Einsele-Scholz et al., 2016; Llambi et al., 2016), but in vivo its physiological roles are primarily fulfilled by BAX and BAK (Ke et al., 2012).
Various molecular hypotheses have been put forward to elucidate the interactions among BH3-only proteins, anti-apoptotic proteins, and BAX/BAK (Shamas-Din et al., 2013). In the direct activation model, BH3 activators (truncated BID [tBID], BIM, PUMA) directly interact with BAX/BAK, while sensitizers shift them from anti-apoptotic proteins (; Kim et al., 2009). In the displacement model, BAX/BAK are always active but controlled by anti-apoptotic proteins. When BH3-only proteins dislocate them, apoptosis occurs (). In the embedded-together model, all interactions arise at the mitochondrial membrane, and the membrane environment regulates binding equilibria (Llambi et al., 2011). The integrated model combines the two previous ideas into Mode 1 (BH3 activator sequestration) and Mode 2 (BAX/BAK sequestration). The prevailing mode depends on the kind of cell and the level of stress. In the membrane (lipid)-mediated spontaneous activation model, clustered regularly interspaced short palindromic repeats (CRISPR)-engineered systems demonstrate that upon neutralization of anti-apoptotic proteins, BAX can spontaneously integrate into the MOM through helix 9. Additionally, the lipid composition of the membrane directly facilitates effector activation, while BH3-only proteins primarily inhibit pro-survival members.
After MOMP, the cytoplasmic release of cytochrome c and the second mitochondria-derived activator of caspase/direct inhibitor of apoptosis-binding protein with low pI (SMAC/DIABLO) from the mitochondrial intermembrane space allows the assembly of the apoptosome. Cytochrome c is typically engaged within intracristal compartments, and its mobilization is facilitated by cristae remodeling (Scorrano et al., 2002). This process entails the breakdown of optic atrophy 1 protein (OPA1) oligomers, which can be facilitated by zinc metallopeptidase protein (OMA1)-dependent OPA1 processing and dynamin-related protein 1 (DRP1)-mediated mitochondrial dynamics following BAX/BAK activation. In the cytosol, cytochrome c binds to APAF1, which then oligomerizes into the heptameric apoptosome. This recruits and activates proCASP9 (Li et al., 1997). After that, active CASP9 processes executioner caspases CASP3 and CASP7. Simultaneously, SMAC/DIABLO undergoes proteolytic maturation, exposing its IAP-binding motif and enabling it to neutralize IAPs, especially X-linked inhibitor of apoptosis protein (XIAP), thereby alleviating caspase inhibition (Verhagen et al., 2000; Eckelman and Salvesen, 2006). Although caspases are the principal executioners of apoptosis downstream of MOMP, they are not strictly required for cell death to occur. When post-mitochondrial caspase activity is inhibited, cellular demise is delayed rather than prevented, and caspase-independent cell death pathways are frequently engaged instead (Galluzzi et al., 2015).
It is also worth noting that MOMP need not be an all-or-nothing event. When permeabilization is confined to only a subset of mitochondria—a phenomenon termed minority MOMP—the resulting sublethal caspase activation is insufficient to kill the cell but can cause DNA damage and genomic instability, with potentially oncogenic consequences (Ichim et al., 2015). Furthermore, if the pro-apoptotic stimulus is transient, cells that have undergone partial caspase activation may recover through a process called anastasis, in which executioner caspase activity is reversibly engaged and subsequently extinguished (Zaitceva et al., 2021).
Beyond caspase activation, MOMP has direct effects on bioenergetics. The release of cytochrome c that accompanies MOMP progressively dissipates the mitochondrial transmembrane potential (Δψm), ultimately leading to the collapse of cellular energy metabolism (Nunnari and Suomalainen, 2012). This bioenergetic failure represents a key mechanism by which cells can die following MOMP in a caspase-independent manner.
In neurons, as in other cell types, the onset of MOMP represents a critical commitment step in intrinsic apoptosis (Tait and Green, 2010). However, the downstream execution phase is characterized by considerably higher activation thresholds and greater buffering capacity than in rapidly dividing non-transformed cells, such as proliferating progenitors or fibroblasts, reflecting the neuron’s pronounced resistance to caspase activation following cytochrome c release (Deshmukh and Johnson, 1998; Martinou and Youle, 2011) (Table 1). Multiple lines of evidence demonstrate that post-mitotic neurons exhibit limited apoptosome competence (Table 1), a phenomenon largely attributable to low APAF1 expression and high levels of endogenous caspase inhibitors (e.g., XIAP). Inhibitors of caspases, therefore, require that the proteases be activated only if a very high threshold is surpassed, thereby providing an important safeguard against unwarranted loss of non-dividing irreplaceable cells (Potts et al., 2003; Wright et al., 2004; Wright et al., 2007). Genetic deletion of XIAP reinstates cytochrome c–dependent caspase activation in mature neurons, indicating that the limitation of the apoptosome is not attributable to an inherent incapacity to form the complex, but rather to tonic caspase suppression (Potts et al., 2003). The release of SMAC/DIABLO after MOMP is crucial in neurons because it neutralizes XIAP, thereby allowing caspase activation (Table 1). Even with cytosolic cytochrome c, many differentiated neurons do not activate executioner caspases unless XIAP is also suppressed. MOMP, therefore, is required but not sufficient to trigger intrinsic apoptosis in neurons (Hollville et al., 2019). After MOMP, neuronal death frequently proceeds via caspase-independent mechanisms due to the post-mitochondrial brake. Loss of cytochrome c causes respiratory chain dysfunction, progressive dissipation of Δψm, impaired ATP production, defective mitochondrial protein import, and increased ROS generation. Given neurons’ extreme dependence on oxidative phosphorylation, these bioenergetic defects alone can drive irreversible degeneration even when caspase activity is minimal. As we will discuss in a subsequent section of this paper, this metabolic collapse is particularly relevant in axons and synaptic compartments.
In neurons, the bioenergetic aspect of MOMP is frequently more deadly than the proteolytic caspase cascade itself (Galluzzi et al., 2009). Thus, neurons are particularly vulnerable to minority MOMP because they live for long periods and have numerous mitochondria, given their very high energy consumption (Table 1). Sublethal caspase activation, resulting in DNA damage, signals for cell-cycle re-entry and synaptic dysfunction without causing rapid cell death, and can be a consequence of minority MOMP. This condition has been associated with neurodegeneration, wherein persistent subthreshold apoptotic signaling leads to neuronal dysfunction rather than immediate loss (Ichim et al., 2015).
In neurons, apoptosome competence is developmentally regulated. During embryonic and early postnatal development, neurons exhibit higher APAF1 levels and lower XIAP levels, enabling efficient cytochrome c–driven caspase activation for physiological developmental apoptosis. In mature neurons, APAF1 is transcriptionally inhibited, directing the system towards MOMP-mediated, caspase-limited degeneration. This arrangement enhances survival following transitory mitochondrial damage but predisposes to gradual, caspase-independent cell death under pathological conditions (Wright et al., 2004).
Anoikis (from the Greek for “homelessness”) is a particular form of intrinsic apoptosis triggered by loss of integrin-mediated adhesion to the extracellular matrix (ECM) or glial substrates. ECM detachment activates an intracellular path involving BIM and BMF, which trigger BAX/BAK-dependent MOMP and subsequent CASP3 activation (Puthalakath et al., 2001; Mailleux et al., 2007; Paoli et al., 2013; ). Anoikis is crucial during neuronal migration, axonal pathfinding, synaptic remodeling, neurodegeneration, and ECM degradation (László et al., 2020). In this case, caspase activation is often restrained, and degeneration can proceed via mitochondrial and calpain-dependent pathways.
Table 3 summarizes the main findings regarding the role of intrinsic apoptosis in central nervous system (CNS) pathologies, along with a few key mechanistic notes.
TABLE 3
| Cell type | Major diseases linked to intrinsic apoptosis | Key mechanistic notes | Selected references |
|---|---|---|---|
| Neurons | AD; PD; HD; ALS; ischemic stroke; TBI | BAX activation, cytochrome c release, CASP9/CASP3 activation in vulnerable neuronal populations; strong contribution of AIF in excitotoxic and ischemic paradigms | Hartmann et al. (2000),Viswanath et al. (2001),Galluzzi et al. (2018),Martin and Wong (2017),Culmsee et al. (2005) |
| Astrocytes | Ischemic stroke; SCI; HIV-associated neurocognitive disorder; glioblastoma therapy response | Mitochondrial apoptosis mainly occurs in severe injury or cytotoxic environments; relative resistance under chronic neurodegeneration | Giffard and Swanson (2005),Sun et al. (2016),Li et al. (2024) |
| Oligodendrocytes | MS; periventricular leukomalacia; SCI; ischemic white matter damage | BAX-dependent apoptosis, mitochondrial ROS sensitivity, and CASP3 activation in demyelinating lesions | Sozmen et al. (2009),Zhang et al. (2015), |
Involvement of intrinsic apoptosis in main CNS diseases.
2.1.2 Extrinsic pathway
Extrinsic apoptosis is a type of RCD that is initiated by signals from outside the cell (Sastry and Rao, 2000). It is carried out by some members of the tumor necrosis factor receptor superfamily (TNFRSF) characterized by an intracellular death domain (DD) and commonly referred to as death receptors. In the nervous system, it is particularly relevant in glial cells, which can promote neuroinflammation, immune-mediated neurotoxicity, and specific neurodegenerative contexts. In addition to death receptors, dependency receptors also can trigger extrinsic apoptosis when their specific ligands fall below a threshold (Wajant, 2002; Gibert and Mehlen, 2015).
TNFRSF comprises FS-7-associated surface antigen receptor (FasR), tumor necrosis factor receptor 1 (TNFR1), TNF-related apoptosis-inducing ligand receptor 1 (TRAILR1, or DR4) and 2 (TRAILR2, or DR5), tumor necrosis factor receptor superfamily 25 (TNFRSF25, or DR3) and 21 (TNFRSF21, or DR6), ectodysplasin A receptor (EDAR), and p75 neurotrophin receptor (p75NTR) (Guicciardi and Gores, 2009). These canonical death receptors have an intracellular DD of 80 amino acids that recruits adaptor proteins after ligand binding, receptor trimerization, and a conformational change in the cytoplasmic tail. FasR and TRAILs directly recruit FADD, whereas TNFR1 first recruits TRADD and then FADD (Wajant, 2002). FADD engagement leads to the assembly of the death-inducing signaling complex (DISC) and the activation of CASP8 and CASP10. CASP8 forms death-effector domain (DED)-mediated filaments, undergoes homodimerization and autoproteolytic maturation, and then directly activates CASP3, or cleaves BID and engages MOMP. Cellular FLICE inhibitory protein (c-FLIP) isoforms finely adjust the composition and activity of DISC. The stoichiometry of c-FLIP isoforms with CASP8 determines whether signaling is pro-apoptotic or pro-survival (Yeh et al., 2000). The transcription of CASP8 and FADD-like apoptosis regulator (CFLAR), which encodes c-FLIP, depends on NF-κB. Expression of c-FLIP is therefore a crucial checkpoint that connects inflammatory signals to resistance to apoptosis ().
Efficient apoptotic signaling necessitates higher-order receptor organization after S-palmitoylation (for FasR and TRAILRs), UDP-N-acetyl-alpha-d-galactosamine polypeptide N-acetylgalactosaminyltransferase 14 (GALNT14)-dependent (Seyrek et al., 2025) O-glycosylation (Matarrese et al., 2005; Toscano et al., 2007; Lichtenstein and Rabinovich, 2013), particularly during neurodegeneration (Lee et al., 2007; Lichtenstein and Rabinovich, 2013), localization in lipid rafts, and the formation of signaling protein oligomerization transduction structures (SPOTS) (Verbrugge et al., 2010). After the FasR/FS-7-associated surface antigen ligand (FasL) interaction, FADD initiates CASP8, which, in turn, initiates CASP3, which finally executes cell death (). Full activation of CASP8 requires that FasR is engulfed in receptosomes after internalization via clathrin/dynamin, followed by coupling to ezrin and actin (Marion et al., 2011).
In contrast, TRAIL receptors can signal apoptosis from the plasma membrane (Wajant, 2003). Ligand presentation is critical to the outcome of ligand-receptor binding, as membrane-bound FasL is pro-apoptotic, whereas soluble FasL is often pro-survival/immunomodulatory. In standard trophic deprivation experiments, blocking FasR and FasL reduces cell death in cultured pheochromocytoma cells 12 (PC12), cerebellar granule cells, and spinal motoneurons (; Le Niculescu et al., 1999; Raoul et al., 1999). FasL upregulation in neurons is a common early event in the apoptotic response to damage or stress (Raoul et al., 2000). Jun amino-terminal kinase (JNK) increases FasL expression in neurons, thereby inducing apoptotic death; in parallel, death can be the result of the inhibition of protein kinase B (PKB) that increases JNK (; Francois and Grimes, 1999; Le Niculescu et al., 1999; Martin-Villalba et al., 1999; ). However, FasR stimulation can lead to neuronal death even in the absence of FasL overexpression (Raoul et al., 1999).
TNFR1 has a death domain that can promote survival and inflammation by activating NF-κB and mitogen-activated protein kinases (MAPKs), or trigger apoptosis by interfering with DISC assembly (Wajant et al., 2003). The final result depends on several factors, including the ubiquitination status of RIPK1, the recruitment of linear ubiquitination assembly complex (LUBAC), and the activity of CASP8 (Douglas and Saleh, 2020). Tumor necrosis factor receptor 2 (TNFR2), in contrast, lacks a death domain. It enhances cell survival after binding to TRAF proteins and promoting NF-κB activation (Patel and Brewer, 2008). Specifically in the nervous system, the two receptors exhibit antagonistic functions during neurodegenerative processes in vivo, with TNFR1 aggravating and TNFR2 reducing neuronal cell loss (Fontaine et al., 2002; Ortí-Casañ et al., 2023).
In neurodegenerative conditions, TRAIL receptors exhibit different behaviors: TRAILR1 and TRAILR2 are proapoptotic; TNF-related apoptosis-inducing ligand receptor 3 (TRAILR3) and 4 (TRAILR4) are decoy receptors, i.e., they bind to specific ligands with high affinity but lack the internal domain required to transmit signals; and the soluble TRAIL receptor osteoprotegerin (OPG) can inhibit TRAIL-induced apoptosis (Emery et al., 1998; ). It is noteworthy that receptor heterodimerization further amplifies signaling events. TRAILR deficiency protects from amyloid β (Aβ) toxicity (Di Benedetto et al., 2022), and astrocyte TRAIL contributes to motor neuron death in amyotrophic lateral sclerosis (ALS) ().
TNFRSF25 (DR3) is another member of the TNFR superfamily that contains a death domain. It triggers apoptosis or NF-κB activation (Heyninck and Beyaert, 2001). In the CNS, it is upregulated under several different conditions, including binge alcohol exposure (Liu et al., 2021), facilitates Aβ-induced neuronal apoptosis (Guan et al., 2023), and is augmented by aging-related exosomes (Liu et al., 2025). These observations are consistent with the neuroprotective effect of TNFRSF25 knockdown (Guan et al., 2023).
Apoptosis during embryonic development, tissue modeling, and neuronal pruning may be promoted by developmental death receptors (TNFRSF21, EDAR, p75NTR). These receptors primarily transmit signals independently from the DISC pathways. TNFRSF21 (DR6) plays a role in axonal pruning and developmental connectivity through several mechanisms (). These comprise amyloid precursor protein (APP) binding and cleavage, leading to caspase-dependent axon self-destruction (Kamal et al., 2001). The receptor is also highly active in differentiated neurons, and its activity increases after injury (Xu et al., 2015). It has unique traits, including the ability to induce apoptosis independently of FADD/CASP8 and its interaction with BAX (Zeng et al., 2012). EDAR initiates a cellular pathway comprising ectodysplasin-A receptor-associated adapter protein (EDARADD), tumor necrosis factor receptor-associated factors (TRAFs), transforming growth factor β-activated kinase 1 (TAK1, or MAP3K7), IκB kinase (IKK), and NF-κB (Morlon et al., 2005). EDAR regulates ectodermal differentiation rather than apoptosis (Thomas et al., 2004). p75NTR shows context-dependent signaling: when it activates JNK, it promotes apoptosis (Harrington et al., 2002), whereas when it activates TRADD and NF-κB, it promotes survival (Yazidi-Belkoura et al., 2003). Proteolytic cleavage and the presence of its Trk coreceptors control the activity of p75NTR. In vivo effects of p75NTR include neuronal apoptosis (Barker, 1998; Barrett, 2000; Raoul et al., 2000; Miller and Kaplan, 2001), suppression of axonal growth, and synaptic regulation (Haase et al., 2008). Differential proteolytic cleavage affects p75NTR signaling in hippocampus and cerebellar granule cells (Vicario et al., 2015).
Dependence receptors (deleted in colorectal carcinoma - DCC, patched 1 protein - PTCH1, unc-5 netrin receptor B/D - UNC5B/UNC5D, neurotrophic receptor tyrosine kinase 3/high-affinity tyrosine kinase neurotrophin receptor C-NTRK3/TrkC) are named for their different activity in the presence or absence of ligand. When a ligand is present, these receptors promote survival and/or differentiation; in its absence, they trigger caspase-dependent apoptosis (Gibert and Mehlen, 2015). The mechanisms of action include CASP9 activation (Fombonne et al., 2012), engagement of p53-dependent pathways (Raveh et al., 2001), and MOMP (Ichim et al., 2013; Zhu et al., 2013). Broadly speaking, they function as tumor suppressors (Mehlen and Tauszig-Delamasure, 2014) and developmental sculpting molecules (Mehlen and Thibert, 2004).
2.2 Non-apoptotic RCD pathways and the concept of non-canonical RCD
There is some confusion in the literature regarding the use of the terms “non-apoptotic RCD” and “non-canonical RCD.” As apoptosis was the first form of RCD to be described, all subsequent modalities of RCD were generally defined as “non-apoptotic RCD” (Galluzzi et al., 2018). This definition encompasses, among others, necroptosis, ferroptosis, parthanatos, autophagy-dependent cell death (ADCD), pyroptosis, axon degeneration (Wallerian-like), and mitoptosis (Table 4). These forms of RCD are defined positively by their own distinct molecular machinery, not by their relationship to the apoptotic pathway. Therefore, non-apoptotic RCD is a broader, modality-based classification, simply meaning a form of RCD that is not apoptosis, regardless of whether the mechanism involved is canonical or non-canonical within its own category.
TABLE 4
| RCD modality | Dominant epigenetic regulators | Primary neuronal compartment(s) | Execution characteristics | Key feature | References |
|---|---|---|---|---|---|
| Necroptosis | DNA methylation; histone modifications regulating RIPK3/MLKL expression | Soma, proximal dendrites | Slow, energy-limited, often incomplete | Usually epigenetically silenced in neurons | Yang et al. (2017),Giallongo et al. (2022),Vecchio et al. (2025) |
| Ferroptosis | Chromatin accessibility at antioxidant and lipid metabolism genes | Synapses, axons, dendrites | Lipid peroxidation without nuclear collapse | Prototype of epigenetically primed degeneration | Rroji et al. (2021),Lan et al. (2023),Li et al. (2023) |
| Parthanatos | PARP1-driven chromatin remodeling; NAD+-dependent sirtuin activity | Nucleus–mitochondria axis | Metabolic catastrophe, AIF-mediated DNA damage | Self-amplifying epigenetic–metabolic loop | Qi et al. (2025), Lu et al. (2024), Fan et al. (2023), Yang et al. (2024) |
| ADCD | Histone methylation balance controls autophagy gene networks | Soma, organelles | Transcription-dependent, delayed | Failure of protective autophagy control | Liu et al. (2018),Mohseni et al. (2024) |
| Pyroptosis | Histone acetylation; chromatin priming of inflammasome genes | Primarily microglia; limited neuronal engagement | Cytokine release leading to neuronal lysis | Indirect neuronal toxicity | Lv et al. (2025), Zhou et al. (2019),Wu et al. (2022), Sun et al. (2019) |
| Axon degeneration (Wallerian-like) | Epigenetic regulation of NMNAT2/SARM1 expression | Axons | NAD+ depletion, cytoskeletal collapse | Fully compartment-autonomous death | Maor-Nof et al. (2016),Wang et al. (2023),Paglione et al. (2025) |
| Mitoptosis | Mitochondrial epigenetics; nuclear–mitochondrial crosstalk | Mitochondria | Selective organelle elimination | Organelle-level death without cell death | Zhu et al. (2014),Stoccoro and Coppedè (2021) |
Features of the main non-apoptotic forms of RCD in the nervous tissue.
The term “non-canonical” should be used in relation to a defined reference pathway. So non-canonical RCD is a relative term—it means regulated, but mechanistically divergent from whatever the canonical route is for that cell death modality. Non-canonical RCD, therefore, refers to a cell death modality that is still regulated and programmed, but deviates from its standard cellular pathway at one or more steps. The key conceptual difference between the two terms is that non-canonical RCD is a mechanistic descriptor—indicating that the death pathway deviates from an established sequence, but not indicating which RCD modality is involved. Non-apoptotic RCD is a modality descriptor—it indicates that the death is not due to apoptosis. Still, it does not indicate whether the mechanism within that modality is canonical. The two definitions, therefore, overlap incompletely. Necroptosis, for example, is non-apoptotic yet canonical within its own framework (Yu et al., 2021). A further complication is that some non-apoptotic RCD pathways share molecular components with apoptosis—for example, CASP3 cleaves gasdermin (GSDM) to initiate pyroptosis (Rogers et al., 2017), and CASP8 plays roles in both apoptosis and in regulating necroptosis (Fritsch et al., 2019)—blurring clean categorical boundaries.
We have very recently reviewed the main types of RCD and their epigenetic mechanisms in the nervous system (Merighi et al., 2026). Readers can consult this paper for a detailed synthesis of past and current research on this topic. Here, for clarity, we provide a concise integrative synthesis of this matter, highlighting the importance of epigenetic control as a unifying principle across the different types of RCD observed in neurons and glia (Tables 4, 5).
TABLE 5
| Cell type | Dominant RCD modalities | Key molecular drivers | Typical ultrastructural features | Functional consequence | Therapeutic sensitivity |
|---|---|---|---|---|---|
| Neurons | Apoptosis | Intrinsic pathway BAX/BAK, MOMP, CASP3, CASP7 | Cell shrinkage, chromatin condensation, nuclear fragmentation, and membrane blebbing | Irreversible circuit damage | Limited, caspase blockade is insufficient to stop RCD |
| Ferroptosis | GPX4 loss | Shrinking mitochondria, increased membrane density, reduction/loss of cristae, and outer membrane rupture | Ferroptosis inhibitors | ||
| Parthanatos | PARP-1, AIF | Shrunken and condensed nuclei, plasma membrane disintegration | PARP1 inhibition | ||
| Astrocytes | Apoptosis | CASP3, CASP8 | Loss of star-shaped morphology, membrane blebbing, nuclear condensation, and organelle alterations | Loss of metabolic and trophic support | Limited, caspase blockade is insufficient to stop RCD |
| Necroptosis | RIPK1/RIPK3, pMLKL | Organelle swelling, membrane rupture, and release of DAMPs | RIPK1 inhibitors | ||
| Pyroptosis | NLRP3 inflammasome, CASP1, GSDMD | Chromatin condensation and fragmentation; swelling, ballooning, and eventual membrane rupture | Inflammasome blockade | ||
| Oligodendrocytes | Apoptosis | CASP3, | Nuclear condensation; cytoplasmic swelling | Demyelination, conduction failure | Limited, caspase blockade is insufficient to stop RCD |
| Necroptosis | RIPK1/RIPK3 pMLKL | Organelle swelling, membrane rupture, and release of DAMPs | Necroptosis inhibition, anti-inflammatory strategies | ||
| Microglia | Pyroptosis | NLRP3, CASP1, GSDMD | Cell swelling, membrane pores, and rapid lysis | Amplified neuroinflammation | Inflammasome and GSDM inhibition |
| Apoptosis | Intrinsic pathway BAX/BAK, MOMP, CASP3, CASP7 | Cell shrinkage, cytoplasmic membrane blebbing, and nuclear fragmentation | Limited, caspase blockade is insufficient to stop RCD |
Summary of the occurrence and main features of different types of non-apoptotic RCD in CNS cells. For references, see the main text.
3 Comparative analysis of the neuronal execution phase in apoptotic and non-apoptotic RCD pathways
The execution phase is the point of no return in RCD, when molecular events that disrupt cellular integrity take over from upstream signaling and stress-sensing pathways. The initiation and licensing phases are highly context-dependent and epigenetically modulated. At the same time, execution depends on the activation of terminal effectors that directly damage cell membranes and organelles, primarily mitochondria (Misgeld and Schwarz, 2017), as well as the cytoskeletal architecture and nuclear integrity (Figure 1). In neurons, execution phases are often diminished, postponed, or spatially confined, indicative of energy limitations, post-mitotic conditions, and pronounced compartmentalization (Figure 1). Neuronal RCD execution does not map cleanly onto the canonical modalities defined in dividing cells (Hollville et al., 2019). Instead, it can be characterized along several independent axes that conventional classifications conflate: whether execution is proteolytic or non-proteolytic; whether it is membrane-centric or nuclear-centric; whether it unfolds rapidly or over extended timescales; and whether it affects the cell globally or in a spatially compartmentalized manner (e.g., restricted to the axon while the soma survives). In neurons, these dimensions combine in ways that cut across canonical boundaries—a death process may, for instance, be non-proteolytic and compartmentalized, or membrane-centric and delayed—reflecting the distinct structural and metabolic constraints of post-mitotic cells.
FIGURE 1
3.1 Apoptotic execution: caspase-centric but spatially modulated
The execution phase of apoptosis comprises a sequence of actions regulated by executioner caspases (Grinshpon et al., 2019), primarily CASP3 and 7 (Table 1). Activated effector caspases cleave numerous substrates, eventually leading to chromatin condensation, DNA fragmentation (), phosphatidylserine (PS) exposure (Segawa and Nagata, 2015), and the formation of apoptotic bodies (). CASP3 leads to DNA fragmentation by accelerating the proteolytic inactivation of caspase-activated DNase inhibitor (ICAD), thereby enabling caspase-activated DNase (CAD) to resume catalytic activity (Enari et al., 1998). The protease also regulates PS internalization and externalization. PS exposure at the cell membrane is achieved by activating phospholipid scramblases, which promote externalization, or by inactivating phospholipid flippases, which favor internalization. At least two distinct mechanisms exist by which cleaved (active) CASP3 induces PS exposure in response to apoptotic stimuli. Initially, CASP3 cleaves XK-related protein 8 (XKR8), which associates with basigin (BSG) or neuroplastin protein (NPTN) to form a phospholipid-scrambling complex that facilitates PS externalization. In the second instance, CASP3 inhibits the ATPase phospholipid-transporting activity of ATPase phospholipid transporter 11A (ATP11A) and 11C (ATP11C) (Segawa et al., 2014). Notably, PS exposure is not consistently correlated with intrinsic or extrinsic apoptosis, as it is a cell-type-specific phenomenon that may be associated with non-apoptotic cell death in necroptosis and efferocytosis (Fadeel et al., 1999; Shlomovitz et al., 2019).
Extrinsic apoptosis can occur in two modes. Certain cells (type I) undergo apoptosis independently of mitochondrial involvement, whilst others (type II) depend on mitochondria to initiate apoptosis (Ozören and El-Deiry, 2002; ). In neurons that are classified as type II cells, and where CASP3 and CASP7 are blocked by XIAP, extrinsic apoptosis necessitates the proteolytic cleavage of BID by CASP8 (Jost et al., 2009; Urresti et al., 2016). Notably, another IAP family member, survivin, has been shown to modulate the basal activity of CASP3 in cerebellar granule neurons cultivated ex vivo (Lossi et al., 2016). In neurons, complete apoptotic execution is relatively rare outside development (Lossi and Merighi, 2003). Several adaptations constrain caspase execution, including high IAP expression (Lossi et al., 2016), compartmental restriction of caspase activation (e.g., synapses and dendrites), and inefficient apoptosome assembly due to low Apaf1 levels in mature neurons. As a result, neurons frequently exhibit partial or sublethal caspase activity, sufficient for synaptic pruning or structural remodeling but insufficient for nuclear collapse (Li and Sheng, 2012; Györffy et al., 2018). Therefore, the execution phase of neuronal apoptosis is a graded process rather than an all-or-none event.
3.2 Necroptotic execution: MLKL-driven membrane catastrophe
Necroptosis is induced by ligand binding to TNF-family death-domain receptors, toll-like receptors 3 and 4 (TLR3/4), pattern-recognition receptors, or virus sensors, all of which converge on receptor interacting serine/threonine kinase 3 (RIPK3) activation via a shared receptor homotypic interaction motif (RHIM) domain (Grootjans et al., 2017). For TNF family receptors, the initiator is RIPK1; for toll-like receptors 3 and 4 (TLR3/4), the initiator is the RHIM-containing adaptor known as TIR-domain-containing adapter-inducing interferon-β (TRIF, or TICAM-1). In the case of the Z-DNA-binding protein ZBP1/DAI, the cytosolic viral sensor itself possesses an RHIM domain.
RIPK1 exists in two primary forms: a “closed conformation,” which is kinase-deficient and stimulates NF-κB and MAPK pathways, and an “open conformation,” which is kinase-active and triggers apoptosis and necroptosis. Via homotypic contact mediated by the RHIM domain, the active kinase form of RIPK1 recruits and activates RIPK3. Inhibition of RIPK3 initiates apoptosis through the ripoptosome, a signaling platform that typically cleaves RIPK3 (Gupta and Liu, 2021). The ripoptosome induces cell death via necroptosis or RIPK3-dependent apoptosis following phosphorylation of RIPK3 at S369 (Gupta and Liu, 2021). The ripoptosome is assembled during the G2 and M phases of the cell cycle, a significant finding given the correlation between apoptosis and neuronal cell proliferation (; Gionchiglia et al., 2021; Merighi et al., 2021). The mixed lineage kinase domain-like pseudokinase (MLKL) serves as the final executioner in necroptosis. MLKL is activated (phosphorylated) by RIPK3 and forms oligomers that move to the cell plasma membrane, producing holes that cause the cell to burst and release its contents (Grootjans et al., 2017), a process referred to as an internal cellular danger signal (DAMP) (Yu et al., 2021). Transgenic models (knockout, kinase-dead knock-in) and pharmacological inhibition suggest that RIPK1, RIPK3, or MLKL are involved in numerous inflammatory, degenerative, and infectious disorders. Necroptotic execution, in contrast to apoptosis, operates independently of proteolytic cascades and results in lytic cell death accompanied by the loss of intracellular contents (Vanden Berghe et al., 2010; Vandenabeele et al., 2010). The epigenetic inhibition of RIPK3 and MLKL is common in neurons, making full necroptotic execution infrequent. When initiated, neuronal necroptosis often remains incomplete due to energetic constraints, leading to dendritic swelling, mitochondrial dysfunction, and neuroinflammation without rapid cell lysis (Dawson and Dawson, 2017). Necroptotic execution in neurons is context-dependent and, in certain neurodegenerative conditions, may be delayed or manifest as protracted structural degeneration rather than rapid membrane rupture. Pathological examinations of Alzheimer’s disease (AD)-affected brains reveal the accumulation of phosphorylated RIPK1, RIPK3, and, predominantly, phosphorylated MLKL (pMLKL) within granulovacuolar degeneration (GVD) in neurons (Koper et al., 2022). In standard necroptosis, the assembly of the necrosome and the translocation of pMLKL to the plasma membrane result in cellular swelling and membrane rupture within hours. In AD neurons with GVD granules, necrosome components concentrate intracellularly, suggesting that membrane rupture and cell death occur with delayed or impaired execution relative to classical necroptosis. These observations have been construed as a variant or prolonged form of necroptosis in neurons. In cases of acute damage (such as ischemia/reperfusion), pRIPK1, pRIPK3, and pMLKL in brain tissue usually peak hours to days following the injury. This timeframe reflects the kinetics of induction rather than a mechanistically prolonged execution, highlighting that neuronal necroptosis occurs over extended durations compared to fast necroptosis in certain non-neural cells (Liao et al., 2020).
3.3 Ferroptotic execution: lipid peroxidation as the lethal event
Uncontrolled iron-dependent lipid peroxidation triggers ferroptosis, leading to severe membrane damage, particularly of polyunsaturated phospholipids. The critical executional event is the dysfunction of antioxidant mechanisms, particularly glutathione peroxidase 4 (GPX4), leading to the buildup of deleterious lipid hydroperoxides (Yang and Stockwell, 2016). The execution pathway proceeds through three basic steps: the iron-dependent Fenton reaction, lipid peroxidation of polyunsaturated fatty acids (PUFAs), and inhibition of the glutathione (GSH)/GPX4 interaction. The Fenton reaction is a chemical process in which ferrous iron and hydrogen peroxide react to generate hydroxyl radicals and ferric iron, both of which are highly reactive and lethal to cells (Dixon and Stockwell, 2014). GPX4 is the main defense against toxic hydroxyl radicals and ferrous iron. GSH acts as a cofactor in the reduction of toxic lipid peroxides into non-toxic lipid alcohols (Costa et al., 2023). If this mechanism does not work, either because the cystine/glutamate antiporter (system Xc−) is blocked or GPX4 is directly inhibited, ROS accumulate quickly. The system Xc− actually provides the cystine needed to synthesize GSH. Intracellular labile iron, often increased through transferrin receptor 1 (TfR1) uptake or reduced storage (ferritinophagy), promotes the conversion of hydrogen peroxide into harmful radicals through the Fenton reaction, hence triggering lipid peroxidation. The enzymes acyl-CoA synthetase long-chain family member 4 (ACSL4) and lysophosphatidylcholine acyltransferase 3 (LPCAT3) augment the membrane content of PUFAs, which are then oxidized by iron-dependent lipoxygenases (LOXs), causing direct damage to membrane integrity. Alongside GPX4, the ferroptosis suppressor protein 1 (FSP1) reduces oxidized coenzyme Q10 (ubiquinone) to its reduced form (ubiquinol), thereby providing a complementary antioxidant mechanism at the plasma membrane that inhibits lipid peroxidation.
The above-described pathway is universal, but neurons are uniquely susceptible to ferroptosis due to their iron-handling mechanisms, high PUFA content, and glutamatergic signaling. Neurons cannot access blood-transferrin-bound iron directly because of the blood-brain barrier (BBB), and thus have a distinctive iron uptake and storage mechanism (Kawabata, 2019). Consequently, neurons must synthesize their own transferrin (Tf) and use TfR1 to take up iron. Neurons also have a poorer ability to store iron in ferritin than glial cells do. Therefore, in nervous tissue, there is a higher percentage of free, redox-active iron (the labile iron pool), which directly catalyzes the Fenton reaction to generate ROS (Ou et al., 2022). Dopaminergic neurons in the substantia nigra (and others) have a specific mechanism of iron storage. These neurons synthesize neuromelanin, a neuron-specific kind of melanin that contains considerable amounts of iron (). Neuromelanin is protective against ferroptosis. However, in Parkinson’s disease (PD), iron-storing neuromelanin may degrade, releasing iron and inducing substantial oxidative stress and ferroptosis (Kaftan Öcal and Armagan, 2025). Neurons are also particularly vulnerable to glutamate-induced ferroptosis. Elevated extracellular glutamate levels, observed, e.g., in AD and PD, inhibit the function of the system Xc− transporter. As a consequence, cystine uptake is blocked, and GSH synthesis is halted, inactivating GPX4 (; ).
Oxytosis is a specialized form of neuronal ferroptosis, previously described as a calcium-dependent, glutamate-induced form of cell death, in which inhibition of system Xc− causes GSH depletion. Still, subsequent damage is primarily driven by ROS accumulation rather than by iron-mediated lipid peroxidation (Tan et al., 2001). The relationship between oxytosis and ferroptosis has been extensively investigated over the past decades (Tang and Kang, 2023). Oxytosis was originally described as a glutamate-induced, calcium-dependent form of neuronal death characterized by inhibition of the Xc− system, depletion of intracellular GSH, accumulation of ROS, and lipid oxidative damage (Tan et al., 2001). Following the identification of ferroptosis in 2012 (Dixon et al., 2012), it became evident that the two processes share key molecular features, including cystine deprivation, GSH depletion, impaired antioxidant defenses, and lethal lipid peroxidation. Subsequent studies demonstrated that oxytosis can be considered a neuronal manifestation of ferroptosis, although additional mechanisms, such as calcium influx and specific neuronal signaling pathways, may also contribute to the oxytotic phenotype. As a result, the concept of ferroptosis has largely subsumed the earlier notion of oxytosis and provided a broader framework for understanding oxidative cell death in both neurological and non-neurological disorders (Tan et al., 2023).
Unlike apoptosis and necroptosis, no caspases or pore-forming proteins are involved in ferroptosis; nuclear morphology is initially preserved; death progresses from membrane dysfunction outward, rather than from the nucleus. In neurons, ferroptotic execution is often compartmentalized, preferentially affecting synapses and axons, consistent with their high lipid content and local iron accumulation. Therefore, ferroptosis is considered a locally executed, metabolically driven death modality (Mattson and Arumugam, 2018).
3.4 Parthanatos: metabolic collapse leads to nuclear execution
Due to severe DNA damage, e.g., from oxidative stress, excitotoxicity, or ischemia, the threshold for PARP1 activation may be exceeded, triggering parthanatos. As a consequence, massive poly (ADP-ribose) (PAR) synthesis, NAD+ and ATP depletion, and the release and nuclear translocation of AIF occur (Wang et al., 2009; Fatokun et al., 2014). PAR polymer accumulation is the main death signal in parthanatos. PAR polymers are toxic to the cell; they initially accumulate in the nucleus, then translocate to the cytosol, and interact with mitochondrial proteins. AIF is the irreversible step in the execution commitment. It induces large-scale DNA fragmentation independently of caspases (Wang et al., 2009). As described in Section 2.1, AIF release engages CypA to drive large-scale DNA fragmentation independently of classical nuclease activity (). This produces fragments of ∼50 kb, unlike oligosomal nuclear laddering in apoptosis (Zhang et al., 2002). In parallel with AIF-mediated nuclear damage, the cell undergoes a bioenergetic collapse characterized by NAD+ and ATP depletion, glycolytic failure, and mitochondrial dysfunction. This metabolic catastrophe accelerates structural disintegration but is not sufficient on its own to execute parthanatos, as AIF nuclear translocation is required. Execution in parthanatos is transcription-independent, rapid once PARP1 activity exceeds a threshold, tightly coupled to chromatin architecture and DNA damage burden. In neurons, parthanatos is a metabolically catastrophic mode of execution, particularly relevant in excitotoxicity, ischemia, and aging, where DNA damage and oxidative stress converge. Neurons undergo parthanatos via a mechanism that, while sharing the core PARP1-dependent pathway with other cell types, is heavily influenced by the unique, high-energy, and excitotoxic environment of the nervous system. The neuronal process is characterized by specific triggers, intense glutamate excitotoxicity, and oxidative stress that drive rapid accumulation of PAR polymers and, often, a combination of parthanatos with other cell death forms, such as apoptosis or necrosis. Overstimulation of N-methyl-D-aspartate (NMDA) receptors, which permit calcium entry into the cell, is a common cause of neuronal parthanatos. The calcium influx stimulates nitric oxide synthase (nNOS), which produces nitric oxide (NO) and ROS, causing severe DNA damage. Parthanatos entails the translocation of AIF to the nucleus across all cell types; however, neurons frequently demonstrate a particular reliance on the mitochondrial-associated proteins BID and BCL-2 interacting protein 3 (BNIP3), or on calpain activation (Cheng et al., 2018), to facilitate AIF release, thereby distinguishing the mitochondrial damage process. Parthanatos is involved in PD, AD, ALS, and stroke (Yang et al., 2024). However, a very recent study demonstrated that PARP1 activity is essential for retinal photoreceptor survival in the human homologous RhoI255del mouse model of autosomal dominant retinitis pigmentosa, underscoring the importance of PARP1 for rod photoreceptor viability rather than death (Zhu et al., 2025). This observation remarks that parthanatos in neurons may be strongly context-dependent (Lee et al., 2024).
3.5 Pyroptotic execution: GSDM-mediated lysis
Pyroptosis execution relies on GSDM pore formation in the plasma membrane following inflammasome-driven CASP1 (canonical execution) or CASP4/5/11 (non-canonical execution) activation. This results in rapid cell swelling, lysis, and cytokine release.
The first step in canonical pyroptotic execution is the assembly of the inflammasome. Danger signals (pathogen-associated molecular patterns - PAMPs, and damage-associated molecular patterns - DAMPs) activate cytosolic sensors (e.g., NLRP3, NLR family CARD domain containing 4 - NLRC4, absent in melanoma 2 - AIM2), leading to apoptosis-associated speck-like protein containing a CARD (ASC) oligomerization, recruitment, and activation of CASP1 (). This initial step commits the cell to pyroptotic execution. Gasdermin D (GSDMD) cleavage represents the irreversible execution step. Active CASP1 cleaves GSDMD and releases its N-terminal fragment from autoinhibition (Shi et al., 2015). The N-terminal segment of GSDMD is then directly responsible for pore formation (Ding et al., 2016). It associates with acidic phospholipids (phosphatidylinositol phosphates, cardiolipin), oligomerizes within the plasma membrane, and generates 10–20 nm holes. Consequently, K+ efflux, Na+ influx, and water entry occur, resulting in cellular swelling and disruption of osmotic balance. Pores also allow the release of interleukin 1β (IL-1β) and interleukin-18 (IL-18) (Flores-Romero et al., 2020). In parallel, CASP1 cleaves pro-IL-1β and pro-IL-18, and mature cytokines exit via GSDMD pores. Cytokine release can precede the complete cell lysis. Membrane rupture amplifies inflammatory signaling. As pore density increases, there is a massive osmotic imbalance, plasma membrane rupture, and release of DAMPs, leading to strong inflammatory propagation.
In non-canonical pyroptosis, in response to cytosolic lipopolysaccharide (LPS), CASP4/5 (human) or CASP11 (mouse) directly binds LPS. Caspases then cleave GSDMD as described above. K+ efflux stimulates NLRP3 as a secondary consequence, thereby activating CASP1 and amplifying cytokine maturation (Downs et al., 2020).
Particular features of neuronal pyroptosis encompass the activation of distinct sensors, namely, AIM2 and NLR family pyrin domain containing 1 (NLRP1), as well as the participation of specific chemokine receptors, C-C chemokine receptor type 5 (CCR5) (Yan et al., 2021b) and C-X-C chemokine receptor type 4 (CXCR4) (Liu et al., 2023), which have been demonstrated to facilitate inflammasome assembly following stroke or hemorrhagic brain injury. Neurons infrequently experience pyroptosis owing to diminished GSDM expression and restricted inflammasome activity (Hao and Feng, 2023). The pyroptotic machinery in the CNS primarily operates in microglia, indirectly facilitating neuronal damage by releasing cytokines rather than directly lysing neurons (Friker et al., 2020). AD is linked to neuroinflammation, characterized by microglial activation driven by Aβ accumulation, and ASCs bind to and cross-seed extracellular Aβ. In microglia, the NLRP3 inflammasome can incorporate ASC released by a pyroptotic cell, and exposure to ASC-Aβ complexes enhances the proinflammatory response, resulting in pyroptotic cell death, the release of functional ASC, and the initiation of a self-perpetuating, detrimental cycle (Friker et al., 2020). The aggregation of ASC-Aβ fibrils also hinders microglial clearance of Aβ. Collectively, these data suggest a shift from acute to chronic Aβ-associated neuroinflammation driven by the formation of ASC-Aβ complexes.
3.6 ADCD: execution depending upon delayed transcription
In contrast to other RCDs, ADCD requires continuous autophagic flux, leading to excessive organelle destruction and metabolic collapse. Slow execution is dependent on chromatin accessibility and ongoing gene expression (Galluzzi et al., 2018). ADCD starts with a commitment phase of sustained autophagic activation. Several persistent cell stressors, e.g., growth factor deprivation, mechanistic target of rapamycin (mTOR) inhibition, ER stress, developmental remodeling signals, and certain neurodegenerative disorders, may lead to mechanistic target of rapamycin complex 1 (mTORC1) inhibition and Unc-51-like autophagy activating kinase 1 (ULK1) activation, thereby initiating phagophore formation (Mizushima and Komatsu, 2011). The phagophore then undergoes nucleation and expansion through the activation of the class III phosphatidylinositol-3 kinase (PI3KC3) complex and the autophagy-related (ATG) conjugation systems, which constitute the core execution machinery. The activation of the PI3KC3 complex (beclin 1, vacuolar protein sorting 34 - VPS34 - and 15 - VPS15, ATG14L) generates phosphatidylinositol 3-phosphate (PI3P) with recruitment of WD-repeat protein interacting with phosphoinositides (WIPI) proteins and nucleation of the isolation membrane (Mizushima and Komatsu, 2011). Microtubule-associated protein 1 light chain 3 (LC3) lipidation is essential for ADCD execution. In ADCD, the lethal step involves hyperactivation of autophagic flux, massive formation of autophagosomes, accelerated fusion with lysosomes, and bulk degradation of cytoplasmic components. Several mechanisms underlie the selective degradation of essential cellular components, including mitochondria (mitophagy beyond the viability threshold), anti-apoptotic proteins, and excessive turnover of the ER and ribosomes. The loss of organelles then leads to metabolic collapse, bioenergetic failure, and structural dismantling. Sustained autophagic flux can result in lysosomal overload and lysosomal membrane permeabilization (LMP), leading to the release of cathepsin and proteolytic damage.
In neurons, ADCD execution is rare and typically reflects a failure of adaptive autophagy control rather than the activation of a dedicated death machinery. In these cells, ADCD occurs through mechanisms that differ from those of other cell types, principally because of their post-mitotic characteristics, specific polarization (axons/dendrites), and dependence on autophagy for homeostasis. ADCD mechanisms in neurons are often geared toward eliminating damaged neurons when repair mechanisms (like mitophagy) fail, rather than the rapid, cleanup-oriented death seen in proliferating cells (Yang et al., 2008; Nixon and Yang, 2012). In neurodegenerative disorders such as AD, neurons display a distinctive pattern of increased autophagy failure. Unlike other cells that might die from simple starvation, neurons often suffer from lysosomal failure. Failure causes a massive buildup of undegraded autophagic vacuoles laden with Aβ, leading to neuronal cell-autonomous death, a form of death referred to as autophagy-lysosomal associated death (ALAD) (Nixon, 2024). In AD, neuronal ADCD is also often associated with a unique abortive attempt to re-enter the cell cycle, which initiates apoptosis but often proceeds via autophagy-dependent pathways (Verdaguer et al., 2002a; Verdaguer et al., 2002b; Guan et al., 2022). A specific subtype of ADCD known as autosis occurs in the neonatal rat brain after hypoxia-ischemia. This form is unique in that it depends not only on autophagy (ATG genes) but also on the Na+/K+-ATPase pump (Depierre et al., 2024).
3.7 Paraptosis: a cell death program independent from caspases requiring de novo protein synthesis
The NCCD has not officially categorized paraptosis as a separate RCD entity with specific molecular markers (Galluzzi et al., 2018); nonetheless, it is mechanistically replicable across several systems. The initiation phase of paraptosis encompasses sustained MAPK/extracellular signal-regulated kinase (ERK) signaling following activation of a signaling pathway involving growth factor receptors, rat sarcoma virus (Ras), rapidly accelerated fibrosarcoma (Raf), and MAPK/ERK kinase (MEK) (Sperandio et al., 2000; Sperandio et al., 2004). Unlike proliferative ERK signaling, persistent ERK activation leads to cell vacuolization and death (Sperandio et al., 2004). The possibility of blocking paraptosis with cycloheximide indicates that it requires de novo protein synthesis (Wang et al., 2012). The central execution feature of paraptosis is massive ER and or mitochondrial swelling. In ER-dominant paraptosis, which can be observed after protein kinase R-like ER kinase (PERK) activation, eukaryotic translation initiation factor 2A (eIF2α) phosphorylation, activating transcription factor 4 (ATF4) induction, or C/EBP homologous protein (CHOP) upregulation (Kunst et al., 2024), ER stress and UPR activation (Merighi and Lossi, 2022) occur. The disruption of proteostasis results from proteasome inhibition, accumulation of misfolded proteins, disturbed Ca2+ homeostasis, and ER dilation. Distended ER cisternae eventually give rise to large vacuoles (Sperandio et al., 2000). Mitochondrial swelling, cristae disorganization, and Δψm dissipation, as a late event, characterize mitochondria-dominant paraptosis. Swelling may result from ion dysregulation, ROS accumulation, or bioenergetic imbalance. Osmotic swelling of the cell is central to its execution (Kunst et al., 2024). Paraptosis in neurons exhibits a morphological outcome similar to that in other cell types, but the triggers and regulatory pathways can be distinctive. Paraptosis is the primary pathway of neuronal death following glutamate excitotoxicity or ischemic injury; it is primarily mediated by Ca2+ overload and ROS accumulation, and mature neurons have highly restricted apoptotic pathways compared to those of other cell types (Hollville et al., 2019).
3.8 Axonal and organelle-restricted execution programs
Diverse cellular and molecular modes of axon degeneration have been described. Axon retraction, axosome discharge, and local degeneration of axon branches are the three primary mechanisms by which developmental axon elimination occurs. In contrast, widespread degeneration (Wallerian degeneration) of the severed portion of the axon is the consequence of axotomy (Neukomm and Freeman, 2014). Axonal execution is mediated by sterile alpha and TIR motif-containing protein 1 (SARM1)-dependent NAD+ depletion, resulting in ATP collapse, calcium influx, and cytoskeletal disintegration. Axonal execution is independent of nuclear or somatic death pathways and totally autonomous (Gerdts et al., 2015; ). Organelle execution programs comprise mitoptosis, ER stress-induced apoptosis, and lysosomal/autophagic cell death (Skulachev, 2002). Mitoptosis consists of selective mitochondrial fragmentation and elimination (Tinari et al., 2007). While protective at low levels, excessive mitoptosis can precipitate energetic failure without immediate plasma membrane rupture (Youle and Narendra, 2011).
4 Morphological and ultrastructural correlates
Morphological analysis remains a keystone for identifying RCD in neurons (Lossi and Merighi, 1998; Lossi et al., 2002a; Lossi et al., 2004; Lossi et al., 2015), particularly given the frequent coexistence of multiple RCD pathways within neurons. Transmission electron microscopy (TEM) provides unparalleled resolution of subcellular alterations, but these must be interpreted within a molecular and temporal framework. Key parameters for a sound ultrastructural analysis include nuclear morphology (chromatin condensation, fragmentation, or dispersion), mitochondrial size and electron density, plasma membrane integrity, status of intracellular organelles (ER, lysosomes), and the presence or absence of cytoplasmic vacuolization. Importantly, no single ultrastructural feature is pathognomonic; rather, the identification of RCD modalities depends on constellations of features. The detection of initial chromatin margination, nuclear fragmentation, mitochondrial condensation, and preserved plasma membranes signifies apoptosis (Lossi et al., 2002b). Necroptosis and MPT-driven necrosis should be suspected when extensive organelle swelling, loss of membrane integrity, and cytoplasmic translucency are prevalent (Naganska and Matyja, 2001). Ferroptosis should be surmised when mitochondria exhibit shrinkage, increased membrane density, and diminished cristae in the absence of pronounced nuclear fragmentation (Qin et al., 2021). Paraptosis exhibits extensive cytoplasmic vacuolization originating from the ER and mitochondria, while the cell maintains a relatively intact nuclear structure (Schneider et al., 2004). Neural cells often exhibit hybrid or sequential morphologies, indicative of cross-talk between routes or temporal progression. For example, apoptotic signaling may transition into secondary necrosis, while ferroptotic lipid peroxidation can coexist with necroptotic membrane rupture. Fixation artifacts, post-mortem delay, and regional metabolic differences further complicate interpretation. Consequently, molecular markers and functional assays must complement ultrastructural analysis (Lossi et al., 2002a).
5 Compartmentalization of neuronal cell death modalities
Neurons are uniquely vulnerable yet remarkably resilient cells. Their post-mitotic state, extreme longevity, and polarized architecture impose biological constraints that fundamentally distinguish neuronal death from that of proliferating somatic cells. Classical models of RCD were derived mainly from non-neuronal systems and assume a relatively uniform, cell-wide execution of death programs. In neurons, however, death is frequently spatially restricted, temporally staged, and compartment-specific, with axons, dendrites, synapses, mitochondria, and even subnuclear domains capable of engaging autonomous degenerative programs. This compartmentalization is not merely a morphological curiosity; it represents a core organizing principle of neuronal vulnerability in development, injury, aging, and neurodegenerative disease (Figure 1). Neuronal death, therefore, emerges as a hierarchically organized process, in which local degeneration may precede, substitute for, or never culminate in somatic cell death (Figure 2).
FIGURE 2
5.1 Structural determinants of compartmentalized death in neurons
Both physical and molecular barriers enforce neuronal compartmentalization. Axons can be separated from the soma by distances exceeding a meter in humans and large animals, necessitating local control of metabolism, calcium buffering, redox balance, and proteostasis. Although dendrites travel much shorter distances, they have similar metabolic requirements, specifically in type I Golgi neurons. Axonal and synaptic compartments depend on localized protein synthesis and degradation mechanisms, region-specific calcium microdomains, mitochondrial transport and anchoring, and compartment-specific signaling scaffolds. These characteristics enable neurons to activate localized stress responses and apoptotic pathways without immediate nuclear participation or transcriptional reprogramming (; Misgeld and Schwarz, 2017). As a consequence, RCD effectors such as caspases, calpains, PARP1, and lipid peroxidation cascades can be activated in a sublethal, spatially restricted manner.
5.2 Axonal death as an autonomous compartmentalized program
As detailed in Section 3.8, axons possess a genetically encoded, NMNAT2/SARM1-dependent self-destruction program that is molecularly and functionally distinct from apoptosis (Gerdts et al., 2015; ). Significantly, axonal degeneration occurs independently of the soma, which may survive for extended periods. This autonomy is evident not only following physical trauma but also in chronic neurodegenerative disorders, such as ALS, peripheral neuropathies, and PD, where axonal pathology occurs before neuronal loss, a condition referred to as “dying-back” degeneration (; Salvadores et al., 2017; ). Axonal degeneration is the prototype of compartment-restricted necrotic-like death, driven by metabolic processes and independent of transcription, so reframing neuronal death as a modular rather than a unitary phenomenon.
5.3 Synaptic degeneration and sublethal caspase activation
Synapses are the most labile neuronal compartments and the earliest sites of pathology in many brain diseases. During development, synaptic pruning is mediated by complement signaling (C1q, C3) and microglial phagocytosis, as well as by localized activation of the apoptotic machinery, notably CASP3 (Mattson and Duan, 1999; Györffy et al., 2018), within dendritic spines and presynaptic terminals (Figure 3). Importantly, this caspase activity is spatially confined, low-level, and transient, and excluded from the nucleus. Consequently, canonical executioner caspases are reallocated toward structural remodeling instead of cellular destruction. In AD and its comorbidities, synaptic loss exhibits a stronger correlation with cognitive impairment than neuronal death. Aβ oligomers and tau pathology cause localized calcium dysregulation, mitochondrial impairment, and caspase activation at synapses, resulting in a synapse-specific degenerative death, known as synaptosis, which may not progress to somatic apoptosis (Selkoe, 2002; Mattson and Arumugam, 2018).
FIGURE 3
5.4 Dendritic compartmentalization of death pathways
Dendrites in general receive synaptic input and exhibit sharp sensitivity to calcium-dependent stress. Excessive glutamatergic stimulation can trigger local excitotoxic cascades, encompassing MPT, calpain activation, ROS production, and lipid peroxidation. These mechanisms may result in dendritic beading, retraction, and fragmentation without causing rapid neuronal death (Hasbani et al., 2001). Localized activation of CASP3 in dendrites has been detected in cerebellar slices using a FRET probe, demonstrating its responsiveness to diverse pro-apoptotic or pro-survival stimuli (Lossi et al., 2016). Other data indicate that ferroptosis-like pathways may contribute to dendritic degeneration associated with aging and disease, particularly in the context of compromised antioxidant defenses (Skouta et al., 2014; Stockwell, 2022).
5.5 Somatic and nuclear execution of neuronal death
When damage signals surpass compartmental containment, they converge on the soma and nucleus, activating transcription-dependent cell death pathways. These encompass intrinsic apoptosis, parthanatos, and PANoptosis (Malireddi et al., 2019; Li and Qu, 2025), an inflammatory form of RCD that integrates molecular features of pyroptosis, apoptosis, and necroptosis through the assembly of a PANoptosome complex, thereby coordinating multiple cell death pathways in response to infection, tissue injury, and inflammatory stimuli. The somatic compartment is particularly responsive to epigenetic status, chromatin accessibility, and DNA repair capability, which together establish the threshold for irreversible mortality (Dawson and Dawson, 2017; Mattson and Arumugam, 2018).
5.6 Mitochondrial and organelle-level compartmentalization
Mitochondria function as semi-autonomous centers of apoptosis within neurons. Localized mitochondrial impairment can initiate mitophagy, which facilitates survival; mitoptosis, characterized by selective mitochondrial fragmentation and removal; and localized ATP deficiency, resulting in axonal or synaptic degeneration. Mitochondrial malfunction activates global apoptotic or necrotic pathways only when it becomes pervasive. This hierarchical escalation highlights the significance of organelle-level quality control in maintaining neuronal survival (Youle and Narendra, 2011).
5.7 Aging, epigenetic drift, and compartmental integrity degradation
The aging process gradually undermines the systems that regulate cell death in a segregated manner. Decreased axonal transport, compromised mitophagy, altered calcium buffering, and epigenetic alterations lower the threshold for inter-compartmental signal transmission. Consequently, localized degenerative occurrences progressively engage global RCD pathways, transforming adaptive compartmental damage into permanent neuronal loss (López-Otín et al., 2013; Mattson and Arumugam, 2018). In neurodegenerative conditions, neuronal integrity deteriorates in a sequential process that commences with synapse failure, progresses to axonal degeneration, and culminates in somatic death. Aging is frequently linked to epigenetic drift (Teschendorff et al., 2013), a progressive, stochastic modification of DNA methylation patterns and other epigenetic markers that accumulates over an individual’s life. We recently examined the epigenetic processes governing the main types of RCD in the nervous system (Merighi et al., 2026).
6 Note on RCD in neurological diseases and therapeutic targeting
The role of RCD in neurological diseases has been the subject of numerous authoritative reviews over the last 10 years (Table 6). Here, we report some fundamental information about this issue and discuss only the key aspects. It is worth considering that distinct neurological conditions engage characteristic but overlapping RCD repertoires, shaped by injury kinetics, metabolic stress, and inflammatory context (Table 7).
TABLE 6
| Subject | Main topics and references |
|---|---|
| General | Role of different RCD forms in several neurodegenerative diseases, and potential therapeutic significance (Guo et al., 2024; Majeed et al., 2025); molecular mechanisms of RCD in different neurodegenerative diseases, pharmacological interventions (Moujalled et al., 2021); interactions of RCD and autophagy (Napoletano et al., 2019); cathepsin D downregulation in neurodegenerative diseases (Mijanovic et al., 2021); role of mitochondria (Dawson and Dawson, 2017) |
| AD | Molecular mechanisms and role in disease (Goel et al., 2022; Thal et al., 2024; Kumari et al., 2025); intervention of ferroptosis and therapeutic mechanisms (Lane et al., 2023; Moorthy et al., 2025; Fang et al., 2026); role of cuproptosis (Zheng et al., 2025) |
| PD | Role of apoptosis (Erekat, 2018; 2025) susceptibility of the nigrostriatal circuit to mitochondrial dysfunction and oxidative stress, involvement of different types of RCD, post-mortem findings in human material (Dionísio et al., 2021); kinases as druggable targets (Mansour et al., 2023); therapeutic strategies (Zhou et al., 2024; Wang et al., 2025); role of ferroptosis (Tu et al., 2025); role of HSP90 (Mansour et al., 2024); types of RCD (Memou et al., 2021); CRISPR editing ( |
| ALS | Molecular mechanisms and role in disease (Thal et al., 2024) |
| HRD | Molecular mechanisms and RCD (Yan et al., 2021a; |
| Apoptosis | Molecular mechanisms and role in disease (Vitale et al., 2023); molecular mechanisms and role in PD (Erekat, 2025) |
| Necroptosis | Role in seizure and epilepsy (Mohseni-Moghaddam et al., 2024); pathogenic mechanisms in neurodegenerative diseases (Kang et al., 2025); role in PD (Regoni et al., 2024; Erekat, 2025) |
| Ferroptosis | Molecular mechanisms and role in disease (Xie et al., 2016; |
| Cuproptosis | Molecular mechanisms and role in AD (Zheng et al., 2025) |
| Autophagy | Molecular mechanisms and role in PD (Erekat, 2022; Erekat, 2025) |
| Paraptosis | Molecular mechanisms and role in disease (Kunst et al., 2024) |
Reviews on RCD and neurodegeneration in the last 10 years (source PubMed).
TABLE 7
| Disease/Condition | Predominant RCD modes | Key mechanisms/Findings |
|---|---|---|
| Neurodevelopmental defects | Apoptosis, ferroptosis, paraptosis-like mechanisms | Dysregulated apoptosis (excessive neuronal death or inadequate physiological pruning) can lead to neurodevelopmental defects (Khazaei et al., 2023; Kim et al., 2026). Ferroptosis and paraptosis-like mechanisms are also implicated ( |
| Ischemic stroke/TBI—Ischemic core | Necroptosis, ferroptosis, MPT-mediated necrosis | Fast ATP depletion, calcium overload, and oxidative stress promote these death pathways in the ischemic core (Fei and Leng, 2026) |
| Ischemic stroke/TBI—Peri-infarct penumbra | Delayed apoptosis, parthanatos | Delayed RCDs predominate in the penumbra, limiting the available treatment window (Koehler et al., 2021) |
| Ischemic stroke/TBI—Glial response | Glial necroptosis, microglial pyroptosis | Exacerbates consequent inflammation and lesion diffusion (Li et al., 2025) |
| AD | Apoptosis, parthanatos, ferroptosis, and pyroptosis active at low levels (Ren et al., 2024) | Neuronal apoptosis leads to synaptic and neuronal degeneration (Kumari et al., 2023). Parthanatos is associated with Aβ-induced DNA damage and oxidative stress (Yang et al., 2024). Ferroptosis is a significant feature characterized by brain iron accumulation, lipid peroxidation, and GPX4 (Feng et al., 2024). Pyroptosis of astrocytes and microglia further exacerbates neuroinflammation (Zhang et al., 2024) |
| PD | Ferroptosis, mitochondria-centric death, apoptosis (late-stage) | Preferential sensitivity of dopaminergic neurons reflects convergence of mitochondrial dysfunction, oxidative stress, and compromised iron metabolism. Ultrastructural mitochondrial anomalies and susceptibility to lipid peroxidation inhibitors support a major ferroptotic/mitochondrial role (Gao et al., 2025). Apoptotic features manifest in advanced phases, indicating temporal stratification of RCD modes (Erekat, 2018) |
| ALS | Apoptosis, parthanatos, ferroptosis, necroptosis | Degenerating motor neurons exhibit apoptotic and parthanatotic features tied to DNA damage and excitotoxicity (Nógrádi et al., 2024). Ferroptosis facilitates selective motor neuron degeneration (Wang et al., 2022). Necroptosis is linked to oligodendrocyte and astrocyte pathology, suggesting non-cell-autonomous, glial-driven mechanisms are pivotal to progression (Pirooznia et al., 2014) |
| MS | Apoptosis, necroptosis, pyroptosis, ferroptosis | Oligodendrocytes die by apoptosis and necroptosis, with necroptosis contributing to the progression of inflammatory demyelination (Cudrici et al., 2006). Microglial pyroptosis intensifies lesion activity, while ferroptotic mechanisms may contribute to chronic lesion progression (Emamnejad et al., 2024) |
Regulated cell death (RCD) in neurological diseases.
Pathway redundancy, temporal dynamics, and cell-type selectivity further complicate therapeutic manipulation of RCD in the nervous system (Table 8). Remarkably, effective intervention relies more on aligning the treatment target with the predominant mode of death at a specific disease stage than on absolute pathway blocking.
TABLE 8
| Disease/Context | Therapeutic strategy |
|---|---|
| Ischemic stroke/TBI | Prompt inhibition of necroptosis (e.g., RIPK1 inhibitors) (Degterev et al., 2019) and ferroptosis (lipophilic antioxidants, iron chelators) (Duo et al., 2025) offers substantial neuroprotection in preclinical models when applied within a limited time frame. PARP1 inhibitors mitigate parthanatos in peri-infarct areas but become ineffective after energy collapse (Stoica et al., 2014; Xu et al., 2023; Han et al., 2024). Caspase inhibitors alone are inadequate because they fail to prevent rapid activation of lytic-regulated cell death pathways (Vandenabeele et al., 2006). |
| AD | Prolonged inhibition of apoptosis is neither practical nor advantageous ( |
| MS | Inhibition of necroptosis in oligodendrocytes (Ofengeim et al., 2015) and suppression of microglial pyroptosis (Feng et al., 2025) or ferroptosis (Van San et al., 2023) mitigate demyelination and inflammatory exacerbation. Broad immunosuppression alone fails to address intrinsic glial death mechanisms, underscoring the need for integrated immunomodulatory and RCD-targeted strategies. |
Therapeutic targeting of RCD pathways.
7 Conclusion
Reliable identification and targeting of RCD in neural tissues require multiparametric approaches integrating biochemical assays, imaging, ultrastructural analysis, and genetic manipulation. Significant barriers to developing effective strategies to combat RCD in the nervous system include compensatory activation of parallel death pathways, systemic toxicity of RCD inhibitors, and difficulty achieving cell-type–specific delivery. These challenges argue for combinatorial, temporally staged therapies rather than single-pathway blockade. Single-marker methods sometimes inaccurately categorize death modalities, especially in chronic disease models characterized by hybrid phenotypes. Principal future problems include delineating predominant RCD routes in vivo, determining whether partial activation of death programs assists adaptive roles, and incorporating cell death into systems-level models of neural network impairment.
Statements
Author contributions
LL: Conceptualization, Data curation, Supervision, Validation, Writing – original draft, Writing – review and editing, Funding acquisition, Investigation. MS: Writing – original draft, Writing – review and editing. CC: Writing – original draft, Writing – review and editing. AM: Writing – original draft, Writing – review and editing, Conceptualization, Data curation, Supervision, Validation.
Funding
The author(s) declared that financial support was received for this work and/or its publication. The original work described in this paper has been supported by local grants from the University of Turin (all authors) and a grant (2022.AI1358.U1558) from Fondazione CRT (LL).
Conflict of interest
The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
The authors LL, AM declared that they were an editorial board member of Frontiers at the time of submission. This had no impact on the peer review process and the final decision.
Generative AI statement
The author(s) declared that generative AI was not used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Glossary
- Δψm
mitochondrial transmembrane potential
- ACSL4
acyl-CoA synthetase long-chain family member 4
- AD
Alzheimer’s disease
- ADCD
autophagy-dependent cell death
- AIF
apoptosis-inducing factor
- AIM2
absent in melanoma 2
- ALS
amyotrophic lateral sclerosis
- Apaf1
apoptosis protease-activated factor 1
- APP
β-amyloid precursor protein
- ASC
apoptosis-associated speck-like protein containing a CARD
- ATF4
activating transcription factor 4
- ATG
autophagy-related
- ATP11A
ATPase phospholipid transporting 11A
- ATP11C
ATPase phospholipid transporting 11C
- Aβ
amyloid β
- BAD
Bcl-XL/Bcl-2-associated death promoter
- BAK
Bcl-2 homologous antagonist/killer
- BAX
Bcl-2-associated X-protein
- BBB
blood-brain barrier
- BCL-2
B-cell lymphoma 2
- BCL-W
BCL-2 like 2 (or BCL-2L2, KIAA0271, protein phosphatase 1 regulatory subnit 51, PPP1R51)
- BH
BCL2-homology
- BID
BH3-interacting domain death agonist
- BIK
BCL-2 interacting killer or NBK
- BIM
BCL-2L11 (or BOD, BCL-2 like 11, Bcl-2 like protein 11)
- BLC-XL
B-cell lymphoma-extra large (or BCL-2 like 1, BCL-2L1, Bcl-X, protein phosphatase 1 regulatory subunit 52, PPP1R52)
- BMF
BCL-2-modifying factor
- BNIP3
BCL-2 interacting protein 3
- BOK
BCL-2 related ovarian killer
- BSG
basigin
- CAD
caspase-activated DNase
- CARD
caspase recruitment domain
- CARD8
caspase recruitment domain family member 8
- CASP1
cysteinyl aspartate-specific protease 1 (or caspase 1, interleukin converting enzyme 1, ICE)
- CASP10
cysteinyl aspartate-specific protease 10 (or caspase 10)
- CASP3
cysteinyl aspartate-specific protease 3 (or caspase 3)
- CASP7
cysteinyl aspartate-specific protease 7 (or caspase 7)
- CASP8
cysteinyl aspartate-specific protease 8 (or caspase 8, FLICE, MASH, Mch5)
- ced-3
cell death abnormality gene 3
- ced-4
cell death abnormality gene 4
- ced-9
cell death abnormality gene 9
- CFLAR
CASP8 and FADD-like apoptosis regulator (or casper, C-FLIP)
- c-FLIP
cellular FLICE inhibitory protein
- CHOP
C/EBP homologous protein
- CRISPR
clustered regularly interspaced short palindromic repeats
- DAMPs
damage-associated molecular patterns
- DCC
deleted in colorectal carcinoma
- DISC
death-inducing signaling complex
- DRP1
dynamin-related protein 1
- ECM
extracellular matrix
- EDAR
ectodysplasin A receptor
- EDARADD
ectodysplasin-A receptor-associated adapter protein
- egl-1
egg-laying defective protein 1
- ER
endoplasmic reticulum
- ERK
extracellular signal-regulated kinase
- EZH2
zeste 2 polycomb repressive complex 2 subunit
- FADD
FAS-associated protein with death domain
- FAK
focal adhesion kinase
- FAS
FS-7-associated surface antigen
- FasL
FS-7-associated surface antigen ligand
- FasR
FS-7-associated surface antigen receptor (or CD95 or APO-1)
- FasR/TNf
FS-7-associated surface antigen receptor/tumor necrosis factor
- FDX1
ferredoxin 1
- FSP1
ferroptosis suppressor protein 1
- FTH1
ferritin heavy chain 1
- GALNT14
UDP-N-acetyl-alpha-d-galactosamine:polypeptide N-acetylgalactosaminyltransferase 14
- GCLC
glutamate-cysteine ligase catalytic subunit
- GDF15
growth/differentiation factor 15
- GIT1
G-protein-coupled receptor kinase-interacting protein 1
- GPX4
glutathione peroxidase 4
- GSDM
gasdermin
- GSDMD
gasdermin D
- GSDME
gasdermin E or DFNA5
- GSH
glutathione
- HMGB1
high mobility group box 1
- HMGCL
3-hydroxy-3-methylglutaryl-CoA lyase
- HMT
histone methyltransferase
- HRD
hereditary retinal degeneration
- HRK
activator of apoptosis harakiri (or HRK, DP5, harakiri, BCL2 interacting protein)
- HSPs
heat shock proteins
- IAP
inhibitors of apoptosis proteins
- ICAD
caspase-activated DNase inhibitor
- ICE
interleukin-1-converting enzyme
- IGF-1
insulin-like growth factor 1
- IGF-1R
insulin-like growth factor 1 receptor
- IL-18
interleukin-18
- IL-1β
interleukin 1β
- JNK
Jun amino-terminal kinase (or JNK-46 or JNK1or JNK1A2)
- LC3
microtubule-associated protein 1 light chain 3
- LPS
lipopolysaccharide
- LUBAC
linear ubiquitination assembly complex
- MAPK
mitogen-activated protein kinase
- MCL-1
myeloid cell leukaemia-1
- MLKL
mixed lineage kinase domain-like protein
- MND
motor neuron disease
- MOM
mitochondrial outer membrane
- MOMP
mitochondrial outer membrane permeabilization
- MPT
mitochondrial permeability transition
- mPTP
mitochondrial permeability transition pore
- MS
multiple sclerosis
- MTP
mitochondrial transition pore
- NF-Κb
nuclear factor kappa-light-chain-enhancer of activated B cells
- NLRP3
nucleotide-binding oligomerization domain, leucine-rich repeat, and pyrin domain 3
- NOXA
phorbol-12-myristate-13-acetate-induced protein 1
- NPTN
neuroplastin protein
- NTRK3
neurotrophic receptor tyrosine kinase 3
- OMA1
zinc metallopeptidase protein (or 2010001O09Rik, DAB1, MPRP-1, YKR087C, or ZMPpeptidase)
- OPA1
optic atrophy 1 protein
- p75NTR
p75 neurotrophin receptor
- PAR
poly (ADP-ribose)
- PARP1
Poly(ADP-Ribose) Polymerase 1 (or PARP)
- PC12
pheochromocytoma cell 12
- PCD
programmed cell death
- PD
Parkinson’s disease
- PI3K
phosphatidylinositol 3-kinase
- PKB
protein kinase B (or Akt)
- PS
phosphatidylserine
- PT
permeability transition
- PTCH1
patched 1 protein
- PUFA
polyunsaturated fatty acids
- PUMA
p53 upregulated modulator of apoptosis (or BC3, JFY-1, BCL-2 binding component 3)
- Ras
rat sarcoma virus
- RCD
regulated cell death
- RER
rough endoplasmic reticulum
- RIPK1
receptor-interacting protein kinase 1
- RIPK3
receptor-interacting protein kinase 3
- ROS
reactive oxygen species
- SMAC/DIABLO
second mitochondria-derived activator of caspase/direct inhibitor of apoptosis-binding protein with low PI
- SPOTS
signaling protein oligomerization transduction structures
- TAB2
transforming growth factor β-activated protein kinase 1 (TAK1) -binding protein (or KIAA0733, MAP3K7IP2)
- TAK1
mitogen-activated protein kinase kinase kinase 7 (or MAP3K7)
- TBI
traumatic brain injury
- tBID
truncated BID
- TEM
transmission electron microscopy
- TLR
toll-like receptor
- TNFR1
tumor necrosis factor receptor 1 (or TNFRSF1A)
- TNFRSF
tumor necrosis factor receptor superfamily
- TNFRSF21
tumor necrosis factor receptor superfamily21 (or DR6)
- TNFRSF25
tumor necrosis factor receptor superfamily 25 (or DR3)
- TRADD
TNFRSF1A associated via death domain
- TRAFs
tumor necrosis factor receptor-associated factors (or EBI6, MGC: 10353, TNF receptor)
- TRAIL
TNF-related apoptosis-inducing ligand (or APO2 ligand)
- TRAILR1
TNF-related apoptosis-inducing ligand receptor 1 (or TNFRSF10A, DR4)
- TRAILR2
TNF-related apoptosis-inducing ligand receptor 2 (or TNFRSF10B, DR5)
- TRAILR4
TNF-related apoptosis-inducing ligand receptor 4 (or TNFRSF10D)
- Trk
high-affinity tyrosine kinase neurotrophin receptor
- ULK1
Unc-51-like autophagy activating kinase 1
- UNC5B
unc-5 netrin receptor B (or p53RDL1, UNC5H2)
- UNC5D
unc-5 netrin receptor D (or KIAA1777, Unc5h4)
- XIAP
X-linked inhibitor of apoptosis protein (or API3, BIRC4, IAP-3, ILP1, MIHA, XLP2)
- XKR8
XK-related protein 8
- ZBP1
Z-DNA binding protein 1
References
1
AbdalkaderM.LampinenR.KanninenK. M.MalmT. M.LiddellJ. R. (2018). Targeting Nrf2 to suppress ferroptosis and mitochondrial dysfunction in neurodegeneration. Front. Neurosci.12, 466. 10.3389/fnins.2018.00466
2
AbramsJ. M.WhiteK.FesslerL. I.StellerH. (1993). Programmed cell death during Drosophila embryogenesis. Development117 (1), 29–43. 10.1242/dev.117.1.29
3
AdamsJ. M.CoryS. (2002). Apoptosomes: engines for caspase activation. Curr.Opin.Cell Biol.14, 715–720. 10.1016/s0955-0674(02)00381-2
4
AhfeldtT.OrdureauA.BellC.SarrafhaL.SunC.PiccinottiS.et al (2020). Pathogenic pathways in early-onset autosomal recessive Parkinson’s disease discovered using isogenic human dopaminergic neurons. Stem Cell Rep.14 (1), 75–90. 10.1016/j.stemcr.2019.12.005
5
AktasO.Schulze-TopphoffU.ZippF. (2007). The role of TRAIL/TRAIL receptors in central nervous system pathology. Front. Biosci.12, 2912–2921. 10.2741/2281
6
AlasiaS.MerighiA.LossiL. (2015). “Transfection techniques and combined immunocytochemistry in cell cultures and organotypic slices,” in Immunocytochemistry and Related Techniques. Editors MerighiA.LossiL. (New York: Springer), 329–355.
7
AlsopA. E.FennellS. C.BartoloR. C.TanI. K.DewsonG.KluckR. M. (2015). Dissociation of Bak α1 helix from the core and latch domains is required for apoptosis. Nat. Commun.6, 6841. 10.1038/ncomms7841
8
AndroulidakiA.LiuF.BebberC. M.KisisI.SakthiveluV.HunoldP.et al (2025). Lack of caspase 8 directs neuronal progenitor-like reprogramming and small cell lung cancer progression. Nat. Commun.16 (1), 11280. 10.1038/s41467-025-67142-4
9
AnnisR. P.SwahariV.NakamuraA.XieA. X.HammondS. M.DeshmukhM. (2016). Mature neurons dynamically restrict apoptosis via redundant premitochondrial brakes. FEBS J.283 (24), 4569–4582. 10.1111/febs.13944
10
ArasR.BarronA. M.PikeC. J. (2012). Caspase activation contributes to astrogliosis. Brain Res.1450, 102–115. 10.1016/j.brainres.2012.02.056
11
ArbourN.VanderluitJ. L.Le GrandJ. N.Jahani-AslA.RuzhynskyV. A.CheungE. C.et al (2008). Mcl-1 is a key regulator of apoptosis during CNS development and after DNA damage. J. Neurosci.28 (24), 6068–6078. 10.1523/JNEUROSCI.4940-07.2008
12
ArtyukhovaM. A.TyurinaY. Y.ChuC. T.ZharikovaT. M.BayırH.KaganV. E.et al (2019). Interrogating Parkinson’s disease associated redox targets: potential application of CRISPR editing. Free Radic. Biol. Med.144, 279–292. 10.1016/j.freeradbiomed.2019.06.007
13
ArurS.UcheU. E.RezaulK.FongM.ScrantonV.CowanA. E.et al (2003). Annexin I is an endogenous ligand that mediates apoptotic cell engulfment. Dev. Cell. 4 (4), 587–598. 10.1016/s1534-5807(03)00090-x
14
BachA. G.JordanB.WegenerN. A.RusnerC.KornhuberM.AbbasJ.et al (2012). Heroin spongiform leukoencephalopathy (HSLE). Clin. Neuroradiol.22 (4), 345–349. 10.1007/s00062-012-0173-y
15
BadingH. (2013). Nuclear calcium signalling in the regulation of brain function. Nat. Rev. Neurosci.14 (9), 593–608. 10.1038/nrn3531
16
BaiI.KeyserC.ZhangZ.RosoliaB.HwangJ. Y.ZukinR. S.et al (2024). Epigenetic regulation of autophagy in neuroinflammation and synaptic plasticity. Front. Immunol.15, 1322842. 10.3389/fimmu.2024.1322842
17
BameX.GilaniS. Z.KamenY.HillR. A. (2026). Dying oligodendrocytes persist without mitochondria. bioRxiv Preprint. 10.64898/2026.01.19.699752
18
BarkerP. A. (1998). p75NTR: a study in contrasts. Cell Death Differ.5 (5), 346–356. 10.1038/sj.cdd.4400375
19
BarnhartB. C.AlappatE. C.PeterM. E. (2003). The CD95 type I/type II model. Semin. Immunol.15 (3), 185–193. 10.1016/s1044-5323(03)00031-9
20
BarralS.BeltramoR.SalioC.AimarP.LossiL.MerighiA. (2014). Phosphorylation of histone H2AX in the mouse brain from development to senescence. Int.J Mol. Sci.15 (1), 1554–1573. 10.3390/ijms15011554
21
BarrettG. L. (2000). The p75 neurotrophin receptor and neuronal apoptosis. Prog. Neurobiol.61 (2), 205–229. 10.1016/s0301-0082(99)00056-8
22
BaudO.LiJ.ZhangY.NeveR. L.VolpeJ. J.RosenbergP. A. (2004). Nitric oxide-induced cell death in developing oligodendrocytes is associated with mitochondrial dysfunction and apoptosis-inducing factor translocation. Eur. J. Neurosci.20 (7), 1713–1726. 10.1111/j.1460-9568.2004.03616.x
23
BayırH.AnthonymuthuT. S.TyurinaY. Y.PatelS. J.AmoscatoA. A.LamadeA. M.et al (2020). Achieving life through death: redox biology of lipid peroxidation in ferroptosis. Cell Chem. Biol.27 (4), 387–408. 10.1016/j.chembiol.2020.03.014
24
BélangerM.AllamanI.MagistrettiP. J. (2011). Brain energy metabolism: focus on astrocyte-neuron metabolic cooperation. Cell Metab.14 (6), 724–738. 10.1016/j.cmet.2011.08.016
25
BenarrochE. E. (2018). Glutamatergic synaptic plasticity and dysfunction in Alzheimer disease: emerging mechanisms. Neurology91 (3), 125–132. 10.1212/wnl.0000000000005807
26
BenarrochE. (2023). What is the role of ferroptosis in neurodegeneration?Neurology101 (7), 312–319. 10.1212/wnl.0000000000207730
27
BerryD. L.BaehreckeE. H. (2007). Growth arrest and autophagy are required for salivary gland cell degradation in drosophila. Cell131 (6), 1137–1148. 10.1016/j.cell.2007.10.048
28
BianchiM.MerighiA. (1986). The relationship between lipofuscin and neuromelanin in some sites of the nervous system of the horse. Exp. Biol.46 (2), 89–99.
29
BilslandJ.HarperS. (2002). Caspases and neuroprotection. Curr. Opin. Investig. Drugs3 (12), 1745–1752.
30
BittnerT.FuhrmannM.BurgoldS.JungC. K. E.VolbrachtC.SteinerH.et al (2009). γ-Secretase inhibition reduces spine density in vivo via an amyloid precursor protein-dependent pathway. J. Neurosci.29 (33), 10405–10409. 10.1523/jneurosci.2288-09.2009
31
BlattN. B.GlickG. D. (2001). Signaling pathways and effector mechanisms pre-programmed cell death. Bioorg. Med. Chem.9, 1371–1384. 10.1016/s0968-0896(01)00041-4
32
BortnerC. D.OldenburgN. B.CidlowskiJ. A. (1995). The role of DNA fragmentation in apoptosis. Trends Cell Biol.5 (1), 21–26. 10.1016/s0962-8924(00)88932-1
33
BouilletP.MetcalfD.HuangD. C.TarlintonD. M.KayT. W.KöntgenF.et al (1999). Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science286 (5445), 1735–1738. 10.1126/science.286.5445.1735
34
BrattonS. B.SalvesenG. S. (2010). Regulation of the Apaf-1-caspase-9 apoptosome. J. Cell Sci.123 (19), 3209–3214. 10.1242/jcs.073643
35
BredesenD. E.RaoR. V.MehlenP. (2006). Cell death in the nervous system. Nature443 (7113), 796–802. 10.1038/nature05293
36
BrouwerR. E.HoefnagelJ.Borger van Der BurgB.JedemaI.ZwindermanK. H.StarrenburgI. C.et al (2001). Expression of co-stimulatory and adhesion molecules and chemokine or apoptosis receptors on acute myeloid leukaemia: high CD40 and CD11a expression correlates with poor prognosis. Br. J. Haematol.115 (2), 298–308. 10.1046/j.1365-2141.2001.03085.x
37
BrozP.DixitV. M. (2016). Inflammasomes: mechanism of assembly, regulation and signalling. Nat. Rev. Immunol.16 (7), 407–420. 10.1038/nri.2016.58
38
BrumattiG.SalmanidisM.EkertP. G. (2010). Crossing paths: interactions between the cell death machinery and growth factor survival signals. Cell Mol. Life Sci.67 (10), 1619–1630. 10.1007/s00018-010-0288-8
39
BrunetA.BonniA.ZigmondM. J.LinM. Z.JuoP.HuL. S.et al (1999). Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell96, 857–868. 10.1016/s0092-8674(00)80595-4
40
BrunetA.DattaS. R.GreenbergM. E. (2001). Transcription-dependent and -independent control of neuronal survival by the PI3K-Akt signaling pathway. Curr. Opin. Neurobiol.11 (3), 297–305. 10.1016/s0959-4388(00)00211-7
41
BuZ. Q.YuH. Y.WangJ.HeX.CuiY. R.FengJ. C.et al (2021). Emerging role of ferroptosis in the pathogenesis of ischemic stroke: a new therapeutic target?ASN Neuro13, 17590914211037505. 10.1177/17590914211037505
42
BuchheitC. L.WeigelK. J.SchaferZ. T. (2014). Cancer cell survival during detachment from the ECM: multiple barriers to tumour progression. Nat. Rev. Cancer14 (9), 632–641. 10.1038/nrc3789
43
BujaL. M. (2021). The cell theory and cellular pathology: discovery, refinements and applications fundamental to advances in biology and medicine. Exp. Mol. Pathol.121, 104660. 10.1016/j.yexmp.2021.104660
44
ButtsB. D.HoudeC.MehmetH. (2008). Maturation-dependent sensitivity of oligodendrocyte lineage cells to apoptosis: implications for normal development and disease. Cell Death Differ.15 (7), 1178–1186. 10.1038/cdd.2008.70
45
CampbellK. J.GrayD. H.AnsteeN.StrasserA.CoryS. (2012). Elevated Mcl-1 inhibits thymocyte apoptosis and alters thymic selection. Cell Death Differ.19 (12), 1962–1971. 10.1038/cdd.2012.84
46
CandéC.CecconiF.DessenP.KroemerG. (2002). Apoptosis-inducing factor (AIF):: key to the conserved caspase-independent pathways of cell death?J. Cell Sci.115 (24), 4727–4734. 10.1242/jcs.00210
47
CandéC.VahsenN.KourantiI.SchmittE.DaugasE.SpahrC.et al (2004). AIF and cyclophilin A cooperate in apoptosis-associated chromatinolysis. Oncogene23 (8), 1514–1521. 10.1038/sj.onc.1207279
48
Canedo-AnteloM.SerranoM. P.ManterolaA.RuizA.LlaveroF.MatoS.et al (2018). Inhibition of Casein kinase 2 protects oligodendrocytes from excitotoxicity by attenuating JNK/p53 signaling Cascade. Front. Mol. Neurosci.11, 333. 10.3389/fnmol.2018.00333
49
CaoY.YangJ. (2024). “Mechanisms of pathological axonal degeneration,” in Wiring the Nervous System: Mechanisms of Axonal and Dendritic Remodelling in Health and Disease. Editors TranT. S.YaronA. (Abingdon: River Publishers), 215–250.
50
CaprarielloA. V.BattC. E.ZippeI.Romito-DiGiacomoR. R.KarlM.MillerR. H. (2015). Apoptosis of oligodendrocytes during early development delays myelination and impairs subsequent responses to demyelination. J. Neurosci.35 (41), 14031–14041. 10.1523/jneurosci.1706-15.2015
51
CertoM.Del Gaizo MooreV.NishinoM.WeiG.KorsmeyerS.ArmstrongS. A.et al (2006). Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell9 (5), 351–365. 10.1016/j.ccr.2006.03.027
52
ChaiX.ZhaoS.FanL.ZhangW.LuX.ShaoH.et al (2016). Reelin and cofilin cooperate during the migration of cortical neurons: a quantitative morphological analysis. Development143 (6), 1029–1040. 10.1242/dev.134163
53
ChangD. W.XingZ.PanY.Algeciras-SchimnichA.BarnhartB. C.Yaish-OhadS.et al (2002). c-FLIP(L) is a dual function regulator for caspase-8 activation and CD95-mediated apoptosis. Embo J.21 (14), 3704–3714. 10.1093/emboj/cdf356
54
ChapmanT. W.KamenY.PiedraE. T.HillR. A. (2024). Oligodendrocyte maturation alters the cell death mechanisms that cause demyelination. J. Neurosci.44 (13), e1794232024. 10.1523/jneurosci.1794-23.2024
55
ChenH. C.KanaiM.Inoue-YamauchiA.TuH. C.HuangY.RenD.et al (2015). An interconnected hierarchical model of cell death regulation by the BCL-2 family. Nat. Cell Biol.17 (10), 1270–1281. 10.1038/ncb3236
56
ChenL.WillisS. N.WeiA.SmithB. J.FletcherJ. I.HindsM. G.et al (2005). Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol. Cell17 (3), 393–403. 10.1016/j.molcel.2004.12.030
57
ChenD.MiaoS.ChenX.WangZ.LinP.ZhangN.et al (2024). Regulated necrosis in glaucoma: focus on ferroptosis and pyroptosis. Mol. Neurobiol.61 (5), 2542–2555. 10.1007/s12035-023-03732-x
58
ChengE. H.SheikoT. V.FisherJ. K.CraigenW. J.KorsmeyerS. J. (2003). VDAC2 inhibits BAK activation and mitochondrial apoptosis. Science301 (5632), 513–517. 10.1126/science.1083995
59
ChengS. Y.WangS. C.LeiM.WangZ.XiongK. (2018). Regulatory role of calpain in neuronal death. Neural Regen. Res.13 (3), 556–562. 10.4103/1673-5374.228762
60
ChestnutB. A.ChangQ.PriceA.LesuisseC.WongM.MartinL. J. (2011). Epigenetic regulation of motor neuron cell death through DNA methylation. J. Neurosci.31 (46), 16619–16636. 10.1523/jneurosci.1639-11.2011
61
ClarkeP. G.ClarkeS. (1996). Nineteenth century research on naturally occurring cell death and related phenomena. Anat. Embryol. Berl.193 (2), 81–99. 10.1007/bf00214700
62
ColemanM. P.HökeA. (2020). Programmed axon degeneration: from mouse to mechanism to medicine. Nat. Rev. Neurosci.21 (4), 183–196. 10.1038/s41583-020-0269-3
63
ColemanM. P.PerryV. H. (2002). Axon pathology in neurological disease: a neglected therapeutic target. Trends Neurosci.25 (10), 532–537. 10.1016/s0166-2236(02)02255-5
64
ConradtB.HorvitzH. R. (1998). The C. elegans protein EGL-1 is required for programmed cell death and interacts with the Bcl-2-like protein CED-9. Cell93, 519–529. 10.1016/s0092-8674(00)81182-4
65
ConusS.RosséT.BornerC. (2000). Failure of Bcl-2 family members to interact with Apaf-1 in normal and apoptotic cells. Cell Death Differ.7 (10), 947–954. 10.1038/sj.cdd.4400729
66
CostaI.BarbosaD. J.BenfeitoS.SilvaV.ChavarriaD.BorgesF.et al (2023). Molecular mechanisms of ferroptosis and their involvement in brain diseases. Pharmacol. Ther.244, 108373. 10.1016/j.pharmthera.2023.108373
67
CowanA. D.SmithN. A.SandowJ. J.KappE. A.RustamY. H.MurphyJ. M.et al (2020). BAK core dimers bind lipids and can be bridged by them. Nat. Struct. Mol. Biol.27 (11), 1024–1031. 10.1038/s41594-020-0494-5
68
CudriciC.NiculescuT.NiculescuF.ShinM. L.RusH. (2006). Oligodendrocyte cell death in pathogenesis of multiple sclerosis: protection of oligodendrocytes from apoptosis by complement. J. Rehabil. Res. Dev.43 (1), 123–132. 10.1682/jrrd.2004.08.0111
69
CulmseeC.ZhuC.LandshamerS.BecattiniB.WagnerE.PellecchiaM.et al (2005). Apoptosis-inducing factor triggered by poly(ADP-ribose) polymerase and Bid mediates neuronal cell death after oxygen-glucose deprivation and focal cerebral ischemia. J. Neurosci.25 (44), 10262–10272. 10.1523/jneurosci.2818-05.2005
70
CzabotarP. E.LesseneG.StrasserA.AdamsJ. M. (2014). Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat. Rev. Mol. Cell Biol.15 (1), 49–63. 10.1038/nrm3722
71
DawsonT. M.DawsonV. L. (2017). Mitochondrial mechanisms of neuronal cell death: potential therapeutics. Annu. Rev. Pharmacol. Toxicol.57, 437–454. 10.1146/annurev-pharmtox-010716-105001
72
DegterevA.OfengeimD.YuanJ. (2019). Targeting RIPK1 for the treatment of human diseases. Proc. Natl. Acad. Sci. U.S.A.116 (20), 9714–9722. 10.1073/pnas.1901179116
73
DepierreP.GinetV.TruttmannA. C.PuyalJ. (2024). Neuronal autosis is Na+/K+-ATPase alpha 3-dependent and involved in hypoxic-ischemic neuronal death. Cell Death Dis.15 (5), 363. 10.1038/s41419-024-06750-2
74
DeshmukhM.JohnsonE. M.Jr. (1998). Evidence of a novel event during neuronal death: development of competence-to-die in response to cytoplasmic cytochrome c. Neuron21, 695–705. 10.1016/s0896-6273(00)80587-5
75
DeshmukhM.KuidaK.JohnsonE. M.Jr. (2000). Caspase inhibition extends the commitment to neuronal death beyond cytochrome c release to the point of mitochondrial depolarization. J. Cell Biol.150 (1), 131–144. 10.1083/jcb.150.1.131
76
Di BenedettoG.BurgalettoC.SerapideM. F.CaltabianoR.MunafòA.BellancaC. M.et al (2022). TRAIL-R deficient mice are protected from neurotoxic effects of Amyloid-β. Int. J. Mol. Sci.23 (19), 11625. 10.3390/ijms231911625
77
DingJ.WangK.LiuW.SheY.SunQ.ShiJ.et al (2016). Pore-forming activity and structural autoinhibition of the gasdermin family. Nature535 (7610), 111–116. 10.1038/nature18590
78
DionísioP. A.AmaralJ. D.RodriguesC. M. P. (2021). Oxidative stress and regulated cell death in Parkinson's disease. Ageing Res. Rev.67, 101263. 10.1016/j.arr.2021.101263
79
DixonS. J.StockwellB. R. (2014). The role of iron and reactive oxygen species in cell death. Nat. Chem. Biol.10 (1), 9–17. 10.1038/nchembio.1416
80
DixonS. J.LembergK. M.LamprechtM. R.SkoutaR.ZaitsevE. M.GleasonC. E.et al (2012). Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell149 (5), 1060–1072. 10.1016/j.cell.2012.03.042
81
DouglasT.SalehM. (2020). Cross-regulation between LUBAC and caspase-1 modulates cell death and inflammation. J. Biol. Chem.295 (16), 5216–5228. 10.1074/jbc.RA119.011622
82
DownsK. P.NguyenH.DorfleutnerA.StehlikC. (2020). An overview of the non-canonical inflammasome. Mol. Asp. Med.76, 100924. 10.1016/j.mam.2020.100924
83
DuoK.FengX.TianX.WangF.ZhaoY.YuJ.et al (2025). Ferroptosis inhibitors: mechanisms of action and therapeutic potential. Cell Mol. Life Sci.82 (1), 441. 10.1007/s00018-025-05958-5
84
EckelmanB. P.SalvesenG. S. (2006). The human anti-apoptotic proteins cIAP1 and cIAP2 bind but do not inhibit caspases. J. Biol. Chem.281 (6), 3254–3260. 10.1074/jbc.M510863200
85
EckhartL.BallaunC.HermannM.VandeBergJ. L.SiposW.UthmanA.et al (2008). Identification of novel Mammalian caspases reveals an important role of gene loss in shaping the human caspase repertoire. Mol. Biol. Evol.25 (5), 831–841. 10.1093/molbev/msn012
86
EckhartL.SachslehnerA. P.SteinbinderJ.FischerH. (2025). Caspase domain duplication during the evolution of Caspase-16. J. Mol. Evol.93 (3), 395–405. 10.1007/s00239-025-10252-w
87
EdlichF. (2018). BCL-2 proteins and apoptosis: recent insights and unknowns. Biochem. Biophys. Res. Commun.500 (1), 26–34. 10.1016/j.bbrc.2017.06.190
88
EdlichF.BanerjeeS.SuzukiM.ClelandM. M.ArnoultD.WangC.et al (2011). Bcl-x(L) retrotranslocates Bax from the mitochondria into the cytosol. Cell145 (1), 104–116. 10.1016/j.cell.2011.02.034
89
Einsele-ScholzS.MalmsheimerS.BertramK.StehleD.JohänningJ.ManzM.et al (2016). Bok is a genuine multi-BH-domain protein that triggers apoptosis in the absence of Bax and Bak. J. Cell Sci.129 (11), 2213–2223. 10.1242/jcs.181727
90
ElmoreS. (2007). Apoptosis: a review of programmed cell death. Toxicol. Pathol.35 (4), 495–516. 10.1080/01926230701320337
91
EmamnejadR.PagninM.PetratosS. (2024). The iron maiden: oligodendroglial metabolic dysfunction in multiple sclerosis and mitochondrial signaling. Neurosci. Biobehav. Rev.164, 105788. 10.1016/j.neubiorev.2024.105788
92
EmeryJ. G.McDonnellP.BurkeM. B.DeenK. C.LynS.SilvermanC.et al (1998). Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J. Biol. Chem.273 (23), 14363–14367. 10.1074/jbc.273.23.14363
93
EnariM.SakahiraH.YokoyamaH.OkawaK.IwamatsuA.NagataS. (1998). A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature391 (6662), 43–50. 10.1038/34112
94
ErekatN. S. (2018). “Apoptosis and its role in Parkinson’s disease,” in Parkinson’s Disease: Pathogenesis and Clinical Aspects. Editors StokerT. B.GreenlandJ. C. (Brisbane, AU: Codon Publications).
95
ErekatN. S. (2022). Autophagy and its association with genetic mutations in parkinson disease. Med. Sci. Monit.28, e938519. 10.12659/msm.938519
96
ErekatN. S. (2025). Programmed cell death and its therapeutic implications in Parkinson’s disease: a review of apoptosis, autophagy, ferroptosis, and necroptosis. Clin. Anat.39, 382–406. 10.1002/ca.70057
97
FadeelB.OorreniusS. (2005). Apoptosis: a basic biological phenomenon with wide-ranging implications in human disease. J. Intern. Med.258 (6), 479–517. 10.1111/j.1365-2796.2005.01570.x
98
FadeelB.GleissB.HögstrandK.ChandraJ.WiedmerT.SimsP. J.et al (1999). Phosphatidylserine exposure during apoptosis is a cell-type-specific event and does not correlate with plasma membrane phospholipid scramblase expression. Biochem. Biophys. Res. Commun.266 (2), 504–511. 10.1006/bbrc.1999.1820
99
FanJ.KangB. G.KamT.-I.BehenskyA. A.RinesJ.KangH. C.et al (2023). Histone H1.2 dependent translocation of poly (ADP-ribose) initiates parthanatos. bioRxiv Preprint. 10.1101/2023.06.18.545460
100
FangY.HanZ.YangS.ChenJ.LiR.ZhangZ.et al (2026). Ferroptosis and Alzheimer’s disease: unraveling the molecular mechanisms and therapeutic opportunities. Front. Cell Dev. Biol.14, 1758041. 10.3389/fcell.2026.1758041
101
FatokunA. A.DawsonV. L.DawsonT. M. (2014). Parthanatos: mitochondrial-linked mechanisms and therapeutic opportunities. Br. J. Pharmacol.171 (8), 2000–2016. 10.1111/bph.12416
102
FeiY.LengQ. (2026). Research progress of ferroptosis in cerebral infarction. Brain Behav.16 (1), e71192. 10.1002/brb3.71192
103
FengL.SunJ.XiaL.ShiQ.HouY.ZhangL.et al (2024). Ferroptosis mechanism and Alzheimer’s disease. Neural Regen. Res.19 (8), 1741–1750. 10.4103/1673-5374.389362
104
FengY.WangL.MaoZ.WangW. (2025). HMGB1 mediates microglia-astrocyte/neuron crosstalk and pyroptosis by the TLR4/NF-κB pathway in multiple sclerosis. Front. Biosci. (Landmark Ed.)30 (5), 37838. 10.31083/fbl37838
105
Fernandez-AlnemriT.LitwackG.AlnemriE. S. (1994). CPP32, a novel human apoptotic protein with homology to Caenorahbitis elegans cell death protein Ced-3 and Mammalian interleukin-1-beta-converting enzyme. J. Biol. Chem.269, 30761–30764.
106
FlemmingW. (1885). Über die bildung von richtungsfiguren in säugethiereiern beim untergang graaf'scher follikel. Arch. Anat. Entwickl1885, 221–244.
107
Flores-RomeroH.RosU.Garcia-SaezA. J. (2020). Pore formation in regulated cell death. EMBO J.39 (23), EMBJ2020105753. 10.15252/embj.2020105753
108
FombonneJ.BisseyP.-A.GuixC.SadoulR.ThibertC.MehlenP. (2012). Patched dependence receptor triggers apoptosis through ubiquitination of caspase-9. Proc. Natl. Acad. Sci.109 (26), 10510–10515. 10.1073/pnas.1200094109
109
FontaineV.Mohand-SaidS.HanoteauN.FuchsC.PfizenmaierK.EiselU. (2002). Neurodegenerative and neuroprotective effects of tumor necrosis factor (TNF) in retinal ischemia: opposite roles of TNF receptor 1 and TNF receptor 2. J. Neurosci.22 (7), Rc216. 10.1523/JNEUROSCI.22-07-j0001.2002
110
FrancoisF.GrimesM. L. (1999). Phosphorylation-dependent Akt cleavage in neural cell in vitro reconstitution of apoptosis. J. Neurochem.73, 1773–1776. 10.1046/j.1471-4159.1999.731773.x
111
FrickerM.TolkovskyA. M.BorutaiteV.ColemanM.BrownG. C. (2018). Neuronal cell death. Physiol. Rev.98 (2), 813–880. 10.1152/physrev.00011.2017
112
FrikerL. L.ScheiblichH.HochheiserI. V.BrinkschulteR.RiedelD.LatzE.et al (2020). β-Amyloid clustering around ASC fibrils boosts its toxicity in microglia. Cell Rep.30 (11), 3743–3754.e3746. 10.1016/j.celrep.2020.02.025
113
FritschM.GüntherS. D.SchwarzerR.AlbertM.-C.SchornF.WerthenbachJ. P.et al (2019). Caspase-8 is the molecular switch for apoptosis, necroptosis and pyroptosis. Nature575 (7784), 683–687. 10.1038/s41586-019-1770-6
114
GalluzziL.MaiuriM. C.VitaleI.ZischkaH.CastedoM.ZitvogelL.et al (2007). Cell death modalities: classification and pathophysiological implications. Cell Death Differ.14 (7), 1237–1243. 10.1038/sj.cdd.4402148
115
GalluzziL.BlomgrenK.KroemerG. (2009). Mitochondrial membrane permeabilization in neuronal injury. Nat. Rev. Neurosci.10 (7), 481–494. 10.1038/nrn2665
116
GalluzziL.Bravo-San PedroJ. M.VitaleI.AaronsonS. A.AbramsJ. M.AdamD.et al (2015). Essential versus accessory aspects of cell death: recommendations of the NCCD 2015. Cell Death Differ.22 (1), 58–73. 10.1038/cdd.2014.137
117
GalluzziL.VitaleI.AaronsonS. A.AbramsJ. M.AdamD.AgostinisP.et al (2018). Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death 2018. Cell Death Differ.25 (3), 486–541. 10.1038/s41418-017-0012-4
118
GaoX.-d.DingJ.-e.XieJ.-x.XuH.-m. (2025). Epigenetic regulation of iron metabolism and ferroptosis in Parkinson’s disease: identifying novel epigenetic targets. Acta Pharmacol. Sin.46 (8), 2075–2092. 10.1038/s41401-025-01499-6
119
García-CáceresC.Lechuga-SanchoA.ArgenteJ.FragoL. M.ChowenJ. A. (2008). Death of hypothalamic astrocytes in poorly controlled diabetic rats is associated with nuclear translocation of apoptosis inducing factor. J. Neuroendocrinol.20 (12), 1348–1360. 10.1111/j.1365-2826.2008.01795.x
120
GarnerT. P.ReynaD. E.PriyadarshiA.ChenH. C.LiS.WuY.et al (2016). An autoinhibited dimeric form of BAX regulates the BAX activation pathway. Mol. Cell63 (3), 485–497. 10.1016/j.molcel.2016.06.010
121
GerdtsJ.BraceE. J.SasakiY.DiAntonioA.MilbrandtJ. (2015). SARM1 activation triggers axon degeneration locally via NAD+ destruction. Science348 (6233), 453–457. 10.1126/science.1258366
122
GiallongoS.LonghitanoL.DenaroS.D'AprileS.TorrisiF.La SpinaE.et al (2022). The role of epigenetics in neuroinflammatory-driven diseases. Int. J. Mol. Sci.23 (23), 15218. 10.3390/ijms232315218
123
GiamM.HuangD. C. S.BouilletP. (2008). BH3-only proteins and their roles in programmed cell death. Oncogene27 (1), S128–S136. 10.1038/onc.2009.50
124
GibertB.MehlenP. (2015). Dependence receptors and cancer: addiction to trophic ligands. Cancer Res.75 (24), 5171–5175. 10.1158/0008-5472.Can-14-3652
125
GiffardR. G.SwansonR. A. (2005). Ischemia-induced programmed cell death in astrocytes. Glia50 (4), 299–306. 10.1002/glia.20167
126
GionchigliaN.GranatoA.MerighiA.LossiL. (2021). Association of caspase 3 activation and H2AX γ phosphorylation in the aging brain: studies on untreated and irradiated mice. Biomedicines9 (9), 1166. 10.3390/biomedicines9091166
127
GleasonA.BushA. I. (2021). Iron and ferroptosis as therapeutic targets in Alzheimer’s disease. Neurotherapeutics18 (1), 252–264. 10.1007/s13311-020-00954-y
128
GlücksmannP. D. (1951). Cell deaths in normal vertebrate ontogeny. Biol. Rev.26, 59–86. 10.1111/j.1469-185x.1951.tb00774.x
129
GoelP.ChakrabartiS.GoelK.BhutaniK.ChopraT.BaliS. (2022). Neuronal cell death mechanisms in Alzheimer’s disease: an insight. Front. Mol. Neurosci.15, 937133. 10.3389/fnmol.2022.937133
130
GräperL. (1919). Mechanische Betrachtungen und Versuche über Zellform und Zellgröße. Arch. für Entwicklungsmechanik Org.45 (3), 443–454. 10.1007/BF02554407
131
GrinshponR. D.ShresthaS.Titus-McQuillanJ.HamiltonP. T.SwartzP. D.ClarkA. C. (2019). Resurrection of ancestral effector caspases identifies novel networks for evolution of substrate specificity. Biochem. J.476 (22), 3475–3492. 10.1042/bcj20190625
132
GrootjansS.Vanden BergheT.VandenabeeleP. (2017). Initiation and execution mechanisms of necroptosis: an overview. Cell Death Differ.24 (7), 1184–1195. 10.1038/cdd.2017.65
133
GroßeL.WurmC. A.BrüserC.NeumannD.JansD. C.JakobsS. (2016). Bax assembles into large ring-like structures remodeling the mitochondrial outer membrane in apoptosis. EMBO J.35 (4), 402–413. 10.15252/embj.201592789
134
GuC.Casaccia-BonnefilP.SrinivasanA.ChaoM. V. (1999). Oligodendrocyte apoptosis mediated by caspase activation. J. Neurosci.19 (8), 3043–3049. 10.1523/jneurosci.19-08-03043.1999
135
GuanP. P.DingW. Y.WangP. (2022). Molecular mechanism of acetylsalicylic acid in improving learning and memory impairment in APP/PS1 transgenic mice by inhibiting the abnormal cell cycle re-entry of neurons. Front. Mol. Neurosci.15, 1006216. 10.3389/fnmol.2022.1006216
136
GuanP.ZhuD.WangP. (2023). Meloxicam inhibits apoptosis in neurons by deactivating tumor necrosis factor receptor superfamily member 25, leading to the decreased cleavage of DNA fragmentation factor subunit α in Alzheimer’s disease. Mol. Neurobiol.60 (1), 395–412. 10.1007/s12035-022-03091-z
137
GuerreroA. D.SchmitzI.ChenM.WangJ. (2012). Promotion of caspase activation by Caspase-9-mediated feedback amplification of mitochondrial damage. J. Clin. Cell Immunol.3 (3), 1000126. 10.4172/2155-9899.1000126
138
GuicciardiM. E.GoresG. J. (2009). Life and death by death receptors. Faseb J.23 (6), 1625–1637. 10.1096/fj.08-111005
139
GuoD.LiuZ.ZhouJ.KeC.LiD. (2024). Significance of programmed cell death pathways in neurodegenerative diseases. Int. J. Mol. Sci.25 (18), 9947. 10.3390/ijms25189947
140
GuptaK.LiuB. (2021). PLK1-mediated S369 phosphorylation of RIPK3 during G2 and M phases enables its ripoptosome incorporation and activity. iScience24 (4), 102320. 10.1016/j.isci.2021.102320
141
GürerG.Gursoy-OzdemirY.ErdemliE.CanA.DalkaraT. (2009). Astrocytes are more resistant to focal cerebral ischemia than neurons and die by a delayed necrosis. Brain Pathol.19 (4), 630–641. 10.1111/j.1750-3639.2008.00226.x
142
GyörffyB. A.KunJ.TörökG.BulyákiÉ.BorhegyiZ.GulyássyP.et al (2018). Local apoptotic-like mechanisms underlie complement-mediated synaptic pruning. Proc. Natl. Acad. Sci.115(24), 6303–6308. 10.1073/pnas.1722613115
143
HaanenC.VermesI. (1996). Apoptosis: programmed cell death in fetal development. Eur. J. Obstetrics Gynecol. Reproductive Biol.64 (1), 129–133. 10.1016/0301-2115(95)02261-9
144
HaaseG.PettmannB.RaoulC.HendersonC. E. (2008). Signaling by death receptors in the nervous system. Curr. Opin. Neurobiol.18 (3), 284–291. 10.1016/j.conb.2008.07.013
145
HanY.WangC.LiX.LiangG. (2024). PARP-1 dependent cell death pathway (Parthanatos) mediates early brain injury after subarachnoid hemorrhage. Eur. J. Pharmacol.978, 176765. 10.1016/j.ejphar.2024.176765
146
HaoW.FengC. (2023). Research progress on pyroptosis and its effect on the central nervous system. Neurobiol. Dis.188, 106333. 10.1016/j.nbd.2023.106333
147
HardwickJ. M.SoaneL. (2013). Multiple functions of BCL-2 family proteins. Cold Spring Harb. Perspect. Biol.5 (2), a008722. 10.1101/cshperspect.a008722
148
HarringtonA. W.KimJ. Y.YoonS. O. (2002). Activation of Rac GTPase by p75 is necessary for c-jun N-terminal kinase-mediated apoptosis. J. Neurosci.22 (1), 156–166. 10.1523/JNEUROSCI.22-01-00156.2002
149
HarrisonJ. F.HollensworthS. B.SpitzD. R.CopelandW. C.WilsonG. L.LeDouxS. P. (2005). Oxidative stress-induced apoptosis in neurons correlates with mitochondrial DNA base excision repair pathway imbalance. Nucleic Acids Res.33 (14), 4660–4671. 10.1093/nar/gki759
150
HartmannA.HunotS.MichelP. P.MurielM. P.VyasS.FaucheuxB. A.et al (2000). Caspase-3: a vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A.97 (6), 2875–2880. 10.1073/pnas.040556597
151
HasbaniM. J.SchliefM. L.FisherD. A.GoldbergM. P. (2001). Dendritic spines lost during glutamate receptor activation reemerge at original sites of synaptic contact. J. Neurosci.21 (7), 2393–2403. 10.1523/jneurosci.21-07-02393.2001
152
HengartnerM. O. (1997). “Cell death,” in Cold Spring Harbor. Editors elegans IIC.RiddleD.BlumenthalT.MeyerB.PriessJ. (NY: Cold Spring Harbor Laboratory Press), 383–415.
153
HengartnerM. O. (2001). Apoptosis: corralling the corpses. Cell104, 325–328. 10.1016/s0092-8674(01)00219-7
154
HengartnerM. O.HorvitzH. R. (1994). Activation of C. elegans cell death protein CED9 by an amino-acid substitution in a domain conserved in Bcl-2. Nature369, 318–320. 10.1038/369318a0
155
HengartnerM. O.EllisR. E.HorvitzH. R. (1992). C. elegans gene ced-9 protects cells from programmed cell death. Nature356, 494–499. 10.1038/356494a0
156
HeyninckK.BeyaertR. (2001). Crosstalk between NF-kappaB-activating and apoptosis-inducing proteins of the TNF-receptor complex. Mol. Cell Biol. Res. Commun.4 (5), 259–265. 10.1006/mcbr.2001.0295
157
HidalgoA.ffrench-ConstantC. (2003). The control of cell number during central nervous system development in flies and mice. Mech. Dev.120 (11), 1311–1325. 10.1016/j.mod.2003.06.004
158
HollvilleE.RomeroS. E.DeshmukhM. (2019). Apoptotic cell death regulation in neurons. FEBS J.286 (17), 3276–3298. 10.1111/febs.14970
159
HorvitzH. R. (1999). Genetic control of programmed cell death in the nematode Caenorhabditis elegans. Cancer Res.59 (7), 1701s–1706s.
160
HuY.BenedictM. A.WuD.InoharaN.NúñezG. (1998). Bcl-XL interacts with Apaf-1 and inhibits Apaf-1-dependent caspase-9 activation. Proc. Natl. Acad. Sci. U. S. A.95 (8), 4386–4391. 10.1073/pnas.95.8.4386
161
IchimG.GenevoisA.-L.MénardM.YuL.-Y.Coelho-AguiarJ. M.LlambiF.et al (2013). The dependence receptor TrkC triggers mitochondria-dependent apoptosis upon Cobra-1 recruitment. Mol. Cell51 (5), 632–646. 10.1016/j.molcel.2013.08.021
162
IchimG.LopezJ.AhmedS. U.MuthalaguN.GiampazoliasE.DelgadoM. E.et al (2015). Limited mitochondrial permeabilization causes DNA damage and genomic instability in the absence of cell death. Mol. Cell57 (5), 860–872. 10.1016/j.molcel.2015.01.018
163
JostP. J.GrabowS.GrayD.McKenzieM. D.NachburU.HuangD. C. S.et al (2009). XIAP discriminates between type I and type II FAS-induced apoptosis. Nature460 (7258), 1035–1039. 10.1038/nature08229
164
JulienO.WellsJ. A. (2017). Caspases and their substrates. Cell Death Differ.24, 1380–1389. 10.1038/cdd.2017.44
165
Kaftan ÖcalG.ArmaganG. (2025). Induction of ferroptotic cell death by neuromelanin pigments in dopaminergic cells. ACS Chem. Neurosci.16 (8), 1500–1510. 10.1021/acschemneuro.5c00029
166
KaleJ.OsterlundE. J.AndrewsD. W. (2018). BCL-2 family proteins: changing partners in the dance towards death. Cell Death Differ.25 (1), 65–80. 10.1038/cdd.2017.186
167
KalkavanH.GreenD. R. (2018). MOMP, cell suicide as a BCL-2 family business. Cell Death Differ.25 (1), 46–55. 10.1038/cdd.2017.179
168
KamalA.Almenar-QueraltA.LeBlancJ. F.RobertsE. A.GoldsteinL. S. (2001). Kinesin-mediated axonal transport of a membrane compartment containing beta-secretase and presenilin-1 requires APP. Nature414 (6864), 643–648. 10.1038/414643a
169
KangA.QiaoY.PanS.YanF.ChenH.BaiY. (2025). From RIPK1 to necroptosis: pathogenic mechanisms in neurodegenerative diseases. Neurochem. Res.50 (3), 194. 10.1007/s11064-025-04448-1
170
KawabataH. (2019). Transferrin and transferrin receptors update. Free Radic. Biol. Med.133, 46–54. 10.1016/j.freeradbiomed.2018.06.037
171
KeF.GrabowS.KellyG. L.LinA.O’ReillyL. A.StrasserA. (2015). Impact of the combined loss of BOK, BAX and BAK on the hematopoietic system is slightly more severe than compound loss of BAX and BAK. Cell Death Dis.6 (10), e1938. 10.1038/cddis.2015.304
172
KeF.VossA.KerrJ. B.O’ReillyL. A.TaiL.EcheverryN.et al (2012). BCL-2 family member BOK is widely expressed but its loss has only minimal impact in mice. Cell Death Differ.19 (6), 915–925. 10.1038/cdd.2011.210
173
KerntM.NeubauerA. S.EiblK. H.WolfA.UlbigM. W.KampikA.et al (2010). Minocycline is cytoprotective in human trabecular meshwork cells and optic nerve head astrocytes by increasing expression of XIAP, survivin, and Bcl-2. Clin. Ophthalmol.4, 591–604. 10.2147/opth.s11216
174
KerrJ. F. R. (1965). A histochemical study of hypertrophy and ischaemic injury of rat liver with special reference to changes in lysosomes. J. Pathol. Bacteriol.90 (2), 419–435. 10.1002/path.1700900210
175
KerrJ. F. R. (1969). An electron-microscope study of liver cell necrosis due to heliotrine. J. Pathol.97 (3), 557–562. 10.1002/path.1710970314
176
KerrJ. F. R. (1971). Shrinkage necrosis: a distinct mode of cellular death. J. Pathol.105 (1), 13–20. 10.1002/path.1711050103
177
KerrJ. F.WyllieA. H.CurrieA. R. (1972). Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br. J. Cancer26, 239–257. 10.1038/bjc.1972.33
178
KhazaeiS.ChenC. C. L.AndradeA. F.KabirN.AzarafsharP.MorcosS. M.et al (2023). Single substitution in H3.3G34 alters DNMT3A recruitment to cause progressive neurodegeneration. Cell186 (6), 1162–1178.e1120. 10.1016/j.cell.2023.02.023
179
KimJ. Y.AnM. J.KimJ.KimC. H.ParkY.ShinG. S.et al (2026). Aberrant maintenance of developmental transcription factor PAX6 promotes neuronal cell death via JNK3 signaling. Cell Death Dis.17 (1), 161. 10.1038/s41419-026-08417-6
180
KimH.TuH. C.RenD.TakeuchiO.JeffersJ. R.ZambettiG. P.et al (2009). Stepwise activation of BAX and BAK by tBID, BIM, and PUMA initiates mitochondrial apoptosis. Mol. Cell36 (3), 487–499. 10.1016/j.molcel.2009.09.030
181
KluckR. M.Bossy-WetzelE.GreenD. R.NewmeyerD. D. (1997). The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science275, 1132–1136. 10.1126/science.275.5303.1132
182
KoehlerR. C.DawsonV. L.DawsonT. M. (2021). Targeting parthanatos in ischemic stroke. Front. Neurol.12, 662034. 10.3389/fneur.2021.662034
183
KoenigU.EckhartL.TschachlerE. (2001). Evidence that caspase-13 is not a human but a bovine gene. Biochem. Biophys. Res. Commun.285 (5), 1150–1154. 10.1006/bbrc.2001.5315
184
KoleA. J.AnnisR. P.DeshmukhM. (2013). Mature neurons: equipped for survival. Cell Death Dis.4 (6), e689. 10.1038/cddis.2013.220
185
KoperM. J.ToméS. O.GaworK.BeletA.Van SchoorE.SchaeverbekeJ.et al (2022). LATE-NC aggravates GVD-mediated necroptosis in Alzheimer’s disease. Acta Neuropathol. Commun.10 (1), 128. 10.1186/s40478-022-01432-6
186
KumariS.DhapolaR.ReddyD. H. (2023). Apoptosis in Alzheimer’s disease: insight into the signaling pathways and therapeutic avenues. Apoptosis28 (7-8), 943–957. 10.1007/s10495-023-01848-y
187
KumariS.DhapolaR.SharmaP.PaidlewarM.VellingiriB.MedhiB.et al (2025). Unravelling neuronal death mechanisms: the role of cytokines and chemokines in immune imbalance in Alzheimer's disease progression. Ageing Res. Rev.112, 102883. 10.1016/j.arr.2025.102883
188
KunstC.TümenD.ErnstM.TewsH. C.MüllerM.GülowK. (2024). Paraptosis—A distinct pathway to cell death. Int. J. Mol. Sci.25 (21), 11478. 10.3390/ijms252111478
189
KutscherL. M.ShahamS. (2017). Non-apoptotic cell death in animal development. Cell Death Differ.24 (8), 1326–1336. 10.1038/cdd.2017.20
190
La RosaP.PetrilloS.FiorenzaM. T.BertiniE. S.PiemonteF. (2020). Ferroptosis in Friedreich’s Ataxia: a metal-induced neurodegenerative disease. Biomolecules10 (11), 1551. 10.3390/biom10111551
191
LanT.SunT. T.WeiC.ChengT.YangF.ZhangJ.-N.et al (2023). Epigenetic regulation of ferroptosis in central nervous system diseases. Mol. Neurobiol.60 (7), 3584–3599. 10.1007/s12035-023-03267-1
192
LaneD. J. R.AlvesF.AytonS. J.BushA. I. (2023). Striking a NRF2: the rusty and rancid vulnerabilities toward ferroptosis in Alzheimer's disease. Antioxid. Redox Signal39 (1-3), 141–161. 10.1089/ars.2023.0318
193
LászlóZ. I.LeleZ.ZöldiM.MiczánV.MógorF.SimonG. M.et al (2020). ABHD4-dependent developmental anoikis safeguards the embryonic brain. Nat. Commun.11 (1), 4363. 10.1038/s41467-020-18175-4
194
Le NiculescuH.BonfocoE.KasuyaY.ClaretF. X.GreenD. R.KarinM. (1999). Withdrawal of survival factors results in activation of the JNK pathway in neuronal cells leading to Fas ligand induction and cell death. Mol. Cell Biol.19, 751–763. 10.1128/mcb.19.1.751
195
LeeS.-U.GrigorianA.PawlingJ.ChenI. J.GaoG.MozaffarT.et al (2007). N-Glycan processing deficiency promotes spontaneous inflammatory demyelination and neurodegeneration. J. Biol. Chem.282 (46), 33725–33734. 10.1074/jbc.M704839200
196
LeeE.KooY.NgA.WeiY.Luby-PhelpsK.JuraszekA.et al (2014). Autophagy is essential for cardiac morphogenesis during vertebrate development. Autophagy10 (4), 572–587. 10.4161/auto.27649
197
LeeE. F.GrabowS.ChappazS.DewsonG.HockingsC.KluckR. M.et al (2016). Physiological restraint of Bak by Bcl-xL is essential for cell survival. Genes Dev.30 (10), 1240–1250. 10.1101/gad.279414.116
198
LeeM. H.UmK. H.LeeS. W.SunY. J.GuD. H.JoY. O.et al (2024). Bi-directional regulation of AIMP2 and its splice variant on PARP-1-dependent neuronal cell death; therapeutic implication for Parkinson's disease. Acta Neuropathol. Commun.12 (1), 5. 10.1186/s40478-023-01697-5
199
LemaireC.AndréauK.SouvannavongV.AdamA. (1998). Inhibition of caspase activity induces a switch from apoptosis to necrosis. FEBS Lett.425 (2), 266–270. 10.1016/S0014-5793(98)00252-X
200
LiJ. Y.QuY. (2025). PANoptosis in neurological disorders: mechanisms, implications, and therapeutic potential. Front. Immunol.16, 1579360. 10.3389/fimmu.2025.1579360
201
LiZ.ShengM. (2012). Caspases in synaptic plasticity. Mol. Brain5, 15. 10.1186/1756-6606-5-15
202
LiP.NijhawanD.BudihardjoI.SrinivasulaS. M.AhmadM.AlnemriE. S.et al (1997). Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell91, 479–489. 10.1016/s0092-8674(00)80434-1
203
LiH.ZhuH.XuC. J.YuanJ. (1998). Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell94, 491–501. 10.1016/s0092-8674(00)81590-1
204
LiY.ZhouM.HuQ.BaiX. C.HuangW.ScheresS. H.et al (2017). Mechanistic insights into caspase-9 activation by the structure of the apoptosome holoenzyme. Proc. Natl. Acad. Sci. U. S. A.114 (7), 1542–1547. 10.1073/pnas.1620626114
205
LiW.LiangL.LiuS.YiH.ZhouY. (2023). FSP1: a key regulator of ferroptosis. Trends Mol. Med.29 (9), 753–764. 10.1016/j.molmed.2023.05.013
206
LiX.XieZ.ZhouQ.TanX.MengW.PangY.et al (2024). TGN-020 alleviate inflammation and apoptosis after cerebral ischemia-reperfusion injury in mice through glymphatic and ERK1/2 signaling pathway. Mol. Neurobiol.61 (2), 1175–1186. 10.1007/s12035-023-03636-w
207
LiX.WeiY.SheY.LongW.ZhouS.ShiM.et al (2025). Targeting glial cell pyroptosis and neuroinflammation in post-stroke depression: from molecular mechanisms to therapeutic strategies. Front. Immunol.16, 1677221. 10.3389/fimmu.2025.1677221
208
LiangH.FesikS. W. (1997). Three-dimensional structures of proteins involved in programmed cell death. J. Mol. Biol.274, 291–302. 10.1006/jmbi.1997.1415
209
LiaoS.ApaijaiN.ChattipakornN.ChattipakornS. C. (2020). The possible roles of necroptosis during cerebral ischemia and ischemia/reperfusion injury. Archives Biochem. Biophys.695, 108629. 10.1016/j.abb.2020.108629
210
LichtensteinR. G.RabinovichG. A. (2013). Glycobiology of cell death: when glycans and lectins govern cell fate. Cell Death Differ.20 (8), 976–986. 10.1038/cdd.2013.50
211
LiuQ. A.HengartnerM. O. (1999). The molecular mechanism of programmed cell death in C. elegans. Ann. N. Y. Acad. Sci.887, 92–104. 10.1111/j.1749-6632.1999.tb07925.x
212
LiuX.KimC. N.YangJ.JemmersonR.WangX. (1996). Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell86, 147–157. 10.1016/s0092-8674(00)80085-9
213
LiuX.ChenN.WangX.HeY.ChenX.HuangY.et al (2006). Apoptosis and proliferation markers in diffusely infiltrating astrocytomas: profiling of 17 molecules. J. Neuropathol. Exp. Neurol.65 (9), 905–913. 10.1097/01.jnen.0000235857.79502.c3
214
LiuC.FuH.LiuX.LeiQ.ZhangY.SheX.et al (2018). LINC00470 coordinates the epigenetic regulation of ELFN2 to distract GBM cell autophagy. Mol. Ther.26 (9), 2267–2281. 10.1016/j.ymthe.2018.06.019
215
LiuW.VetrenoR. P.CrewsF. T. (2021). Hippocampal TNF-death receptors, caspase cell death cascades, and IL-8 in alcohol use disorder. Mol. Psychiatry26 (6), 2254–2262. 10.1038/s41380-020-0698-4
216
LiuC.YaoK.TianQ.GuoY.WangG.HeP.et al (2023). CXCR4-BTK axis mediate pyroptosis and lipid peroxidation in early brain injury after subarachnoid hemorrhage via NLRP3 inflammasome and NF-κB pathway. Redox Biol.68, 102960. 10.1016/j.redox.2023.102960
217
LiuY.LiuS.YanB.YinZ.LiaoP.WangY.et al (2025). Brain-derived exosomes from aged mice accelerate cognitive decline in repeated mild traumatic brain injury by activating neuronal Tnfrsf25. Exp. Gerontol.211, 112931. 10.1016/j.exger.2025.112931
218
LlambiF.MoldoveanuT.TaitS. W.Bouchier-HayesL.TemirovJ.McCormickL. L.et al (2011). A unified model of Mammalian BCL-2 protein family interactions at the mitochondria. Mol. Cell44 (4), 517–531. 10.1016/j.molcel.2011.10.001
219
LlambiF.WangY. M.VictorB.YangM.SchneiderD. M.GingrasS.et al (2016). BOK is a non-canonical BCL-2 family effector of apoptosis regulated by ER-Associated degradation. Cell165 (2), 421–433. 10.1016/j.cell.2016.02.026
220
López-OtínC.BlascoM. A.PartridgeL.SerranoM.KroemerG. (2013). The hallmarks of aging. Cell153 (6), 1194–1217. 10.1016/j.cell.2013.05.039
221
LossiL. (2022). The concept of intrinsic versus extrinsic apoptosis. Biochem. J.479 (3), 357–384. 10.1042/bcj20210854
222
LossiL.MerighiA. (1998). Apoptosis of undifferentiated neuroepithelial cells and granule cell precursors in the post-natal rabbit cerebellar cortex occurs within a few hours after cell proliferation. It. J. Anat. Embryol.103 (3), 22–23.
223
LossiL.MerighiA. (2003). In vivo cellular and molecular mechanisms of neuronal apoptosis in the Mammalian CNS. Progr. Neurobiol.69, 287–312. 10.1016/s0301-0082(03)00051-0
224
LossiL.ZagzagD.GrecoM. A.MerighiA. (1998). Apoptosis of undifferentiated progenitors and granule cell precursors in the post-natal human cerebellar cortex correlates with expression of BCL-2, ICE and CPP-32 proteins. J. Comp. Neurol.399, 359–372.
225
LossiL.MiolettiS.AimarP.BrunoR.MerighiA. (2002a). “In vivo analysis of cell proliferation and apoptosis in the CNS,” in Cellular and Molecular Methods in Neuroscience Research. Editors MerighiA.CarmignotoG. (New York, NY: Springer Verlag), 235–258.
226
LossiL.MiolettiS.MerighiA. (2002b). Synapse-independent and synapse-dependent apoptosis of cerebellar granule cells in postnatal rabbits occur at two subsequent but partly overlapping developmental stages. Neuroscience112, 509–523. 10.1016/s0306-4522(02)00112-4
227
LossiL.GambinoG.MiolettiS.MerighiA. (2004). In vivo analysis reveals different apoptotic pathways in pre- and post-migratory cerebellar granule cells of rabbit. J. Neurobiol.60, 437–452. 10.1002/neu.20032
228
LossiL.GambinoG.FerriniF.AlasiaS.MerighiA. (2009). Posttranslational regulation of BCL2 levels in cerebellar granule cells: a mechanism of neuronal survival. Dev. Neurobiol.69 (13), 855–870. 10.1002/dneu.20744
229
LossiL.GambinoG.SalioC.MerighiA. (2010). Autophagy regulates the post-translational cleavage of BCL-2 and promotes neuronal survival. Scientific World J.10, 924–929. 10.1100/tsw.2010.82
230
LossiL.CastagnaC.MerighiA. (2015). “Neuronal cell death: an overview of its different forms in central and peripheral neurons,” in Neuronal Cell Death. Editors LossiL.MerighiA.1254th edition (New York, NY: Springer Verlag), 1–18.
231
LossiL.CocitoC.AlasiaS.MerighiA. (2016). Ex vivo imaging of active caspase 3 by a FRET-based molecular probe demonstrates the cellular dynamics and localization of the protease in cerebellar granule cells and its regulation by the apoptosis-inhibiting protein survivin. Mol. Neurodegener.11 (1), 1–20. 10.1186/s13024-016-0101-8
232
LuY.FuW.XingW.WuH.ZhangC.XuD. (2024). Transcriptional regulation mechanism of PARP1 and its application in disease treatment. Epigenetics & Chromatin17 (1), 26. 10.1186/s13072-024-00550-w
233
LuoX.BudihardjoI.ZouH.SlaughterC.WangX. (1998). Bid, a Bcl2 interacting protein, mediates cytochorme c release from mitochondria in response to activation of cell death surface receptors. Cell94, 481–490. 10.1016/s0092-8674(00)81589-5
234
LvY.SunF.PuB. (2025). HDAC1 promotes hippocampal neuronal pyroptosis in epileptic mice through the miR-15a-5p/Caspase-1 axis. Neurochem. Res.50 (2), 125. 10.1007/s11064-025-04372-4
235
Madden FelicellaM.JenK. Y. (2013). “Bcl-2 gene family,” in Brenner’s Encyclopedia of Genetics. Editors MaloyS.HughesK.2nd edition (San Diego: Academic Press), 310–312.
236
MailleuxA. A.OverholtzerM.SchmelzleT.BouilletP.StrasserA.BruggeJ. S. (2007). BIM regulates apoptosis during mammary ductal morphogenesis, and its absence reveals alternative cell death mechanisms. Dev. Cell12 (2), 221–234. 10.1016/j.devcel.2006.12.003
237
MajeedN. S.SalamA. A.FarhanS. R.AbdulrazzaqS. A.MenonS. V.KaurM.et al (2025). Multifaceted roles of Bcl-2 family proteins: regulatory roles in apoptosis, physiological functions, and therapeutic potential. Curr. Med. Sci.45 (6), 1319–1335. 10.1007/s11596-025-00124-1
238
MalireddiR. K. S.KesavardhanaS.KannegantiT.-D. (2019). ZBP1 and TAK1: master regulators of NLRP3 inflammasome/pyroptosis, apoptosis, and necroptosis (PAN-optosis). Front. Cell. Infect. Microbiol.9, 406. 10.3389/fcimb.2019.00406
239
MansourH. M.MohamedA. F.El-KhatibA. S.KhattabM. M. (2023). Kinases control of regulated cell death revealing druggable targets for Parkinson's disease. Ageing Res. Rev.85, 101841. 10.1016/j.arr.2022.101841
240
MansourH. M.MohamedA. F.KhattabM. M.El-KhatibA. S. (2024). Heat shock protein 90 in Parkinson’s disease: profile of a serial killer. Neuroscience537, 32–46. 10.1016/j.neuroscience.2023.11.031
241
Maor-NofM.RomiE.Sar ShalomH.UlisseV.RaananC.NofA.et al (2016). Axonal degeneration is regulated by a transcriptional program that coordinates expression of Pro- and anti-degenerative factors. Neuron92 (5), 991–1006. 10.1016/j.neuron.2016.10.061
242
MarionS.HoffmannE.HolzerD.Le ClaincheC.MartinM.SachseM.et al (2011). Ezrin promotes actin assembly at the phagosome membrane and regulates phago-lysosomal fusion. Traffic12 (4), 421–437. 10.1111/j.1600-0854.2011.01158.x
243
MarksN.BergM. J. (1999). Recent advances on neuronal caspases in development and neurodegeneration. Neurochem. Int.35, 195–220. 10.1016/s0197-0186(99)00061-3
244
MartinL. J.WongM. (2017). Enforced DNA repair enzymes rescue neurons from apoptosis induced by target deprivation and axotomy in mouse models of neurodegeneration. Mech. Ageing Dev.161, 149–162. 10.1016/j.mad.2016.06.011
245
MartinL. J.KaiserA.YuJ. W.NataleJ. E.Al-AbdullaN. A. (2001). Injury-induced apoptosis of neurons in adult brain is mediated by p53-dependent and p53-independent pathways and requires Bax. J. Comp. Neurol.433 (3), 299–311. 10.1002/cne.1141
246
Martin-VillalbaA.HerrI.JeremiasI.HahneM.BrandtR.VogelJ.et al (1999). CD95 ligand (Fas-L/APO-1L) and tumor necrosis factor-related apoptosis-inducing ligand mediate ischemia-induced apoptosis in neurons. J. Neurosci.19, 3809–3817. 10.1523/JNEUROSCI.19-10-03809.1999
247
MartinouJ.-C.YouleR. J. (2011). Mitochondria in apoptosis: Bcl-2 family members and mitochondrial dynamics. Dev. Cell21 (1), 92–101. 10.1016/j.devcel.2011.06.017
248
MatarreseP.TinariA.MormoneE.BiancoG. A.ToscanoM. A.AscioneB.et al (2005). Galectin-1 sensitizes resting human T lymphocytes to Fas (CD95)-mediated cell death via mitochondrial hyperpolarization, budding, and fission. J. Biol. Chem.280 (8), 6969–6985. 10.1074/jbc.M409752200
249
MattsonM. P.ArumugamT. V. (2018). Hallmarks of brain aging: adaptive and pathological modification by metabolic states. Cell Metab.27 (6), 1176–1199. 10.1016/j.cmet.2018.05.011
250
MattsonM. P.DuanW. (1999). “Apoptotic” biochemical cascades in synaptic compartments: roles in adaptive plasticity and neurodegenerative disorders. J. Neurosci. Res.58 (1), 152–166.
251
MehlenP.Tauszig-DelamasureS. (2014). Dependence receptors and colorectal cancer. Gut63 (11), 1821–1829. 10.1136/gutjnl-2013-306704
252
MehlenP.ThibertC. (2004). Dependence receptors: between life and death. Cell Mol. Life Sci.61 (15), 1854–1866. 10.1007/s00018-004-3467-7
253
MeierP.EvanG. (1998). Dying like flies. Cell95, 295–298. 10.1016/s0092-8674(00)81760-2
254
MemouA.DimitrakopoulosL.KedaritiM.KentrosM.LamprouA.Petropoulou-VathiL.et al (2021). Defining (and blocking) neuronal death in Parkinson's disease: does it matter what we call it?Brain Res.1771, 147639. 10.1016/j.brainres.2021.147639
255
MerighiA.LossiL. (2022). Endoplasmic reticulum stress signaling and neuronal cell death. Int. J. Mol. Sci.23 (23), 15186. 10.3390/ijms232315186
256
MerighiA.GionchigliaN.GranatoA.LossiL. (2021). The phosphorylated form of the histone H2AX (γH2AX) in the brain from embryonic life to old age. Molecules26 (23), 7198. 10.3390/molecules26237198
257
MerighiA.CastagnaC.SbrizM.LossiL. (2026). Non-canonical regulated cell death and epigenetic mechanisms in the nervous system. Front. Cell Death5, 1793102. 10.3389/fceld.2026.1793102
258
MichaelidisT. M.SendtnerM.CooperJ. D.AiraksinenM. S.HoltmannB.MeyerM.et al (1996). Inactivation of bcl-2 results in progressive degeneration of motoneurons, sympathetic and sensory neurons during early postnatal development. Neuron17 (1), 75–89. 10.1016/s0896-6273(00)80282-2
259
MichelsJ.JohnsonP. W.PackhamG. (2005). Mcl-1. Int. J. Biochem. Cell Biol.37 (2), 267–271. 10.1016/j.biocel.2004.04.007
260
MigheliA.CavallaP.MarinoS.SchifferD. (1994). A study of apoptosis in normal and pathologic nervous tissue after in situ end-labeling of DNA strand breaks. J. Neuropathol. Exp. Neurol.53 (6), 606–616. 10.1097/00005072-199411000-00008
261
MijanovicO.PetushkovaA. I.BrankovicA.TurkB.SolovievaA. B.NikitkinaA. I.et al (2021). Cathepsin D-Managing the delicate balance. Pharmaceutics13 (6), 837. 10.3390/pharmaceutics13060837
262
MillerF. D.KaplanD. R. (2001). Neurotrophin signalling pathways regulating neuronal apoptosis. Cell. Mol. Life Sci.58 (8), 1045–1053. 10.1007/PL00000919
263
MisgeldT.SchwarzT. L. (2017). Mitostasis in neurons: maintaining mitochondria in an extended cellular architecture. Neuron96 (3), 651–666. 10.1016/j.neuron.2017.09.055
264
MizushimaN.KomatsuM. (2011). Autophagy: renovation of cells and tissues. Cell147 (4), 728–741. 10.1016/j.cell.2011.10.026
265
MohseniM.BehzadG.FarhadiA.BehrooziJ.MohseniH.ValipourB. (2024). MicroRNAs regulating autophagy: opportunities in treating neurodegenerative diseases. Front. Neurosci., 18, 1397106. 10.3389/fnins.2024.1397106
266
Mohseni-MoghaddamP.Khaleghzadeh-AhangarH.AtabakiR. (2024). Role of necroptosis, a regulated cell death, in seizure and epilepsy. Neurochem. Res.49 (1), 1–13. 10.1007/s11064-023-04010-x
267
MoorthyH.SainS.PadhiD.GovindarajuT. (2025). The pathological nexus and multipronged approaches to mitigate ferroptosis and Alzheimer's disease. J. Med. Chem.68 (19), 19828–19845. 10.1021/acs.jmedchem.5c00917
268
MoriishiK.HuangD. C.CoryS.AdamsJ. M. (1999). Bcl-2 family members do not inhibit apoptosis by binding the caspase activator Apaf-1. Proc. Natl. Acad. Sci. U. S. A.96 (17), 9683–9688. 10.1073/pnas.96.17.9683
269
MorlonA.MunnichA.SmahiA. (2005). TAB2, TRAF6 and TAK1 are involved in NF-κB activation induced by the TNF-receptor, Edar and its adaptator Edaradd. Hum. Mol. Genet.14 (23), 3751–3757. 10.1093/hmg/ddi405
270
MoujalledD.StrasserA.LiddellJ. R. (2021). Molecular mechanisms of cell death in neurological diseases. Cell Death Differ.28 (7), 2029–2044. 10.1038/s41418-021-00814-y
271
MuradF.Garcia-SaezA. J. (2021). Bcl-xL inhibits tBid and Bax via distinct mechanisms. Faraday Discuss.232, 86–102. 10.1039/d0fd00045k
272
NaganskaE.MatyjaE. (2001). Ultrastructural characteristics of necrotic and apoptotic mode of neuronal cell death in a model of anoxia in vitro. Folia Neuropathol.39 (3), 129–139.
273
NapoletanoF.BaronO.VandenabeeleP.MollereauB.FantoM. (2019). Intersections between regulated cell death and autophagy. Trends Cell Biol.29 (4), 323–338. 10.1016/j.tcb.2018.12.007
274
NeukommL. J.FreemanM. R. (2014). Diverse cellular and molecular modes of axon degeneration. Trends Cell Biol.24 (9), 515–523. 10.1016/j.tcb.2014.04.003
275
NewmeyerD. D.Bossy-WetzelE.KluckR. M.WolfB. B.BeereH. M.GreenD. R. (2000). Bcl-xL does not inhibit the function of Apaf-1. Cell Death Differ.7 (4), 402–407. 10.1038/sj.cdd.4400665
276
NguyenT. T. M.GilletG.PopgeorgievN. (2021). Caspases in the developing central nervous system: apoptosis and beyond. Front. Cell Dev. Biol.9, 702404. 10.3389/fcell.2021.702404
277
NicholsonD. W.AliA.ThornberryN. A.VaillancourtJ. P.DingC. K.GallantM.et al (1995). Identification and inhibition of the ICE/CED-3 protease necessary for Mammalian apoptosis. Nature376, 37–43. 10.1038/376037a0
278
NixonR. A. (2024). Autophagy-lysosomal-associated neuronal death in neurodegenerative disease. Acta Neuropathol.148 (1), 42. 10.1007/s00401-024-02799-7
279
NixonR. A.YangD. S. (2012). Autophagy and neuronal cell death in neurological disorders. Cold Spring Harb.Perspect.Biol.4 (10), a008839. 10.1101/cshperspect.a008839
280
NógrádiB.Nógrádi-HalmiD.Erdélyi-FurkaB.KádárZ.CsontT.GáspárR. (2024). Mechanism of motoneuronal and pyramidal cell death in amyotrophic lateral sclerosis and its potential therapeutic modulation. Cell Death Discov.10 (1), 291. 10.1038/s41420-024-02055-7
281
NuñezG.ClarkeM. F. (1994). The Bcl-2 family of proteins: regulators of cell death and survival. Trends Cell Biol.4, 399–403. 10.1016/0962-8924(94)90053-1
282
NuñezG.LondonL.HockenberyD.AlexanderM.McKearnJ. P.KorsmeyerS. J. (1990). Deregulated Bcl-2 gene expression selectively prolongs survival of growth factor-deprived hemopoietic cell lines. J. Immunol.144 (9), 3602–3610.
283
NunnariJ.SuomalainenA. (2012). Mitochondria: in sickness and in health. Cell148 (6), 1145–1159. 10.1016/j.cell.2012.02.035
284
OfengeimD.ItoY.NajafovA.ZhangY.ShanB.DeWittJ. P.et al (2015). Activation of necroptosis in multiple sclerosis. Cell Rep.10 (11), 1836–1849. 10.1016/j.celrep.2015.02.051
285
OkouchiM.EkshyyanO.MaracineM.AwT. Y. (2007). Neuronal apoptosis in neurodegeneration. Antioxid. Redox Signal9 (8), 1059–1096. 10.1089/ars.2007.1511
286
Ortí-CasañN.BoeremaA. S.KöpkeK.EbskampA.KeijserJ.ZhangY.et al (2023). The TNFR1 antagonist Atrosimab reduces neuronal loss, glial activation and memory deficits in an acute mouse model of neurodegeneration. Sci. Rep.13 (1), 10622. 10.1038/s41598-023-36846-2
287
OuM.JiangY.JiY.ZhouQ.DuZ.ZhuH.et al (2022). Role and mechanism of ferroptosis in neurological diseases. Mol. Metab.61, 101502. 10.1016/j.molmet.2022.101502
288
OzörenN.El-DeiryW. S. (2002). Defining characteristics of types I and II apoptotic cells in response to TRAIL. Neoplasia (New York, N.Y.)4 (6), 551–557. 10.1038/sj.neo.7900270
289
PacherP.HajnóczkyG. (2001). Propagation of the apoptotic signal by mitochondrial waves. Embo J.20 (15), 4107–4121. 10.1093/emboj/20.15.4107
290
PaglioneM.RestivoL.ZakhiaS.Llobet RosellA.TerenzioM.NeukommL. J. (2025). Local translatome sustains synaptic function in impaired Wallerian degeneration. EMBO Rep.26 (1), 61–83. 10.1038/s44319-024-00301-8
291
PajarilloE.Nyarko-DanquahI.DigmanA.ViedC.SonD. S.LeeJ.et al (2023). Astrocytic Yin Yang 1 is critical for murine brain development and protection against apoptosis, oxidative stress, and inflammation. Glia71 (2), 450–466. 10.1002/glia.24286
292
PaoliP.GiannoniE.ChiarugiP. (2013). Anoikis molecular pathways and its role in cancer progression. Biochim. Biophys. Acta1833 (12), 3481–3498. 10.1016/j.bbamcr.2013.06.026
293
ParanjapeN.StrackS.LehmlerH.-J.DoornJ. A. (2024). Astrocyte mitochondria are a sensitive target of PCB52 and its human-relevant metabolites. ACS Chem. Neurosci.15 (15), 2729–2740. 10.1021/acschemneuro.4c00116
294
ParkW.WeiS.KimB.-S.KimB.BaeS.-J.ChaeY. C.et al (2023). Diversity and complexity of cell death: a historical review. Exp. Mol. Med.55 (8), 1573–1594. 10.1038/s12276-023-01078-x
295
ParsadanianA. S.ChengY.Keller-PeckC. R.HoltzmanD. M.SniderW. D. (1998). Bcl-xL is an antiapoptotic regulator for postnatal CNS neurons. J. Neurosci.18 (3), 1009–1019. 10.1523/JNEUROSCI.18-03-01009.1998
296
PatelJ. R.BrewerG. J. (2008). Age-related differences in NFkappaB translocation and Bcl-2/Bax ratio caused by TNFalpha and Abeta42 promote survival in middle-age neurons and death in old neurons. Exp. Neurol.213 (1), 93–100. 10.1016/j.expneurol.2008.05.007
297
PembertonJ. M.PogmoreJ. P.AndrewsD. W. (2021). Neuronal cell life, death, and axonal degeneration as regulated by the BCL-2 family proteins. Cell Death Differ.28 (1), 108–122. 10.1038/s41418-020-00654-2
298
PhelkaA. D.SadoffM. M.MartinB. P.PhilbertM. A. (2006). BCL-XL expression levels influence differential regional astrocytic susceptibility to 1,3-dinitrobenzene. Neurotoxicol.27 (2), 192–200. 10.1016/j.neuro.2005.09.006
299
PihánP.Carreras-SuredaA.HetzC. (2017). BCL-2 family: integrating stress responses at the ER to control cell demise. Cell Death Differ.24 (9), 1478–1487. 10.1038/cdd.2017.82
300
PiroozniaS. K.DawsonV. L.DawsonT. M. (2014). Motor neuron death in ALS: programmed by astrocytes?Neuron81 (5), 961–963. 10.1016/j.neuron.2014.02.024
301
Plascencia-VillaG.PerryG. (2021). Preventive and therapeutic strategies in Alzheimer's disease: focus on oxidative stress, redox metals, and ferroptosis. Antioxid. Redox Signal34 (8), 591–610. 10.1089/ars.2020.8134
302
PopgeorgievN.JabbourL.GilletG. (2018). Subcellular localization and dynamics of the Bcl-2 family of proteins. Front. Cell Dev. Biol.6, 13. 10.3389/fcell.2018.00013
303
PottsP. R.SinghS.KnezekM.ThompsonC. B.DeshmukhM. (2003). Critical function of endogenous XIAP in regulating caspase activation during sympathetic neuronal apoptosis. J. Cell Biol.163 (4), 789–799. 10.1083/jcb.200307130
304
PutchaG. V.DeshmukhM.JohnsonE. M.Jr. (2000). Inhibition of apoptotic signaling cascades causes loss of trophic factor dependence during neuronal maturation. J. Cell Biol.149 (5), 1011–1018. 10.1083/jcb.149.5.1011
305
PuthalakathH.VillungerA.O'ReillyL. A.BeaumontJ. G.CoultasL.CheneyR. E.et al (2001). Bmf: a proapoptotic BH3-only protein regulated by interaction with the myosin V actin motor complex, activated by anoikis. Science293 (5536), 1829–1832. 10.1126/science.1062257
306
QiK.MuY.HuY.LiJ.LiuJ. (2025). Comprehensive landscape of cell death mechanisms: from molecular cross-talk to therapeutic innovation in oncology. Front. Cell Dev. Biol.13, 1611055. 10.3389/fcell.2025.1611055
307
QinD.WangJ.LeA.WangT. J.ChenX.WangJ. (2021). Traumatic brain injury: ultrastructural features in neuronal ferroptosis, glial cell activation and polarization, and blood-brain barrier breakdown. Cells10 (5), 1009. 10.3390/cells10051009
308
QuX.ZouZ.SunQ.Luby-PhelpsK.ChengP.HoganR. N.et al (2007). Autophagy gene-dependent clearance of apoptotic cells during embryonic development. Cell128 (5), 931–946. 10.1016/j.cell.2006.12.044
309
RaoulC.HendersonC. E.PettmannB. (1999). Programmed cell death of embryonic motoneurons triggered through the Fas death receptor. J. Cell Biol.147, 1049–1062. 10.1083/jcb.147.5.1049
310
RaoulC.PettmannB.HendersonC. E. (2000). Active killing of neurons during development and following stress: a role for p75(NTR) and Fas?Curr. Opin. Neurobiol.10, 111–117. 10.1016/s0959-4388(99)00055-0
311
RavehT.DroguettG.HorwitzM. S.DePinhoR. A.KimchiA. (2001). DAP kinase activates a p19ARF/p53-mediated apoptotic checkpoint to suppress oncogenic transformation. Nat. Cell Biol.3 (1), 1–7. 10.1038/35050500
312
RegoniM.ValtortaF.SassoneJ. (2024). Dopaminergic neuronal death via necroptosis in Parkinson's disease: a review of the literature. Eur. J. Neurosci.59 (6), 1079–1098. 10.1111/ejn.16136
313
RenL.ZhangQ.ZhouJ.WangX.ZhuD.ChenX. (2024). Leveraging diverse regulated cell death patterns to identify diagnosis biomarkers for Alzheimer's disease. J. Prev. Alzheimers Dis.11 (6), 1775–1788. 10.14283/jpad.2024.119
314
Rena HesseA.HagemeierK.LürbkeA.HeldJ.FriedmanH.PetersonA.et al (2012). XIAP protects oligodendrocytes against cell death in vitro but has no functional role in toxic demyelination. Glia60 (2), 271–280. 10.1002/glia.21261
315
RenaultT. T.TeijidoO.MissireF.GanesanY. T.VeloursG.ArokiumH.et al (2015). Bcl-xL stimulates Bax relocation to mitochondria and primes cells to ABT-737. Int. J. Biochem. Cell Biol.64, 136–146. 10.1016/j.biocel.2015.03.020
316
RicciJ. E.GottliebR. A.GreenD.R. (2003). Caspase-mediated loss of mitochondrial function and generation of reactive oxygen species during apoptosis. J. Cell Biol.160 (1), 65–75. 10.1083/jcb.200208089
317
RinholmJ. E.HamiltonN. B.KessarisN.RichardsonW. D.BergersenL. H.AttwellD. (2011). Regulation of oligodendrocyte development and myelination by glucose and lactate. J. Neurosci.31 (2), 538–548. 10.1523/jneurosci.3516-10.2011
318
RogersC.Fernandes-AlnemriT.MayesL.AlnemriD.CingolaniG.AlnemriE. S. (2017). Cleavage of DFNA5 by caspase-3 during apoptosis mediates progression to secondary necrotic/pyroptotic cell death. Nat. Communications8, 14128. 10.1038/ncomms14128
319
RoosW. P.ThomasA. D.KainaB. (2016). DNA damage and the balance between survival and death in cancer biology. Nat. Rev. Cancer16 (1), 20–33. 10.1038/nrc.2015.2
320
RrojiO.KumarA.KaruppagounderS. S.RatanR. R. (2021). Epigenetic regulators of neuronal ferroptosis identify novel therapeutics for neurological diseases: HDACs, transglutaminases, and HIF prolyl hydroxylases. Neurobiol. Dis.147, 105145. 10.1016/j.nbd.2020.105145
321
SalehA.SrinivasulaS. M.AcharyaS.FishelR.AlnemriE. S. (1999). Cytochrome c and dATP-mediated oligomerization of Apaf-1 is a prerequisite for Procaspase-9 activation. J. Biol. Chem.274 (25), 17941–17945. 10.1074/jbc.274.25.17941
322
SalvadoresN.SanhuezaM.ManqueP.CourtF. A. (2017). Axonal degeneration during aging and its functional role in neurodegenerative disorders. Front. Neurosci.11, 451. 10.3389/fnins.2017.00451
323
SalvesenG. S.DixitV. M. (1997). Caspases: intracellular signaling by proteolysis. Cell91 (4), 443–446. 10.1016/S0092-8674(00)80430-4
324
SastryP. S.RaoK. (2000). Apoptosis in the nervous system. J. Neurochem.74, 1–20. 10.1046/j.1471-4159.2000.0740001.x
325
SchneiderD.GerhardtE.BockJ.MüllerM. M.WolburgH.LangF.et al (2004). Intracellular acidification by inhibition of the Na+/H+-exchanger leads to caspase-independent death of cerebellar granule neurons resembling paraptosis. Cell Death Differ.11 (7), 760–770. 10.1038/sj.cdd.4401377
326
SchwartzL. M.MilliganC. E. (1996). Cold thoughts of death: the role of ICE proteases in neuronal cell death. Trends Neurosci.19 (12), 555–562. 10.1016/s0166-2236(96)10067-9
327
ScorranoL.AshiyaM.ButtleK.WeilerS.OakesS. A.MannellaC. A.et al (2002). A distinct pathway remodels mitochondrial cristae and mobilizes cytochrome c during apoptosis. Dev. Cell2 (1), 55–67. 10.1016/S1534-5807(01)00116-2
328
SegawaK.NagataS. (2015). An apoptotic ‘Eat Me’ signal: phosphatidylserine exposure. Trends Cell Biol.25 (11), 639–650. 10.1016/j.tcb.2015.08.003
329
SegawaK.KurataS.YanagihashiY.BrummelkampT. R.MatsudaF.NagataS. (2014). Caspase-mediated cleavage of phospholipid flippase for apoptotic phosphatidylserine exposure. Science344 (6188), 1164–1168. 10.1126/science.1252809
330
SelkoeD. J. (2002). Alzheimer’s disease is a synaptic failure. Science298 (5594), 789–791. 10.1126/science.1074069
331
SeyrekK.EspeJ.KönigC.WohlfrommF.LavrikI. N. (2025). Glycans on death receptors as sweet markers and signaling checkpoints. Front. Cell Death4, 1585989. 10.3389/fceld.2025.1585989
332
ShahamS.HorvitzH. R. (1996). Developing Caenorhabitis elegans neurons may contain both cell-death protective and killer activities. Genes Dev.10, 578–591. 10.1101/gad.10.5.578
333
Shamas-DinA.KaleJ.LeberB.AndrewsD. W. (2013). Mechanisms of action of Bcl-2 family proteins. Cold Spring Harb. Perspect. Biol.5 (4), a008714. 10.1101/cshperspect.a008714
334
ShiJ.ZhaoY.WangK.ShiX.WangY.HuangH.et al (2015). Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature526 (7575), 660–665. 10.1038/nature15514
335
ShindlerK. S.LathamC. B.RothK. A. (1997). Bax deficiency prevents the increased cell death of immature neurons in bcl-x-deficient mice. J. Neurosci.17 (9), 3112–3119. 10.1523/JNEUROSCI.17-09-03112.1997
336
ShlomovitzI.SpeirM.GerlicM. (2019). Flipping the dogma—phosphatidylserine in non-apoptotic cell death. Cell Commun. Signal.17 (1), 139. 10.1186/s12964-019-0437-0
337
SinghR.LetaiA.SarosiekK. (2019). Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins. Nat. Rev. Mol. Cell Biol.20 (3), 175–193. 10.1038/s41580-018-0089-8
338
SkoutaR.DixonS. J.WangJ.DunnD. E.OrmanM.ShimadaK.et al (2014). Ferrostatins inhibit oxidative lipid damage and cell death in diverse disease models. J. Am. Chem. Soc.136 (12), 4551–4556. 10.1021/ja411006a
339
SkulachevV. P. (2002). Programmed death phenomena: from organelle to organism. Ann. N. Y. Acad. Sci.959 (1), 214–237. 10.1111/j.1749-6632.2002.tb02095.x
340
SochalskaM.TuzlakS.EgleA.VillungerA. (2015). Lessons from gain- and loss-of-function models of pro-survival Bcl2 family proteins: implications for targeted therapy. Febs J.282 (5), 834–849. 10.1111/febs.13188
341
SozmenE. G.KolekarA.HavtonL. A.CarmichaelS. T. (2009). A white matter stroke model in the mouse: axonal damage, progenitor responses and MRI correlates. J. Neurosci. Methods180 (2), 261–272. 10.1016/j.jneumeth.2009.03.017
342
SperandioS.de BelleI.BredesenD. E. (2000). An alternative, nonapoptotic form of programmed cell death. Proc. Natl. Acad. Sci.97(26), 14376–14381. 10.1073/pnas.97.26.14376
343
SperandioS.PoksayK.de BelleI.LafuenteM.LiuB.NasirJ.et al (2004). Paraptosis: mediation by MAP kinases and inhibition by AIP-1/Alix. Cell Death Differentiation11, 1066–1075. 10.1038/sj.cdd.4401465
344
SpringerJ. E.AzbillR. D.KnappP. E. (1999). Activation of the caspase-3 apoptotic cascade in traumatic spinal cord injury. Nat. Med.5 (8), 943–946. 10.1038/11387
345
StefanisL.ParkD. S.FriedmanW. J.GreeneL. A. (1999). Caspase-dependent and -independent death of camptothecin-treated embryonic cortical neurons. J. Neurosci.19 (15), 6235–6247. 10.1523/JNEUROSCI.19-15-06235.1999
346
StewartB. W. (1994). Mechanisms of apoptosis: integration of genetic, biochemical, and cellular indicators. JNCI86, 1286–1296. 10.1093/jnci/86.17.1286
347
StiedaL. (1872). Die Bildung des Knochengewebes: Festschrift des Naturforschervereins zu Riga, zur Feier des Fünfzigjährigen Bestehens der Gesellschaft Practischer Aerzte zu Riga. Leipzig: Engelmann.
348
StoccoroA.CoppedèF. (2021). Mitochondrial DNA methylation and human diseases. Int. J. Mol. Sci.22 (9), 4594. 10.3390/ijms22094594
349
StockwellB. R. (2022). Ferroptosis turns 10: emerging mechanisms, physiological functions, and therapeutic applications. Cell185 (14), 2401–2421. 10.1016/j.cell.2022.06.003
350
StoicaB. A.LoaneD. J.ZhaoZ.KabadiS. V.HanscomM.ByrnesK. R.et al (2014). PARP-1 inhibition attenuates neuronal loss, microglia activation and neurological deficits after traumatic brain injury. J. Neurotrauma31 (8), 758–772. 10.1089/neu.2013.3194
351
StokaV.TurkV.BredesenD. E. (2007). Differential regulation of Smac/DIABLO and Hsp-70 during brain maturation. Neuromolecular Med.9 (3), 255–263. 10.1007/s12017-007-8007-9
352
SunC.YinN.WenR.LiuW.JiaY.HuL.et al (2016). Silver nanoparticles induced neurotoxicity through oxidative stress in rat cerebral astrocytes is distinct from the effects of silver ions. Neurotoxicol.52, 210–221. 10.1016/j.neuro.2015.09.007
353
SunL. O.MulinyaweS. B.CollinsH. Y.IbrahimA.LiQ.SimonD. J.et al (2018). Spatiotemporal control of CNS myelination by oligodendrocyte programmed cell death through the TFEB-PUMA axis. Cell175 (7), 1811–1826.e1821. 10.1016/j.cell.2018.10.044
354
SunQ.WangS.ChenJ.CaiH.HuangW.ZhangY.et al (2019). MicroRNA-190 alleviates neuronal damage and inhibits neuroinflammation via Nlrp3 in MPTP-induced Parkinson’s disease mouse model. J. Cell Physiol.234 (12), 23379–23387. 10.1002/jcp.28907
355
SunZ.ZhangX.SoK. F.JiangW.ChiuK. (2024). Targeting microglia in Alzheimer’s disease: pathogenesis and potential therapeutic strategies. Biomolecules14 (7), 833. 10.3390/biom14070833
356
SunH.QianH.QianH.QianM. (2025). From tradition to innovation: acupuncture therapies targeting ferroptosis in neurological disorders. Brain Behav.15 (9), e70827. 10.1002/brb3.70827
357
SusinS. A.LorenzoH. K.ZamzamiN.MarzoI.SnowB. E.BrothersG. M.et al (1999). Molecular characterization of mitochondrial apoptosis-inducing factor. Nature397, 441–446. 10.1038/17135
358
SusinS. A.DaugasE.RavagnanL.SamejimaK.ZamzamiN.LoefflerM.et al (2000). Two distinct pathways leading to nuclear apoptosis. J.Exp Med.192 (4), 571–580. 10.1084/jem.192.4.571
359
TaitS. W.GreenD. R. (2010). Mitochondria and cell death: outer membrane permeabilization and beyond. Nat. Rev. Mol. Cell Biol.11 (9), 621–632. 10.1038/nrm2952
360
TaitS. W.GreenD. R. (2013). Mitochondrial regulation of cell death. Cold Spring Harb. Perspect. Biol.5 (9), a008706. 10.1101/cshperspect.a008706
361
TakumaK.BabaA.MatsudaT. (2004). Astrocyte apoptosis: implications for neuroprotection. Prog. Neurobiol.72 (2), 111–127. 10.1016/j.pneurobio.2004.02.001
362
TanS.SchubertD.MaherP. (2001). Oxytosis: a novel form of programmed cell death. Curr. Top. Med. Chem.1 (6), 497–506. 10.2174/1568026013394741
363
TanY.DongX.ZhuangD.CaoB.JiangH.HeQ.et al (2023). Emerging roles and therapeutic potentials of ferroptosis: from the perspective of 11 human body organ systems. Mol. Cell Biochem.478 (12), 2695–2719. 10.1007/s11010-023-04694-3
364
TanabeH.EguchiY.KamadaS.MartinouJ. C.TsujimotoY. (1997). Susceptibility of cerebellar granule neurons derived from Bcl-2-deficient and transgenic mice to cell death. Eur. J. Neurosci.9 (4), 848–856. 10.1111/j.1460-9568.1997.tb01434.x
365
TangD.KangR. (2023). From oxytosis to ferroptosis: 10 years of research on oxidative cell death. Antioxid. Redox Signal.39 (1-3), 162–165. 10.1089/ars.2023.0356
366
TeschendorffA. E.WestJ.BeckS. (2013). Age-associated epigenetic drift: implications, and a case of epigenetic thrift?Hum. Mol. Genet.22 (R1), R7–R15. 10.1093/hmg/ddt375
367
ThalD. R.GaworK.MoonenS. (2024). Regulated cell death and its role in Alzheimer’s disease and amyotrophic lateral sclerosis. Acta Neuropathol.147 (1), 69. 10.1007/s00401-024-02722-0
368
ThomaidouD.MioneM. C.CavanaghJ. F.ParnavelasJ. G. (1997). Apoptosis and its relation to the cell cycle in the developing cerebral cortex. J. Neurosci.17, 1075–1085. 10.1523/JNEUROSCI.17-03-01075.1997
369
ThomasL. R.HensonA.ReedJ. C.SalsburyF. R.ThorburnA. (2004). Direct binding of Fas-associated death domain (FADD) to the tumor necrosis factor-related apoptosis-inducing ligand receptor DR5 is regulated by the death effector domain of FADD. J. Biol. Chem.279 (31), 32780–32785. 10.1074/jbc.M401680200
370
ThornberryN. A.LazebnikY. (1998). Caspases: enemies within. Science281, 1312–1316. 10.1126/science.281.5381.1312
371
TinariA.GarofaloT.SoriceM.EspostiM. D.MalorniW. (2007). Mitoptosis: different pathways for mitochondrial execution. Autophagy3 (3), 282–284. 10.4161/auto.3924
372
TodtF.CakirZ.ReichenbachF.EmschermannF.LauterwasserJ.KaiserA.et al (2015). Differential retrotranslocation of mitochondrial Bax and Bak. Embo J.34 (1), 67–80. 10.15252/embj.201488806
373
ToscanoM. A.BiancoG. A.IlarreguiJ. M.CrociD. O.CorrealeJ.HernandezJ. D.et al (2007). Differential glycosylation of TH1, TH2 and TH-17 effector cells selectively regulates susceptibility to cell death. Nat. Immunol.8 (8), 825–834. 10.1038/ni1482
374
TuR.HanZ.ZhangH.JiaX.SunT.LiuH.et al (2025). From pathogenesis to treatment: the emerging role of ferroptosis in Parkinson’s disease. Front. Immunol.16, 1709561. 10.3389/fimmu.2025.1709561
375
UrrestiJ.Ruiz-MeanaM.CocciaE.ArévaloJ. C.CastellanoJ.Fernández-SanzC.et al (2016). Lifeguard inhibits fas ligand-mediated endoplasmic reticulum-calcium release mandatory for apoptosis in type II apoptotic cells. J. Biol. Chem.291 (3), 1221–1234. 10.1074/jbc.M115.677682
376
Van SanE.DebruyneA. C.VeeckmansG.TyurinaY. Y.TyurinV. A.ZhengH.et al (2023). Ferroptosis contributes to multiple sclerosis and its pharmacological targeting suppresses experimental disease progression. Cell Death Differ.30 (9), 2092–2103. 10.1038/s41418-023-01195-0
377
Vanden BergheT.VanlangenakkerN.ParthoensE.DeckersW.DevosM.FestjensN.et al (2010). Necroptosis, necrosis and secondary necrosis converge on similar cellular disintegration features. Cell Death Differ.17 (6), 922–930. 10.1038/cdd.2009.184
378
VandenabeeleP.Vanden BergheT.FestjensN. (2006). Caspase inhibitors promote alternative cell death pathways. Sci. STKE2006 (358), pe44. 10.1126/stke.3582006pe44
379
VandenabeeleP.GalluzziL.Vanden BergheT.KroemerG. (2010). Molecular mechanisms of necroptosis: an ordered cellular explosion. Nat. Reviews. Mol. Cell Biol.11 (10), 700–714. 10.1038/nrm2970
380
VauxD. L.WeissmanI. L.KimS. K. (1992). Prevention of programmed cell death in Caenorhabditis elegans by human bcl-2. Science258 (5090), 1955–1957. 10.1126/science.1470921
381
VecchioA.ColasuonnoF.OcchigrossiL.PitolliC.BellancaV.CiccaroneF.et al (2025). Epigenetic modulation of RIPK3 by transglutaminase 2-dependent serotonylation of H3K4me3 affects necroptosis. Cell Mol. Life Sci.82 (1), 154. 10.1007/s00018-025-05640-w
382
VerbruggeI.JohnstoneR. W.SmythM. J. (2010). SnapShot: extrinsic apoptosis pathways. Cell143 (7), 1192–1192.e2. 10.1016/j.cell.2010.12.004
383
VerdaguerE.García-JordàE.JiménezA.StrangesA.SuredaF. X.CanudasA. M.et al (2002a). Kainic acid-induced neuronal cell death in cerebellar granule cells is not prevented by caspase inhibitors. Br. J. Pharmacol.135 (5), 1297–1307. 10.1038/sj.bjp.0704581
384
VerdaguerE.Garcia-JordaE.CanudasA. M.DominguezE.JimenezA.PubillD.et al (2002b). Kainic acid-induced apoptosis in cerebellar granule neurons: an attempt at cell cycle re-entry. Neuroreport13 (4), 413–416. 10.1097/00001756-200203250-00010
385
VerhagenA. M.EkertP.PakuschM.SilkeJ.ConnollyL. M.ReidG. E.et al (2000). Identification of DIABLO, a Mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell102, 43–53. 10.1016/s0092-8674(00)00009-x
386
VicarioA.KisiswaL.TannJ. Y.KellyC. E.IbanezC. F. (2015). Neuron-type-specific signaling by the p75NTR death receptor is regulated by differential proteolytic cleavage. J. Cell Sci.128 (8), 1507–1517. 10.1242/jcs.161745
387
VillungerA.MichalakE. M.CoultasL.MüllauerF.BöckG.AusserlechnerM. J.et al (2003). p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa. Science302 (5647), 1036–1038. 10.1126/science.1090072
388
VirchowR. (1858). Cellularpathologie in Ihre Begrundung Auf Physiologische und Pathologische Gewebelehre. Berlin, Germany: A. Hirschwal.
389
ViswanathV.WuY.BoonplueangR.ChenS.StevensonF. F.YantiriF.et al (2001). Caspase-9 activation results in downstream caspase-8 activation and bid cleavage in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease. J. Neurosci.21 (24), 9519–9528. 10.1523/jneurosci.21-24-09519.2001
390
VitaleI.ManicG.De MariaR.KroemerG.GalluzziL. (2017). DNA damage in stem cells. Mol. Cell66 (3), 306–319. 10.1016/j.molcel.2017.04.006
391
VitaleI.PietrocolaF.GuilbaudE.AaronsonS. A.AbramsJ. M.AdamD.et al (2023). Apoptotic cell death in disease-current understanding of the NCCD 2023. Cell Death Differ.30 (5), 1097–1154. 10.1038/s41418-023-01153-w
392
VoglerM.BraunY.SmithV. M.WesthoffM. A.PereiraR. S.PieperN. M.et al (2025). The BCL2 family: from apoptosis mechanisms to new advances in targeted therapy. Signal Transduct. Target Ther.10 (1), 91. 10.1038/s41392-025-02176-0
393
VogtC. (1842). Untersuchungen uber die Entwicklungsgeschichte der Geburtshelferkröte (Alytes obstetricans). Solothurn, Switzerland: Jent und Gassmann.
394
VolobouevaL. A.SuhS. W.SwansonR. A.GiffardR. G. (2007). Inhibition of mitochondrial function in astrocytes: implications for neuroprotection. J. Neurochem.102 (4), 1383–1394. 10.1111/j.1471-4159.2007.04634.x
395
WadiaJ. S.Chalmers-RedmanR. M. E.JuW. J. H.CarlileG. W.PhillipsJ. L.FraserA. D.et al (1998). Mitochondrial membrane potential and nuclear changes in apoptosis caused by serum and nerve growth factor withdrawal: time course and modification by (−)-Deprenyl. J. Neurosci.18 (3), 932–947. 10.1523/jneurosci.18-03-00932.1998
396
WajantH. (2002). The Fas signaling pathway: more than a paradigm. Science296 (5573), 1635–1636. 10.1126/science.1071553
397
WajantH. (2003). Death receptors. Essays Biochem.39, 53–71. 10.1042/bse0390053
398
WajantH.PfizenmaierK.ScheurichP. (2003). Tumor necrosis factor signaling. Cell Death Differ.10 (1), 45–65. 10.1038/sj.cdd.4401189
399
WangY.DawsonV. L.DawsonT. M. (2009). Poly(ADP-ribose) signals to mitochondrial AIF: a key event in parthanatos. Exp. Neurol.218 (2), 193–202. 10.1016/j.expneurol.2009.03.020
400
WangW. B.FengL. X.YueQ. X.WuW. Y.GuanS. H.JiangB. H.et al (2012). Paraptosis accompanied by autophagy and apoptosis was induced by celastrol, a natural compound with influence on proteasome, ER stress and Hsp90. J. Cell Physiol.227 (5), 2196–2206. 10.1002/jcp.22956
401
WangT.TomasD.PereraN. D.CuicB.LuikingaS.VidenA.et al (2022). Ferroptosis mediates selective motor neuron death in amyotrophic lateral sclerosis. Cell Death Differ.29 (6), 1187–1198. 10.1038/s41418-021-00910-z
402
WangX.-W.YangS.-G.HuM.-W.WangR.-Y.ZhangC.KosanamA. R.et al (2023). Histone methyltransferase Ezh2 coordinates Mammalian axon regeneration via regulation of key regenerative pathways. J. Clin. Invest.134 (3), e163145. 10.1172/JCI163145
403
WangW.ThomasE. R.XiaoR.ChenT.GuoQ.LiuK.et al (2025). Targeting mitochondria-regulated ferroptosis: a new frontier in Parkinson's disease therapy. Neuropharmacol.274, 110439. 10.1016/j.neuropharm.2025.110439
404
WhiteE. (1996). Life, death, and the pursuit of apoptosis. Genes Dev.10, 1–15. 10.1101/gad.10.1.1
405
WooM.HakemR.MakT. W. (2000). Executionary pathway for apoptosis: lessons from mutant mice. Cell Res.10 (4), 267–278. 10.1038/sj.cr.7290054
406
WrightK. M.LinhoffM. W.PottsP. R.DeshmukhM. (2004). Decreased apoptosome activity with neuronal differentiation sets the threshold for strict IAP regulation of apoptosis. J. Cell Biol.167 (2), 303–313. 10.1083/jcb.200406073
407
WrightK. M.SmithM. I.FarragL.DeshmukhM. (2007). Chromatin modification of Apaf-1 restricts the apoptotic pathway in mature neurons. J. Cell Biol.179 (5), 825–832. 10.1083/jcb.200708086
408
WuZ.TanJ.LinL.ZhangW.YuanW. (2022). microRNA-140-3p protects hippocampal neuron against pyroptosis to attenuate sevoflurane inhalation-induced post-operative cognitive dysfunction in rats via activation of HTR2A/ERK/Nrf2 axis by targeting DNMT1. Cell Death Discov.8 (1), 290. 10.1038/s41420-022-01068-4
409
XieY.HouW.SongX.YuY.HuangJ.SunX.et al (2016). Ferroptosis: process and function. Cell Death Differ.23 (3), 369–379. 10.1038/cdd.2015.158
410
XuY.WangD.LuoY.LiW.ShanY.TanX.et al (2015). Beta amyloid-induced upregulation of death receptor 6 accelerates the toxic effect of N-terminal fragment of amyloid precursor protein. Neurobiol. Aging36 (1), 157–168. 10.1016/j.neurobiolaging.2014.07.027
411
XuX.SunB.ZhaoC. (2023). Poly (ADP-Ribose) polymerase 1 and parthanatos in neurological diseases: from pathogenesis to therapeutic opportunities. Neurobiol. Dis.187, 106314. 10.1016/j.nbd.2023.106314
412
XueD.ShahamS.HorvitzH. R. (1996). The Caenorhabitis elegans cell-death protein CED-3 is a cysteine protease with substrate specificity similar to those of the human CPP32 protease. Genes Dev.10, 1073–1083. 10.1101/gad.10.9.1073
413
YanJ.ChenY.ZhuY.Paquet-DurandF. (2021a). Programmed non-apoptotic cell death in hereditary retinal degeneration: crosstalk between cGMP-Dependent pathways and PARthanatos?Int. J. Mol. Sci.22 (19), 10567. 10.3390/ijms221910567
414
YanJ.XuW.LenahanC.HuangL.WenJ.LiG.et al (2021b). CCR5 activation promotes NLRP1-Dependent neuronal pyroptosis via CCR5/PKA/CREB pathway after intracerebral hemorrhage. Stroke52(12), 4021–4032. 10.1161/STROKEAHA.120.033285
415
YangJ.LiuX.BhallaK.KimC. N.IbradoA. M.CaiJ.et al (1997). Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science275, 1129–1132. 10.1126/science.275.5303.1129
416
YangD. S.KumarA.StavridesP.PetersonJ.PeterhoffC. M.PawlikM.et al (2008). Neuronal apoptosis and autophagy cross talk in aging PS/APP mice, a model of Alzheimer's disease. Am. J. Pathology173 (3), 665–681. 10.2353/ajpath.2008.071176
417
YangZ.JiangB.WangY.NiH.ZhangJ.XiaJ.et al (2017). 2-HG inhibits necroptosis by stimulating DNMT1-dependent hypermethylation of the RIP3 promoter. Cell Rep.19 (9), 1846–1857. 10.1016/j.celrep.2017.05.012
418
YangL.GuttmanL.DawsonV. L.DawsonT. M. (2024). Parthanatos: mechanisms, modulation, and therapeutic prospects in neurodegenerative disease and stroke. Biochem. Pharmacol.228, 116174. 10.1016/j.bcp.2024.116174
419
YangW. S.StockwellB. R. (2016). Ferroptosis: death by lipid peroxidation. Trends Cell Biol.26 (3), 165–176. 10.1016/j.tcb.2015.10.014
420
YanumulaA.CusickJ. K. (2021). “Biochemistry, extrinsic pathway of apoptosis,” in Statpearls. Treasure Island, FL: StatPearls Publishing Copyright © 2021.
421
Yazidi-BelkouraI. E.AdriaenssensE.DolléL.DescampsS.HondermarckH. (2003). Tumor necrosis factor receptor-associated death domain protein is involved in the neurotrophin receptor-mediated antiapoptotic activity of nerve growth factor in breast cancer cells. J. Biol. Chem.278 (19), 16952–16956. 10.1074/jbc.M300631200
422
YehW.-C.ItieA.EliaA. J.NgM.ShuH.-B.WakehamA.et al (2000). Requirement for casper (c-FLIP) in regulation of death receptor–induced apoptosis and embryonic development. Immunity12 (6), 633–642. 10.1016/S1074-7613(00)80214-9
423
YiY.JiaP.XieP.PengX.ZhuX.YinS.et al (2025). Beyond oxidative stress: ferroptosis as a novel orchestrator in neurodegenerative disorders. Front. Immunol.16, 1683876. 10.3389/fimmu.2025.1683876
424
YouleR. J.NarendraD. P. (2011). Mechanisms of mitophagy. Nat. Rev. Mol. Cell Biol.12 (1), 9–14. 10.1038/nrm3028
425
YuS. W.WangH.PoitrasM. F.CoombsC.BowersW. J.FederoffH. J.et al (2002). Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor. Science297, 259–263. 10.1126/science.1072221
426
YuZ.JiangN.SuW.ZhuoY. (2021). Necroptosis: a novel pathway in neuroinflammation. Front. Pharmacol.12, 701564. 10.3389/fphar.2021.701564
427
YuanJ. (1995). Molecular control of life and death. Curr.Opin.Cell Biol.7, 211–214. 10.1016/0955-0674(95)80030-1
428
YuanS.AkeyC. W. (2013). Apoptosome structure, assembly, and procaspase activation. Structure21 (4), 501–515. 10.1016/j.str.2013.02.024
429
YuanJ.ShahamS.LedouxS.EllisH. M.HorvitzH. R. (1993). The C. elegans cell death gene ced-9 encodes a protein similar to Mammalian interleukin-1beta converting enzyme. Cell75, 641–652. 10.1016/0092-8674(93)90485-9
430
ZaitcevaV.KopeinaG. S.ZhivotovskyB. (2021). Anastasis: return journey from cell death. Cancers13 (15), 3671. 10.3390/cancers13153671
431
ZengL.LiT.XuD. C.LiuJ.MaoG.CuiM.-Z.et al (2012). Death receptor 6 induces apoptosis not through type I or type II pathways, but via a unique mitochondria-dependent pathway by interacting with Bax protein. J. Biol. Chem.287 (34), 29125–29133. 10.1074/jbc.M112.362038
432
ZhangX.ChenJ.GrahamS. H.DuL.KochanekP. M.DraviamR.et al (2002). Intranuclear localization of apoptosis-inducing factor (AIF) and large scale DNA fragmentation after traumatic brain injury in rats and in neuronal cultures exposed to peroxynitrite. J. Neurochem.82 (1), 181–191. 10.1046/j.1471-4159.2002.00975.x
433
ZhangW.ZhuX.LiuY.ChenM.YanS.MaoX.et al (2015). Nur77 was essential for neurite outgrowth and involved in Schwann cell differentiation after sciatic nerve injury. J. Mol. Neurosci.57 (1), 38–47. 10.1007/s12031-015-0575-9
434
ZhangJ. B.JiaX.CaoQ.ChenY. T.TongJ.LuG. D.et al (2023). Ferroptosis-regulated cell death as a therapeutic strategy for neurodegenerative diseases: current status and future prospects. ACS Chem. Neurosci.14 (17), 2995–3012. 10.1021/acschemneuro.3c00406
435
ZhangS.GaoZ.FengL.LiM. (2024). Prevention and treatment strategies for Alzheimer's disease: focusing on microglia and astrocytes in neuroinflammation. J. Inflamm. Res.17, 7235–7259. 10.2147/jir.S483412
436
ZhengN.ZhouQ.ChenZ.XieL.YangX.ChenZ.et al (2025). Cuproptosis: mechanisms and links with Alzheimer's disease. J. Neurophysiol.134 (6), 1853–1876. 10.1152/jn.00370.2025
437
ZhouY.GuY.LiuJ. (2019). BRD4 suppression alleviates cerebral ischemia-induced brain injury by blocking glial activation via the inhibition of inflammatory response and pyroptosis. Biochem. Biophys. Res. Commun.519 (3), 481–488. 10.1016/j.bbrc.2019.07.097
438
ZhouJ.JinY.LeiY.LiuT.WanZ.MengH.et al (2020). Ferroptosis is regulated by mitochondria in neurodegenerative diseases. Neurodegener. Dis.20 (1), 20–34. 10.1159/000510083
439
ZhouM.XuK.GeJ.LuoX.WuM.WangN.et al (2024). Targeting ferroptosis in Parkinson’s disease: mechanisms and emerging therapeutic strategies. Int. J. Mol. Sci.25 (23), 13042. 10.3390/ijms252313042
440
ZhouZ.ZhangY.LiuS.TangH.YangL.LuY.et al (2026). Ferroptosis in Alzheimer’s disease: molecular mechanisms and advances in therapeutic strategies. Front. Neurosci.19, 1673315. 10.3389/fnins.2025.1673315
441
ZhuY.LiY.HaraguchiS.YuM.OhiraM.OzakiT.et al (2013). Dependence receptor UNC5D mediates nerve growth factor depletion-induced neuroblastoma regression. J. Clinical Invest.123 (7), 2935–2947. 10.1172/JCI65988
442
ZhuM.LiW. W.LuC. Z. (2014). Histone decacetylase inhibitors prevent mitochondrial fragmentation and elicit early neuroprotection against MPP+. CNS Neurosci. Ther.20 (4), 308–316. 10.1111/cns.12217
443
ZhuY.FallatahA. H. A.JiaoK.SeeligerM. W.Paquet-DurandF. (2025). PARP activity is essential for retinal photoreceptor survival in the human homologous Rho(I255del) mouse model for autosomal dominant retinitis pigmentosa. J. Neurochem.169 (12), e70319. 10.1111/jnc.70319
444
ZimmermannK. C.BonzonC.GreenD. R. (2001). The machinery of programmed cell death. Pharmacol. Ther.92, 57–70. 10.1016/s0163-7258(01)00159-0
Summary
Keywords
apoptosis, glia, neurons, non-canonical RCD, regulated cell death
Citation
Lossi L, Sbriz M, Castagna C and Merighi A (2026) Regulated cell death in the nervous system: a framework for execution diversity and spatially restricted degeneration. Front. Cell Death 5:1823132. doi: 10.3389/fceld.2026.1823132
Received
04 March 2026
Revised
24 June 2026
Accepted
25 June 2026
Published
05 August 2026
Volume
5 - 2026
Edited by
Adrian Ting, Mayo Clinic, United States
Reviewed by
Annette Vivi Jacobsen, Masaryk University, Czechia
Andrew Davidson, University of Glasgow, United Kingdom
Updates

Check for updates
Copyright
© 2026 Lossi, Sbriz, Castagna and Merighi.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Laura Lossi, laura.lossi@unito.it
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.